Pathological Mechanisms Underpinning Amelogenesis Imperfecta in Mice carrying an Amelogenin Mutation by Kingswell, Nicola Jo
Pathological Mechanisms Underpinning Amelogenesis 
Imperfecta in Mice Carrying an Amelogenin Mutation 
 
 
Nicola Jo Kingswell 
 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
The University of Leeds 
Department of Oral Biology 
Leeds Dental Institute 
School of Medicine and Dentistry 
 
July, 2015 
- ii - 
The candidate confirms that the work submitted is his/her own, except where 
work which has formed part of jointly-authored publications has been 
included. The contribution of the candidate and the other authors to this 
work has been explicitly indicated below. The candidate confirms that 
appropriate credit has been given within the thesis where reference has 
been made to the work of others.   
• Is the 32kDa Fragment the Functional Enamelin Unit in all Species? 
S.J. Brookes, N.J. Kingswell, M.J. Barron, M.J. Dixon, J. Kirkham,  
European Journal Oral Science, 2011: 119 (Supplement 1): 345-350 
The candidate carried out the work reported in supplemental figure S4(c); 
and contributed to the writing and final approval of the manuscript. 
 
• A mutation in the mouse Amelx tri-tyrosyl domain results in impaired 
secretion of amelogenin and phenocopies human X-linked amelogenesis 
imperfecta. Martin J. Barron, Steven J. Brookes, Jennifer Kirkham, Roger C. 
Shore, Charlotte Hunt, Aleksandr Mironov, Nicola J. Kingswell, Joanne 
Maycock, C. Adrian Shuttlecock, Michael J. Dixon,  Human Molecular 
Genetics, April 2010 ; volume 19, number 7: 1230-47 
The candidate contributed to dissection of samples, extraction of proteins 
and optimising the SDS PAGE and Western blot data reported. The 
candidate also sourced the sequence alignments, and contributed to the 
writing and final approval of the manuscript.   
 
This copy has been supplied on the understanding that it is copyright 
material and that no quotation from the thesis may be published without 
proper acknowledgement. 
 
Assertion of moral rights: 
The right of Nicola Jo Kingswell to be identified as Author of this work has 
been asserted by her in accordance with the Copyright, Designs and 
Patents Act 1988. 
 
© 2015 The University of Leeds and Nicola Jo Kingswell 
- iii - 
Acknowledgements 
I would like to thank my supervisors Professor Jennifer Kirkham and Dr 
Steven Brookes for their continual help, support and guidance. I would like 
to thank all the members of the Oral Biology department for their help over 
the last few years, with particular thanks to Mrs Claire Godfrey, Mr Adam 
Steel, Dr Sarah Myers, Dr Jo Maycock and Mrs Jackie Hudson. 
Special thanks to colleagues at Manchester University including Professor 
Mike Dixon, Dr Martin Barron and Dr Adrian Shuttleworth. 
This research has been funded by the Wellcome Trust. Without their 
funding, none of this work would have been possible. 
Many thanks to my friends and family, for support, retail therapy and 
listening to me moan. Much appreciated. Special thanks to my Mum for 
always being there, no matter what. 
I will always be eternally grateful for the support of the biotechnology team at 
Intertek Pharmaceutical Services Manchester. To my American friend, Jeff 
Beauchaine, for thinking sticks, moral support and proofreading. To Ashleigh 
Wake for her unwavering belief in me. 
Thanks to Drew for all his love, understanding and patience. Love you. 
This thesis is dedicated to my Dad, Charles Kingswell (1949-2004), whom I 
have inherited so much from. He’d have thought this was ‘bizzo’! 
- iv - 
Abstract 
Mice carrying a Y64H amelogenin mutation phenotypically mimic human 
amelogenesis imperfecta. Affected ameloblasts are characterised by the presence 
of abnormal cytoplasmic vesicles of retained amelogenin.  Protein-protein binding 
studies using recombinant wild type and Y64H amelogenin revealed that the 
mutation increased amelogenin-amelogenin binding. This may drive intracellular 
aggregation of Y64H amelogenin, explaining the abnormal retention. Intracellular 
protein aggregation causes ER stress which triggers the UPR. The UPR attempts 
to restore proteostasis but as a last resort triggers apoptosis. SEM of affected 
enamel showed initially secreted enamel is normal; coincident with UPR in pro-
survival mode. The final outer enamel is abnormal; indicative of UPR induced 
ameloblast apoptosis.   Q-RT-PCR was used to measure ER stress related gene 
expression in affected ameloblasts. Expression levels of ER stress genes increased 
but not significantly (significance was reached in later studies by others in the 
research consortium). Amelogenin expression was shown to be significantly 
reduced in affected ameloblasts; reduced protein expression being a known pro-
survival tactic employed during ER stress.      
A steady-state in vitro mineralisation system was used to examine the effect of the 
Y64H mutation on mineral nucleation by recombinant amelogenins in isolation or in 
conjunction with recombinant 32 kDa enamelin. Data showed that the Y64H 
mutation did not affect the nucleating potential suggesting that the pathological 
mechanism driving AI in affected mice is linked to ER stress rather than dysfunction 
of secreted amelogenin.  
An unexpected finding was that the 32 kDa enamelin (much lauded in the literature 
as a functional species) may be unique to pig amelogenesis and its functional 
significance is therefore debateable 
In summary, the mechanism driving AI in these mice is associated with intracellular 
ER stress. Extracellular dysfunction of mutated enamel proteins has been the focus 
of AI research but the involvement of ER stress provides additional therapeutic 
options for treating AI.     
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Chapter 1 
Introduction 
This section is concerned with a review of the current literature pertaining to 
this thesis. With special reference to dental enamel it provides an introduction to the 
development of the teeth, the structures of the dental tissues, the process of 
biomineralisation, the role of the organic matrix and its proteins in biomineralisation, 
diseases due to protein mutations, and an overview of the crystalline structure of 
the minerals deposited during tooth enamel biomineralisation. 
It is worthwhile to bear in mind the important factors driving research in the 
field of oral biology and dentistry. Although much is known about the development 
and formation of dental tissues in many species, including the underlying 
biochemical processes and genetics, there are still key questions that remain 
unanswered. The modern diet and lifestyle have shown that there are real 
requirements for alternative solutions for caries prevention and repair to the 
common practice of ‘drilling and filling’. Achievements in material science and 
engineering have provided new synthetic materials for caries repair and fillings. 
Composite materials have become the normal solution for hard-wearing, long 
lasting and cosmetically pleasing dental fillers. However, could there be an 
opportunity to include biological materials to encourage enamel to self-repair? If so, 
which biological materials should, or even could be included to optimise repair of 
the dental enamel? Recently, self-assembling peptides that can infiltrate early 
caries lesions and form mineralising scaffolds have been shown to repair early 
lesions (Brunton et al., 2013). Understanding which of the enamel extracellular 
matrix proteins are important for mineral nucleation and growth, and the interplay 
between these proteins could provide further developments in caries lesion repair. 
This insight could be provided through the study of genetic diseases of 
mineralisation that effect normal enamel development. Though relatively rare, 
genetic diseases of enamel formation, amelogenesis imperfecta (AI), can have a 
major effect on wellbeing and quality of life for sufferers. Understanding the 
underlying genetic changes and the resulting structural changes in the enamel may 
shed light on the pathological mechanisms and processes driving AI. Such 
processes may be targets for drug interventions that allow AI to be treated while 
enamel is still developing. This thesis is concerned with a mouse model of AI; the 
genetic mutation involved being linked to the developing enamel matrix protein 
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amelogenin. The broad aim is to understand the role of amelogenin in 
amelogenesis in both normal wild type mice and mice suffering from AI linked to an 
amelogenin mutation. 
 1.1 Biomineralisation 
1.1.1 An introduction to biomineralisation 
Biomineralisation is the production of minerals by living organisms, often used 
to harden or lend mechanical strength to existing tissues. Examples include calcium 
phosphate in bones and teeth, silicates in algae, and carbonates in diatoms and 
invertebrates. Overall, the formation of biomineralised tissues in all species (algae, 
molluscs, mammals and birds) appears to be regulated by the same fundamental 
processes (Boskey, 2003). Organic molecules are often employed as ‘templates’ to 
initiate and control the biomineralisation process. In fact, biomineralisation is known 
to be under strict controls, but the precise processes involved are yet to be fully 
understood. There is plenty of evidence that extracellular matrix proteins in 
mineralised tissues play a major role in the precise location and morphology of 
mineral crystals (Zhu et al., 2007). The mineralised tissues of the human body vary 
enormously according to the crystal size and shape, arrangement of the crystals, 
distribution and amounts of trace ions, and the resulting physiochemical properties 
(such as solubility and porosity). These variations reflect the functional adaptations 
of these mineralised tissues (Boskey, 2003). 
The evidence for biomineralisation goes back millions of years as 
demonstrated by the presence of fossils of bones and shells. Biomineralisation 
involves selecting, extracting and uptake of elements from a local environment, 
and, under strict biological rules, incorporating these elements into functional 
structures. It is an interdisciplinary study at the interface of chemistry, biology and 
material sciences, and impacts on palaeontology, sedimentology, dentistry and 
medicine. The incorporation of inorganic materials into organic tissues offers 
structural support and mechanical strength, but also aids protection, motion, cutting, 
buoyancy, grinding and storage (Mann, 2001; Lowenstam and Weiner, 1989; 
Simkiss and Wilbur, 1989). 
  The skeleton is an excellent example of an integrated biomineralisation 
machine. The structure and organisation of the skeletal tissues derive from a highly 
complex system, specially evolved to withstand mechanical stress. The 
biomineralisation of bone, dentine and dental enamel share many similarities, with 
specific differences for specialised structure and function. The skeletal tissues are 
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composed of calcium phosphate in the form of hydroxyapatite (HAP) 
(Ca10(PO4)6(OH)2), along with proteins. Hydroxyapatite has a complex chemistry in 
biological systems because the mineral is not pure (non-stoichiometric), often being 
calcium deficient and enriched in carbonate (CO32-) which replaces phosphate 
(PO43-) ions in various lattice sites (Simkiss and Wilbur, 1989).  Carbonate can also 
substitute for hydroxide ions (Barralet et al., 1998) and these substitutions of 
phosphate or hydroxide by carbonate in hydroxyapatite influence the crystallinity 
and crystal size. Bone is used by the body as a reservoir for phosphate, calcium 
and magnesium homeostasis (Palmer et al., 2008). 
 
1.1.2 The chemistry of biomineralisation 
  Biomineralisation takes place in four biological sites: epicellular (cell wall), 
intercellular (in the spaces between cells), intracellular (inside cellular 
compartments) and extracellular (within or on a macromolecular framework outside 
the cell) (Lowestam, 1981). Most biologically controlled mineralisation processes 
occur in intracellular or extracellular sites. 
 There are four fundamental chemical factors governing biomineralisation; 
solubility, supersaturation, nucleation and crystal growth. A crucial factor in 
determining the thermodynamic conditions for precipitation is the solubility of the 
inorganic materials. The extent to which a solution is out of equilibrium is given by 
supersaturation, which also influences the rates of nucleation and growth. These 
four factors are chemically controlled in biomineralisation by co-ordinated ion 
transport and molecular-based promoters and inhibitors (Watabe, 1989). 
Solubility refers to the number of moles of an inorganic salt that will dissolve in 
one litre of solvent at a given temperature. The solubility of an organic salt depends 
on the balance between crystal lattice energy and ion solvation and complexation in 
aqueous solution. Solubility is a key factor in the biological mineralisation of calcium 
phosphates such as hydroxyapatite. Ions such as sodium, magnesium, ammonium, 
potassium, iron, carbonate and fluoride are easily incorporated into the 
hydroxyapatite lattice structure (LeGeros 1991). They have a significant effect on 
hydroxyapatite solubility. An example of this is prevention of tooth enamel erosion 
by fluoride. Weak acids such as fruit acids in food and juices attack the 
hydroxyapatite crystals of enamel. If fluoride is present, the dissolved calcium and 
phosphate ions reprecipitate into the less soluble fluorapatite (FAP). Hydroxyl ions 
in the HAP lattice are substituted by fluoride ions as saliva is always supersaturated 
with respect to FAP (Larsen 1975). This substitution changes the mineral solubility 
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sufficiently to reduce enamel demineralisation and resist caries formation. The 
solubility product (ksp) is a critical factor in determining the thermodynamic limit for 
the onset of inorganic precipitation, When the solubility product is less than the 
activity product (AP) of a solution then precipitation will occur until equilibrium is 
reached (ksp=AP).  
 A solution is supersaturated when it contains molecules at a higher 
concentration than is normally possible under a given set of conditions. When a 
compound is at saturation there is a dynamic equilibrium between ions in the solid 
phase and ions in solution. At supersaturation, this equilibrium is shifted in the 
direction of the free ions in solution.  Supersaturation can be achieved by chemical 
reactions, temperature changes, composition changes and changes in ionic 
activities. Biological systems can fine tune ion transport to achieve the correct 
supersaturation levels for biomineralisation (reviewed by Mann, 2001). 
Supersaturation is highly regulated in biology through the process of boundary 
organised biomineralisation. The activation energy and rate of nucleation are 
determined by the interfacial energy of the critical nucleus and the level of 
supersaturation. These factors can be biologically controlled in biomineralisation 
through the evolutionary design of organic matrices and the membrane regulation 
of ion concentration gradients (Addadi et al., 1985; Currey, 1984). Biological 
systems need to regulate supersaturation levels as increases in supersaturation 
lead to decreases in nucleation activation energy and therefore an increased rate of 
nucleation. This can cause a sudden ‘runaway’ in the crystallisation process and a 
pathological deposition of mineral.  The presence of foreign particles, or a suitable 
surface, can cause increases in nucleation rates at any supersaturation level by so 
called heterogeneous nucleation. The nuclei are stabilised by attachment to these 
external substrates. Biological systems use heterogeneous nucleation and 
overcome any difficulties by regulating the activation energy for nucleation via 
interfacial interactions (Mann, 2007). 
 
1.1.3 The biology of biomineralisation 
Biomineralisation is controlled through the supramolecular organisation of 
organic templating molecules that determine the shape and size of the mineral 
deposits and the chemical mechanisms of their deposition (Weiner and Addadi, 
1991). Structural control involves the preferential nucleation of a specific crystal 
face or axis by molecular recognition at the surface of an organic matrix. 
Morphogenesis involves a patterning process that gives rise to time-dependent 
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vectorial growth. This gives control over the complex formation of biominerals. 
Higher order structures are constructed by a series of integrated processes that 
extend across a range of length scales (Mann, 2001). 
  The organic matrix provides several functions. In some cases such as bone 
and dentine,  it needs a mechanical design to provide strength and toughness for 
activity, so that the final biomineralised tissue is ‘fit for purpose’. It needs to play a 
role in mineral passivation; stabilising minerals on the matrix surface. It needs to be 
involved in mineral nucleation; controlling the location and organisation of 
nucleation sites, and the structure and orientation of the mineral crystals. Finally the 
matrix needs to be involved in spatial delineation and organisation; portioning 
microenvironments to control mineral growth. 
 Even in the simplest support systems, the incorporation of mineral crystals 
into the macromolecular framework must be able to resist compression, bending 
and tension.  Such a framework is usually designed to have the minimal amount of 
material to perform the appropriate function. There are many possible solutions to 
the actual mechanical structure of the organic matrix using this least-weight 
approximation, fine tuning of the final design will be performed by the stresses 
placed upon the matrices during and after synthesis. Matrix rigidity requires cross-
linking of strands on connecting fibres or stacks of sheets. The mineral crystals will 
provide the necessary strength and hardness making the final biomineralised tissue 
suitable for its intended use. 
The constituent macromolecules of organic matrices must be mostly 
hydrophobic. This is because they are produced in an aqueous environment and if 
they were not hydrophobic they would dissolve. However, for controlling biomineral 
nucleation, ions and hydrated species are necessary which would interact with this 
hydrophobic surface. A general model to encompass both the structural and 
functional activities of the matrix would be a structural framework of mostly 
hydrophobic molecules associated with anchored hydrophilic molecules to provide 
a nucleating surface. This model has been proposed from studies on mineralised 
extracellular tissues. Collagen, chitin and cellulose are well-documented framework 
macromolecules. Collagen in particular is key to biomineralisation in bone and 
dentine.  The acidic macromolecules are more difficult to isolate so less information 
is known about them. They are defined as acidic due to the large numbers of 
aspartic acid and glutamic acid residues present, and also threonine and serine 
residues modified with phosphate groups. The acidic macromolecules are often 
glycoproteins; proteins with covalently linked polysaccharide side chains containing 
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sulphate and carboxylic acid residues. In bone and dentine, the framework 
macromolecule is collagen, and the acidic macromolecules include the 
glycoproteins; osteopontin and osteonectin, the proteoglycans chondroitin sulphate 
and keratin sulphate, gamma-carboxyglutamic acid (Gla)-containing proteins and 
osteocalcin. In dental enamel, the major framework protein macromolecule is 
amelogenin, and the acidic macromolecule is enamelin (Mann et al., 2001). 
1.1.4 Biomineralisation in dental enamel 
Mature dental enamel is the hardest substance in the human body due to its 
high mineral content (over 95% by weight) and it is a highly organised structure. 
The formation of enamel, the process known as amelogenesis, is the result of a 
highly orchestrated series of extracellular processes that control the nucleation, 
growth and organisation of forming mineral crystals. Vertebrate biomineralised 
tissues, such as tooth enamel, dentine, cementum and bone, all contain crystalline 
mineral with a similar chemical composition and atomic structure to hydroxyapatite 
(Margolis et al., 2006). 
 Biomineralisation in dental enamel obeys the underlying laws of chemistry 
and depends on the precipitation of the calcium phosphate mineral salts from 
biological fluids, supersaturated with respect to the mineral phase, followed by a 
period of subsequent crystal growth. As described previously this process is 
thought to be initiated and controlled by the extracellular matrix proteins. The ECM 
is presumed to provide the required stereochemical template that provides the initial 
nucleation site for mineral deposition whilst also serving to regulate and direct any 
subsequent crystal growth occurring (Addadi and Weiner, 1985).  
Dental enamel, the main focus of this thesis, is unique in that the ECM is not a 
collagenous matrix like in bone, dentine and cementum but a specialised enamel 
matrix which orchestrates the process of enamel formation. The unique nature of 
the developing enamel proteins is reflected in the mature tissue itself as enamel is 
the most highly mineralised tissue in mammalian biology and in contrast to other 
mineralised tissues; it is acellular and cannot be naturally remodelled. It is assumed 
that enamel biomineralisation can act as a paradigm for biomineralisation in general 
(Currey, 1984; Mann, 2001).  
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1.2 Structure and composition of the tooth. 
1.2.1 Overview of the structure of the tooth 
 The developing tooth is a useful tool for investigating the underlying 
processes involved in biomineralisation in mammalian systems.  Biomineralisation 
in the tooth, as in all skeletal tissues, involves the ordered deposition and controlled 
growth of inorganic crystals on organic protein matrices to form tissues with 
specialised structures and functions. There are a number of components to human 
teeth that are ideal to for these investigations. Teeth comprise of three distinct 
mineralised tissues; enamel, dentine, and cementum, together with the non-
mineralised pulp tissue (figure 1).  
 
Figure 1.  Diagram of the normal tooth (molar) showing the crown, root and 
gingival margin. (Ten Cate, 1998). 
 
Enamel, the most highly mineralised tissue in the mammalian body, covers 
the crown, the exposed surface of the tooth and provides a hard surface for biting 
and chewing. Dentine, located underneath the enamel layer, is less mineralised 
than enamel but is a useful paradigm for bone construction. Dentine has tiny tubes 
(dentinal tubules) running from the pulp cavity outwards which are filled with the 
odontoblast processes. The dentinal tubules are also involved in pain sensation. 
Their exposure results in tooth sensitivity.  In the centre of the tooth is the pulp 
cavity, which houses the dental pulp. The pulp is a soft tissue organ which includes 
the blood vessels to supply the tooth with nutrients to keep it alive, and nerves 
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which sense pressure and pain. The cementum covers the root dentine in the jaw 
and provides anchorage for the periodontal ligament to keep the tooth in place. 
(Bosshardt and Nanci, 1997; Berkovitz et al., 2009). 
Though not part of the tooth, the periodontum consists of several different cell 
types, namely fibroblasts (cells that secrete the extracellular matrix and collagen of 
connective tissues), cementoblasts (cells that secrete cementum at the root of the 
tooth), osteoblasts (cells that secrete bone tissue), osteoclasts (cells that resorb 
bone tissue), macrophages (immune cells that engulf cell debris and foreign 
particles) and epithelial cells (cells that form the soft tissues). It is a connective 
tissue comprising of collagen, proteoglycans, glycoproteins and oxytalan (pre-
elastin). The extracellular matrix (ECM) of the periodontum consists mainly of fibrils 
of type I collagen, typical of most soft connective tissues.  The fibroblast cells 
secrete and degrade this ECM.  Between the collagen fibrils is a ground substance 
composed of the proteoglycans, glycoproteins and other minor components. Islands 
of epithelial cells can be found within the periodontum. These are known as the ‘cell 
rests of Malassez’ and are remnants of the development processes of the tooth root 
(Ten Cate,  1998). 
The development of the tooth is a multi-stage process during which teeth form 
from embryonic cells, and following the process of odontogenesis, erupt into the 
mouth. Many diverse species have teeth and the underlying processes for tooth 
development are largely conserved across all species. Enamel, dentine and 
cementum must all develop during the appropriate stage of development for healthy 
teeth. In humans, primary teeth start to form between 6 and 8 weeks in utero and 
the permanent dentition begins to form in the 20th week (Ash et al., 2003). 
 The tooth bud is an aggregation of cells, also referred to as the tooth germ, 
that eventually forms the tooth. The tooth bud consists of 3 parts; the enamel organ, 
the dental papillae and the dental follicle. The outer enamel epithelium, the inner 
enamel epithelium, stellate reticulum and the stratum intermedium all work together 
to make up the enamel organ. The inner enamel epithelium cells eventually form 
the ameloblast cells which secrete the enamel matrix proteins. The growth of the 
cervical loop cells into the surrounding tissues forms the Hertwig’s epithelial root 
sheath (HERS) which determines the shape of the tooth root. The dental papillae 
encompass cells that eventually form the odontoblasts cells, the cells that form 
dentine. The junction between the dental papillae and the inner enamel epithelium, 
the dentine-enamel junction (DEJ) determines the shape of the crown. The dental 
follicle gives rise to the cementoblast cells that form the cementum of the tooth, the 
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osteoblast cells that form the alveolar bone around the roots, and the fibroblast cells 
that form the periodontal ligament. The cementum overlays the radicular dentine. 
The periodontal ligament connects the tooth to the alveolar bone (Ten Cate, 1998). 
A histological slide of the tissues and cells in a rabbit molar is shown in figure 2. 
Dentine
Pulp
Ameloblasts
Epithelium
Enamel
Artifactual spaces
Enamel
Ameloblasts
 
Figure 2. Histology of developing tooth with enamel, dentine, ameloblasts, 
and pulp labelled. Tooth bud is in maturation/crown stage.  Section of a 
non-erupted rabbit molar stained with H&E to show different tissue 
types. 
 
1.2.2 Overview of enamel composition and structure 
Mature tooth enamel covers the visible parts of the erupted tooth in the mouth. 
It is not present on the roots of the teeth. Physically, tooth enamel is very hard and 
brittle. It relies on the underlying dentine for resilience. The microstructure of 
enamel has evolved to prevent fractures and shear within it. Enamel is translucent 
and the colour of the tooth is dictated by the dentine. Teeth appear to yellow with 
age due to the thinning of the enamel through wear allowing more of the dentine to 
be visible. Chemically, mature enamel is composed of 96-99% by weight 
hydroxyapatite mineral (Ca10(PO4)6OH2), a naturally occurring form of calcium 
apatite, with 3% water and 1% organic matter (non-collagenous protein) 
(Lowenstam and Weiner, 1989). The apatite minerals are a group of phosphate 
minerals formed and utilised in biological systems, defined by their high 
concentrations of OH- ions (hydroxyapatite), F- ions (fluoroapatite) or Cl- ions 
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(chloroapatite) in the mineral crystal (Boivin 2007). Hydroxyapatite is the same 
mineral found in bone and dentine, although the hydroxyapatite crystals in enamel 
are much larger, elongated and less carbonated (Daculsi et al., 1984). The mineral 
content of dentine and bone is less at 65-70% by weight (Goldberg et al., 2011).  
The composition of enamel is variable, between and within teeth, due to 
developmental factors and the effects of exposure in the mouth. Minor constituents 
of mature enamel typically include 3.0% w/w carbonate, 0.4 % w/w chloride, 0.2 % 
w/w magnesium, 0.01 % w/w fluoride and other trace elements (Elliot et al., 1994). 
The exact composition can vary with depth within the tissue. For example, from the 
surface towards the enamel-dentine junction, there is an increase in carbonate and 
magnesium concentration that parallels a decrease in crystallinity (Legfros et al., 
1996,). The concentration of fluoride, in contrast, is highest at the enamel surface 
and declines extremely rapidly with depth (Hallsworth and Weatherell, 1969). 
Margolis and Moreno (1990) calculated that up to 26% of hydroxyl ion sites are 
substituted by fluoride at the outer enamel surface. Developing enamel contains a 
high proportion of proteins which are progressively removed as the tissue matures, 
with the protein content dropping from approximately 20% in the developing enamel 
(Eastoe 1964) to less than 1% (Robinson et al., 1981; Simmer and Fincham, 1995) 
weight for weight. Fluoride is readily incorporated into hydroxyapatite, stabilising the 
lattice and reducing the solubility of the mineral phase (Cooper and de Leeuw, 
2004). 
It is difficult to accurately determine the percentage of water in enamel and its 
distribution between the mineral and organic phases. The mean values of these are 
usually given as 95% weight  and 86% volume (Angmar et al., 1963), but have 
more recently been recalculated as 98% weight  and 96% volume (Elliott et al., 
1998). Water within enamel provides the medium for diffusion of ions in de - and re 
–mineralization, therefore knowledge of the volume fraction is fundamentally 
important. At the start of a caries lesion forming, there is a preferential loss of 
carbonate (Hallsworth et al., 1973) and magnesium (Hallsworth et al., 1972). 
Increased fluoride concentration is found in caries lesions (Hallsworth and 
Weatherell, 1969), with variably elevated levels (maximum detected 21,700 ppm) in 
the surface zone (Pearce et al., 1995). In mature enamel, magnesium-containing 
whitlockite crystals, identified by SEM and electron probe microanalysis, found in 
lamellae have been associated with dissolution and reprecipitation of mineral in 
caries (Kodaka et al., 1992).   
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Figure 3. SEM of bovine enamel showing the arrangement of prismatic and 
interprismatic enamel. Prisms are in transverse section. (Image provided 
by S.J. Brookes). 
In humans, the distinction between prismatic and interprismatic enamel is not 
as clear as in bovine enamel (figure 3), with the apical surfaces of the prisms being 
continuous with the apical surfaces of the interprismatic enamel. 
 In rodent incisor enamel, the prisms decussate with interprismatic enamel 
weaving between the ordered layers of prismatic enamel (figure 4). This structural 
difference may allow the rodent incisors to fracture at the biting edge along 
controlled fracture planes corresponding to the rows of decussating prisms running 
transversely across the incisor such that a sharp chisel like biting edge is 
maintained by wear. 
 
 Figure 4.  Scanning electron microscopy (SEM) image of mouse enamel 
showing prism decussation. 
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The developing hydroxyapatite crystals forming the prismatic and 
interprismatic enamel appear to have a roughly hexagonal cross-section (figure 5) 
with a width of 60-90 nm, thickness of 25-30 nm and a length that may span the 
entire enamel thickness unbroken (Arends & Jongebloed 1978; Kerebel et al., 
1979).  
 
Figure 5. Transmission electron microscopy (TEM) image of rat enamel 
crystals in exhibiting am hexagonal cross section. The crystals far left 
are visualised in longitudinal section (image provided by S.J. Brookes).   
 
That said, enamel crystal morphology is disputed and the hexagonal shape 
apparent when viewing enamel sections using TEM may be a shadowing artefact 
created by sections taken through rectangular crystals  In any event, the 
hydroxyapatite crystals of mature enamel tend to be less regular in appearance as 
they keep growing to fill all the available space and may have undergone repeated 
episodes of de- and  re-mineralisation though the crystals are still arranged into 
prisms (Warshawsky et al., 1987). 
The enamel forming ameloblasts secrete a proteinaceous extracellular matrix 
(ECM) on the dentine surface, and as they migrate away from the dentine the 
enamel matrix left behind partially mineralises with immature hydroxyapatite 
crystals which grow lengthwise in pursuit of the retreating ameloblasts  (Garant, 
2003).  The amount of ECM secreted therefore defines the thickness of the mature 
tooth enamel. Enamel secretion is associated with circadian rhythms resulting in 
regular, daily cross-striations with a 5 µm periodicity in humans (Fitzgerald and 
Verveniolis, 1998). When viewed microscopically, these cross-striations run parallel 
to the long axis of the tooth. Many researchers have stated that these cross-
- 31 - 
striations are a result of the metabolic activity of the ameloblasts over 24 hour 
periods (Risnes, 1986; Dean, 1987, 1989; Boyde 1989, 1990). Experiments using 
lab primates of known ages injected with markers have shown good correlation of 
the cross-striations with circadian rhythms and therefore a potential tool for 
determining age from crown formation (Mimura, 1939; Bromage, 1991; Dean, 1998; 
Smith, 2006), Despite this evidence, other researchers have claimed these 
correlations to be nothing more than a fluke and a source of error in determining 
age from teeth (Warshawsky et al, 1984; Mann et al., 1990). Analysis of the teeth 
from 5 children exhumed from a 19th Century London crypt was performed by 
Antonine et al., 2009. The age of the children was known but kept from the 
researchers. Microscopic analysis of the permanent dentition of the children 
showed that the formation of the cross-striations do follow circadian rhythms in the 
ameloblast cells, allowing the ages of the children to be correctly identified. 
There are also less frequent incremental striations, the Striae of Retzius (SR), 
which appear as brown lines in the enamel when viewed microscopically. Where 
the SR terminate on the enamel surface, pits appear known as perikymata (Beynon 
and Dean, 1988).  These are most noticeable on the surface enamel of canine 
teeth, and become less visible as the enamel is worn and smoothed. These 
grooves and pits have been used to try to determine times of crown formation, 
enamel growth patterns and even used in archaeology to try to determine the age 
of a human at death (Reid et al., 1998; Antoine et al., 2000; Reid and Ferrell, 2005). 
The SR appear at regular intervals, similar to the daily cross-striations, signifying 
changes in the ameloblasts activity. However, darker banding may occur when 
significant stress of illness has occurred, implying that the SR may also be affected 
by physiological strains, similar to the Andresen lines in dentine (Dean and 
Scandrett, 1996). 
Mature enamel can resist acid attack due to the lack of organic material 
(Weatherall, 1975).  This removal of the organic matrix leaves a strong, tough, 
inorganic surface for mastication, but also means that lost enamel tissue cannot 
regenerate as the ameloblasts completely disappear once the enamel has matured 
and erupted (Sasaki and Garant, 1986). In the mouth, the surface of enamel is in a 
constant flux of demineralisation and remineralisation. Consumption of acidic food 
or beverages such as fruit, juices and carbonated beverages or the presence of 
plaque acids produced by bacterial metabolism cause a reduction in mineral density 
due to demineralisation within the outer surface of the enamel. This can lead to 
erosion and caries respectively. The saliva contains mineral ions at supersaturated 
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levels and can remineralise the outer surface of enamel to some extent though lost 
tissue cannot be replaced (Ten Cate and Duijusters, 1982). 
Once the ameloblasts stop secreting ECM, the ECM in the enamel is removed 
by proteases, creating space for the immature HAP crystallites to undergo 
secondary mineralisation and grow in width and  thickness until the space is largely 
occluded by mineral (Bartlett et al., 2003). This is described in more detail later 
(See section 1.3.4) 
1.3 Tooth development 
1.3.1 Embryological origins 
Teeth are ectodermally-derived organs, similar to hair, nails, scales and 
feathers, whose development relies on epithelial-mesenchymal interactions 
mediated by conserved signalling pathways present in other tissue developmental 
processes. Teeth develop as a combination of ectoderm and mesenchyme based 
upon continuous and dynamic reciprocal signalling interactions (Pipsa and Thesleff, 
2003). The development of most ectodermal organs begins in the same way, with a 
thickening of the epithelium. This is the initiation stage, where in teeth, the dental 
placode forms. The epithelium then buds into the mesenchyme and neural-crest 
derived mesenchyme condenses around the epithelium. This is known as the bud 
stage. Many ectodermally-derived organs share similarity at the bud stage, with 
specificity elicited at the transition in the next stage (Jernvall and Fortelius, 2000). 
The inside of the tooth bud contains the stellate reticulum cells that secrete 
glycoaminoglycans (GAGs). As the GAGs are secreted, water is drawn in between 
the cells, stretching them apart. Cells of the stellate reticulum maintain contact with 
one another via desmosomes, giving them their unique star-shaped appearance as 
they are stretched apart (Yildirim, 2013). In teeth, the next stage is known as the 
cap stage. The cap is formed by growth and folding of the epithelium 
(Koussoulakou et al., 2009). Here the cervical loop is formed which will form the 
stem cell niche in continuously growing teeth, or the Hertwig’s epithelial root sheath 
(HERS) in teeth with limited growth. The inner enamel epithelium (IEE) is formed 
inside the cap bordering the dental papillae, and consists of a layer of columnar 
cells. The outer enamel epithelium (OEE) covers the outer part of the cap and is a 
layer of cuboidal cells located on the periphery of the enamel organ (Marson et al, 
2005). The next stage is the bell stage where more extensive growth and folding of 
the dental epithelium occurs. This folding corresponds to the final cusp pattern of 
the teeth, determining the function of the tooth. The stratum intermedium is a layer 
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of 2 to 3 cells in thickness between the inner enamel epithelium and the stellate 
reticulum. It is first seen early in the bell stage, at approximately 14 weeks in utero.  
The ameloblast cells differentiate from the IEE and the odontoblasts differentiate 
from the dental papillae. This differentiation is regulated by epithelium and 
mesenchyme interactions (D’Souza, 2002, Nanci, 2008,). At this stage, all 
structures are still part of the crown.  The roots are formed during post-natal 
development. The cervical loops undergo structural changes, where the HERS 
fragments into a fenestrated network of epithelial cells named the Epithelial Rests 
of Malassez (ERM).  See figure 6 for an overview of tooth embryological 
development.  
 
Figure 6.  Diagram of the different stages of tooth development. The initiation, 
bud, cap and bell stages are shown with the involvement of the different 
tissue and cell types at each stage. 
 
Defining these stages of tooth development is an attempt to describe changes 
that actually occur along a continuum. Development is not really divided into 
developmental “snap shots” and so it can be difficult, even histologically, to identify 
which stage of development a tooth is in. The dental papilla consists of the 
condensed ectomesenchymal cells, and is separated from the enamel organ by the 
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basal lamina. The dental follicle covers the enamel organ and dental papilla, and 
the dental follicle, dental papilla and the enamel organ are collectively known as the 
tooth germ.  The dental papilla is the source of the pulp in a tooth, and the dental 
follicles differentiate to produce the odontoblasts cementoblasts, osteoblasts and 
fibroblasts (Yildirim, 2013).  
 
1.3.2 Overview of amelogenesis 
As described in the previous section, the development of the tooth requires 
epithelial – mesenchymal interactions, reciprocating between the differentiating 
odontoblasts of the dentine and the differentiating ameloblasts of the enamel organ 
(Ruch et al., 1995). The process whereby the ameloblast cells form the tooth 
enamel is known as amelogenesis and this section will describe that process. 
Ameloblasts only become fully functional after the first layer of dentine has formed 
and in turn it has been hypothesised by Nanci, 2008, that the ameloblasts may 
secrete growth factors or other proteins that influence the terminal differentiation of 
the odontoblast cells, possibly by interactions with the basement membrane. 
During amelogenesis, ameloblasts pass through discrete development stages 
that correlate with the various stages of enamel formation. This occurs in 3 stages; 
the secretory stage, the transition stage, and the maturation stage. 
 
1.3.3 The ameloblasts and amelogenesis 
The ameloblast cells secrete extracellular enamel matrix proteins, such as 
amelogenin, enamelin and ameloblastin, which mineralise to form enamel (Simmer 
et al., 2010). The ameloblast cell morphology is changeable and dependent upon 
the stage of activity the cell is in. The ameloblast cell in the secretory stage is 4 µm 
in diameter and 70 µm in length while the ameloblast cell in the maturation stage is 
approximately 40 µm in length (Reith 1970). The secretory end of the ameloblast 
cells ends in a 6-sided pyramidal projection known as the Tomes’ process, giving 
the ameloblast cells in the secretory stage a hexagonal appearance (Avery 2011). 
The angulation of the Tomes process determines the orientation of the enamel 
prisms. The ameloblasts form as a single layer on the newly formed dentine layer 
and progressively move away from the dentine, secreting enamel proteins into the 
space they leave behind as they progress. The ameloblast cells control the ionic 
and organic composition of the enamel by adjusting their secretory and resorbative 
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activities to maintain favourable conditions for biomineralisation (Berkowitz et al., 
2009). 
Once the first layer of dentine is formed, it induces the adjacent 
preameloblasts to complete their differentiation into ameloblasts and secrete 
enamel. The secretory ameloblasts are polarised, tall, columnar cells with Tomes’ 
processes (conical shapes processes) at their distal ends. Tomes’ processes 
interdigitate with the surface of the forming enamel giving it a picket fence 
appearance (Warshawsky et al., 1987). The Tomes’ processes determine the 
orientation of the newly formed (nucleated) enamel hydroxyapatite crystals. The 
organelle content of the secretory ameloblasts is mainly protein synthesising 
organelles such as the Golgi complex and granular Endoplasmic Reticulum. 
Plentiful mitochondria and secretory granules are also present. Junctional 
complexes, tight junctions and desmosomes are present at the distal and proximal 
ends of the ameloblasts. Desmosomes and gap junctions are also present at the 
ameloblasts lateral surfaces. Towards the end of the secretory stage, the Tomes’ 
processes are lost, and the last formed layers of enamel are prismless accordingly 
(Smith 1998). When ameloblasts are forming new enamel, their Golgi apparatus is 
extensive and occupies much of the supranuclear compartment (Nanci et al., 1993; 
Smith and Nanci, 1996). The secretory granules are directed to two spatially 
separate secretory sites, located on the Tomes’ process, an apical extension. Here 
they release their contents constitutively to build up interprismatic and prism enamel 
(Nanci and Warshawsky, 1984).  
It has been postulated that amelogenesis occurs in 5 distinct phases. Phase 1 
is the secretory stage. Here the enamel proteins are synthesised, secreted and 
become partially mineralised (nucleation of the crystals, approximately 30% 
mineralised). Unlike other mineralised tissues such as bone or dentine, there is no 
non-mineralised ‘pre-enamel’ (Hu et al., 2007). The crystals are elongated but 
extremely thin in width and thickness and are supported by the matrix. During this 
stage the metallomatrix proteinase 20 (MMP-20) is co-secreted  which process the 
enamel proteins to generate a complicated spectrum of discrete processing 
products. At some point protein secretion all but stops and the ameloblasts cease 
their migration. It has been hypothesised that the ameloblasts spend approximately 
300 days in the secretory stage before moving into the maturation stage (phase 5) 
and begin degradation (Hillson, 1986). 
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Phase 2 is the assembly of amelogenin into nanospheres (covered in section 
1.3.4.1.2) and phase 3 is the subsequent formation of elongated ribbon like 
crystallites (section 1.3.4.1.2). 
Once the dental enamel reaches its full thickness, the ameloblasts enter a 
brief transitional stage. Their height is decreased, by approximately 50% to 40µm, 
and protein synthesising organelles are dramatically reduced in number (Smith and 
Nanci, 1996). The Tomes’ processes are also removed (Reith, 1970).  Many 
lysosomes and autophagic vacuoles are also present. The transition stage is 
characterised by a reduction in the ameloblast numbers, by as much as 50%, via 
apoptosis. Ameloblast morphology also changes, from that of secretory cells to that 
of one similar to epithelial cells involved in ion transport (Smith, 1998). This is the 
fourth phase and is characterised by the resorption of the organic matrix and its 
replacement with fluid. 
 The fifth phase is the maturation stage and is characterised by the loss of 
enamel ECM proteins and water, and by a massive influx of calcium and phosphate 
mineral ions, which provide for growth of hydroxyapatite crystals (96% 
mineralisation) (Berkowitz et al., 2002)..  Ameloblasts now begin to secrete catalytic 
amounts of the serine protease kallikrein-4, which quickly degrades residual matrix 
proteins leaving behind the crystal architecture previously ‘sketched out’ in the 
secretory stage bathed in fluid (enamel fluid) (Tanabe, 1984). At the beginning of 
the maturation stage the crystals occupy about 30% of the tissue volume but the 
ameloblasts begin pumping mineral ions into the enamel fluid which promotes 
growth in width and thickness of the crystals until they eventually occlude more than 
90% of the tissue volume in readiness for the tooth to erupt into the mouth 
(Robinson and Kirkham, 1986). Ultimately the ameloblasts atrophy and the cellular 
layer is lost entirely from the mature erupted tissue (Kim et al., 2008). Thus, 
throughout amelogenesis, ameloblast cells control the ionic and organic 
composition of the enamel by adjusting their secretory and resorbtive activities to 
maintain favourable conditions for biomineralisation (Berkovitz  et al., 2009).  The 
maturation stage is the phase where most mineralisation occurs, thought he exact 
timings and mechanisms in the process are not yet fully defined due to complexity 
of amelogenesis (Suga, 1989). 
Unlike collagen based calcified tissues, such as bone, enamel matrix proteins 
are almost completely degraded by extracellular enzymes (Smith, 1998). This 
means that enamel achieves its high mineral content through a maturation process. 
The ameloblasts alter between two phenotypes depending on the morphology of 
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their distal ends. Numerous microvillae in the ameloblasts distal ends form either a 
ruffled end (RE), or an even, straight edge (SE). In the rat incisor, 60% of 
maturation ameloblasts are found in the ruffle-ended morphology, 20% are in the 
smooth-ended form, and twenty percent are transitionary (Takano, 1995). The 
extracellular fluid related to the RE ameloblasts is acidic (as low as pH 5.8). The 
extracellular fluid in enamel related to the SE ameloblasts is of more neutral pH (pH 
7.2). In rodent incisors, the SE ameloblasts are only present for a short duration 
(20% of cycle time), before they recreate the RE form. Some mammals have three 
cycles per day (RE – SE – RE, every 8 hours) (Avery, 2002). These two 
morphologies are grouped into alternating bands during maturation. 
Ameloblasts lose their differentiation and become short, cuboidal cells which 
form a multi-layered structure with other layers of the dental organ, known as the 
reduced enamel epithelium (Sasaki, 1984). This structure remains on the surface of 
the newly formed dental enamel until the tooth erupts into the mouth. The reduced 
enamel epithelium separates the enamel from the dental sac, protecting it from 
contact with connective tissues in the dental sac. If contact between the newly 
secreted enamel and the dental sac accidentally occurs, the enamel can be 
resorbed at the contact area resulting in pitting, or the dental sac cells differentiate 
into cementoblasts and secrete cementum on the enamel surface. The reduced 
dental epithelium and the oral epithelium jointly form the dentinogingival junction 
(DGJ) of the erupting tooth. 
The complete removal of the ECM in mature enamel is an interesting 
conundrum in itself. Is it possible that the enamel proteinases are so efficient that 
they remove all but a few very short peptides of the ECM to allow almost complete 
mineralisation of the enamel? It has been proposed that the ameloblast cells 
remove the enamel matrix as efficiently as they secrete it. It is likely that the 
processes of diffusion, pinocytosis and endocytosis cooperate to remove the ECM 
during enamel biomineralisation. 
There is great variation between animal models with regards to enamel 
formation therefore a precise model for human enamel formation remains elusive 
(Boyde 1997). SEM, X-ray crystallography and position sensitive synchrotron X-ray 
diffraction of archeological human tooth samples at varying stages of enamel 
maturation have shown an inverse correlation between mineral content distribution 
and variations in crystallographic parameters as a function of maturation time. 
Mineral density homogeneity increases as the enamel matures while the 
crystallographic parameters are heterogeneous even in fully mature enamel. The 
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rate of mineral formation and mineral organisation are not equal in enamel. Full 
mineralisation of the enamel layer occurs earlier on maturation while the 
organisation of the crystallites is a slower process and continues for longer 
(Simmons et al., 2013). 
1.3.4  Enamel matrix proteins 
To recap, the enamel ECM consists of several different proteins, including the 
major ECM proteins amelogenin (approximately 90%), ameloblastin and enamelin 
and the minor ECM proteins including amelotin, the tuft proteins, sulphated 
proteins, biglycan, and the proteases enamelysin (matrix metalloprotease -20 – 
MMP-20) and kallikrein-4 (KLK-4) (Smith, 1998; Nanci, 2008). 
Historically, the ameloblasts have been described as secreting two broad 
categories of ECM proteins; the amelogenins and the non-amelogenins (reviewed 
by Hu et al., 2005). The importance of the enamel matrix proteins in enamel 
development has been shown through a series of genetic studies.  Both transgenic 
mice expressing mutated amelx (Paine et al., 2001, 2003) and amelx knockout 
mice (Gibson et al., 2001) exhibit major enamel structural defects resulting in 
reduced enamel thickness and altered prism structure. Identification of point 
mutations in enamelin and ameloblastin in amelogenesis imperfecta and gene 
knockout studies of  enamelin and ameloblastin have shown that both are essential 
for enamel development (Fukumoto et al., 2004; Masuya et al., 2005; Poulter et al., 
2014a and b). 
1.3.4.1 Amelogenin 
Developing tooth enamel contains about 30% protein by volume (Fukae et al., 
1983) of which amelogenins comprises 90% (Hammarstrom 1997). The amelogenin 
gene exists on human X (AMELX) and Y (AMELY) chromosomes. AMELX and 
AMELY are  86% homologous and contain 7 exons though AMELX is expressed at 
levels 10 fold higher than that of AMELY (Salido et al., 1992).  
To complicate matters, the amelogenin gene is subject to alternative mRNA 
splicing which generates several nascent amelogenins molecules that can be 
translationally modified by phosphorylation at serine 16 (they are not glycosylated) 
(Fincham et al., 1998). Most of the alternatively spliced variants are produced in 
small amounts (Bartlett and Simmer, 1999) and their significance remains unclear. 
Further heterogeneity is generated by extracellular proteolytic processing of 
nascent amelogenins by MMP-20 immediately following their secretion into the 
matrix. This produces a range of smaller proteins and peptides that form the bulk of 
the developing matrix.  Full-length nascent amelogenin can be found in plenty in the 
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newly secreted, outermost enamel layer. Processing of the amelogenin results in 
smaller fragments being present in the older, deeper enamel layers (Fukae et al., 
1980). 
Newly secreted amelogenin has a molecular weight of 16-20 kDa (Smith and 
Nanci, 1996) depending on the species and the alternatively spliced isoform in 
question. SDS-PAGE studies show the molecular size to be higher than it actually 
is due to the high proline content (Termine et al.,1980). Using terminology based on 
relative molecular weights determined by SDS-PAGE, the newly secreted major 
amelogenin molecule prior to any processing is referred to as the ’25 kDa parent 
amelogenin.’ An alternative nomenclature for amelogenins is to use a prefix such as 
P for pig, M for mouse etc. and then a number corresponding to the number of 
amino acids contained in the protein. So, P173 would be the full length parent pig 
amelogenin of 173 residues. The corresponding mouse amelogenin would be M180 
(mouse amelogenin contains an extra 7 amino acids). 
Amelogenin primary structure consists of three domains:- 
1) a highly conserved amino terminal sequence of 44-45 amino acids, that 
comprise the tyrosine rich amelogenin peptide (TRAP) containing 6 tyrosine 
residues, with 3 in the ATMP region 
2) a central hydrophobic core of 100-130 residues rich in leucine, proline, 
histidine and glutamine 
3) the amelogenin carboxyl-terminal peptide (ACP) which ends with the acidic 
hydrophilic teleopeptide sequence of 13 amino acids – WPATDKTKREEVD 
 
 Most of the 25 kDa parent amelogenin amino acid sequence (derived from 
cDNA and direct protein sequencing) for human, bovine, porcine, murine and rat is 
highly conserved between species (Lyngstadaas et al., 1990). This suggests great 
functional importance. There are additional residues present in the bovine x-linked 
amelogenin in exon 6, which appear to be derived from tandem duplication of DNA 
within exon 6 (Bonass et al., 1994). The 25 kDa parent amelogenin is the major 
amelogenin present in the outer secretory stage enamel (Fukae et al., 1980; Aoba 
et al., 1992A).  
In pig, the 25 kDa parent amelogenin (P173) is rapidly degraded to give a 
range of products; these are shown in figure 7. Firstly, the C-terminal teleopeptide 
of 12 amino acids is cleaved, leaving a 23 kDa amelogenin of 161 residues (P161) 
(Yamakoshi et al., 1994). 
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  With time the 23 kDa P161 amelogenin is processed from the C-terminal to 
give the 20 kDa P148 (Fukae et al., 1983; Aoba et al., 1992B; Yamakoshi et al., 
1994). The 20 kDa amelogenin accumulates in the deeper enamel layers and 
appears much more stable than the 25 kDa P173 parent or 23 kDa P161 
amelogenin, neither of which is present in the deeper enamel layers (Aoba et al., 
1987A, B, C; Aoba et al., 1992A, B). The 20 kDa amelogenin accumulates within 
the tissue during the secretory stage so we can conclude that its breakdown must 
be fairly slow. Further cleavage occurs between residues 45 (Trp) and 46 (Leu), 
forming a 5 kDa tyrosine-rich amelogenin peptide (TRAP – residues 1-45) (Fincham 
et al., 1981; Yamakoshi et al., 1994) and a larger 13 kDa peptide (residues 46-148) 
(Tanabe 1984;  Aoba  et al., 1987C). The TRAP sequence is highly conserved and 
contains an N-acetyl glucosamine binding motif that may be functionally important 
(Ravindranath et al., 1999). This domain contains 3 tyrosine residues and is also 
known as the amelogenin tri-tyrosyl motif peptide (ATMP) and will be discussed 
separately later. An alternative processing route for P148 involves cleavage 
between residues 62 and 63 which produces an “extended TRAP” (residues 1-62) 
and an 11 kDa fragment (residues 63-148). Both the 11 and 13 kDa fragments are 
extremely soluble (in complete contrast to the other amelogenin fragments) and are 
thought to diffuse out of the developing matrix. Further processing of the TRAP is 
likely as several peptides with molecular weights lower than TRAP have been 
discovered in developing bovine enamel (Brookes et al., 1995).  
 The porcine amelogenin breakdown has been described here as porcine 
material has been used extensively by researchers in the field of enamel biology 
due to its relative abundance compared to human and rodent material. 
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Figure 7.  Extracellular processing of porcine 25 kDa amelogenin, 
showing the breakdown to 23 kDa and 20 kDa daughter proteins, and the 
further processing via the major and minor routes that generate TRAP 
and low molecular weight fragments (adapted from Brookes et al., 1995) 
 
1.3.4.1.1 The importance of the amelogenin ATMP domain 
The ATMP is found at the C-terminus of the TRAP and comprises of amino 
acids 33-45 of the full length parent amelogenin. The importance of the highly 
conserved 13 amino acid ATMP region of amelogenin has been investigated by 
Ravindranath et al. in a series of studies (1999, 2000, 2001, 2003, and 2004). The 
sequence consists of the amino acids PYP SYG YEP MGGW. In their initial study, 
Ravindranath et al. (1999) demonstrated the lectin-like activity of amelogenin by its 
ability to bind N-acetyl-D-glucosamine (GlcNAc) in a dose dependent fashion. 
Lectins are proteins that specifically bind (or cross-link) soluble carbohydrates or 
carbohydrate moieties. Lectins are involved in cell adhesion and have no apparent 
catalytic activity.  
Ravindranath et al. (1999) tested 2 recombinant amelogenins and 6 synthetic 
peptides. The recombinant murine amelogenins were rM179 full length murine 
amelogenin and rM166 murine amelogenin lacking the ACP sequence. The 
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synthetic peptides were TRAP (contains ATMP), LRAP (does not contain ATMP; 
LRAP is the leucine rich amelogenin peptide, and one of the amelogenin splicing 
isoforms that lacks the ATMP sequence due to alternative splicing of amelogenin 
mRNA), ACP, ATMP, T-ATMP (where the third proline of ATMP is mutated to 
threonine (T)) and F-ATMP (where all three tyrosines of ATMP are mutated to 
phenylalanine (F)).  Ravindranath et al. (1999) showed that rM179, rM166 and 
TRAP all exhibited lectin-like behaviour but LRAP and ACP did not. This confirmed 
that the lectin-like activity is located in the ATMP domain. The synthetic ATMP also 
bound to GlcNAc, but was unable to do so if the third proline was mutated to 
threonine (T-ATMP) or if all three tyrosines were mutated to phenylalanine The 
mutation of the third proline to threonine mimics a point mutation seen in human X-
linked AI (Collier et al., 1997) and more importantly for the work presented here, the 
first of the 3 tyrosines is substituted for histidine in the Y64H amelogenin mutation 
carried by the mice studied in this thesis. 
 The hypothesis of this inaugural paper was that amelogenins exhibit lectin-
like behaviour and bind to the sugar residues of enamel matrix glycoproteins 
(EMGs) at the DEJ to facilitate biomineralisation. This could imply a co-chaperone 
role for the EMG’s during amelogenin secretion, or a EMG chaperoning of 
amelogenin to the site of amelogenesis.  
  ATMP has 50% sequence homology with the lectin wheat germ agglutination 
(WGA) i.e.:  
 ATMP = PYP SYG YEP MGGW 
 WGA =  CCS QYG YCG MGGD 
WGA is a lectin that binds tightly to GlcNAc (Peters et al., 1979; Wright, 
1984). Intrapeptide tyrosyl residues (Y) in WGA have also been implicated in sugar 
binding (Wright, 1984). The ATMP region also shows sequence similarity to the 
GlcNAc binding domain of the lectin UEA-II (Yamamoto et al., 1990). In contrast to 
WGA and VEA-II which have multiple sugar binding sites, amelogenin only has the 
single putative binding site (ATMP).  In the follow up paper, Ravindranath et al. 
(2000) hypothesised that amelogenins may interact with peptides that mimic the 
sugar GlcNAc (GlcNAc mimicking peptides, GMPs). The GlcNAc binding motifs of 
several lectins recognise and bind to specific GlcNAc mimicking peptides found in 
cytokeratins (Shikhman et al., 1994). The GMP sequence SFG-SGF-GGY is found 
in the N-terminal region of cytokeratins 14, 16 and 17.  Dosimetric binding of [3H] 
GMP to amelogenin rM179 and rM166 and TRAP was exhibited when the full 
length amelogenin was degraded to TRAP the ligand preference of the ATMP 
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changed from GlcNAc to GMP. The binding of GMP to TRAP was shown to be 20 
fold stronger than the binding of GlcNAc, suggesting that GMP is the preferential 
binding ligand of TRAP. This suggests that proteolytic degradation of amelogenin 
may modulate its lectin-like GMP binding properties.  Cytokeratin 14 (exhibiting a 
GMP in its N-terminal) is synthesized by ameloblasts prior to amelogenin synthesis 
and is seen as a marker for ameloblasts in the developing tooth (Tabata et al., 
1996). The GMP sequence in cytokeratin 14 has been shown to bind to 
amelogenin, and could be a possible candidate for interactions with amelogenins 
during amelogenesis (Ravindranath et al., 2000). However, cytokeratin 14 has not 
been identified in the extracellular matrix so this or any such role may be related to 
an intracellular function as amelogenin is synthesised and secreted by ameloblasts. 
The idea that cytokeratin 14 functions as an amelogenin binding protein was 
reinforced by Ravindranath et al. (2001) who suggested a role as a molecular 
chaperone for cytokeratin 14 during amelogenesis. Confocal laser scanning 
microscopy (CLSM) showed the co-assembly of amelogenin and cytokeratin 14 in 
the perinuclear region of ameloblasts in new-born (day 0) mice. Migration of the co-
assembly to the apical regions was shown from day 1, peaking at days 3-5. 
Dissociation occurred at the Tomes’ processes by day 9. Could cytokeratin 14 be a 
molecular chaperone for the secretion of the nascent amelogenin polypeptide? 
Chaperones are a class of proteins that bind newly synthesised proteins in the 
endoplasmic reticulum, promote correct folding and prevent abnormal aggregation 
between hydrophobic domains of the client proteins (Beissinger and Buchner, 
1998). Certainly, isolated amelogenin is highly aggregative with low solubility under 
physiological conditions and it might be expected that nascent amelogenin would 
require careful chaperoning during its secretion to prevent untimely intracellular 
aggregation which could lead to endoplasmic reticulum stress; a pathological state 
potentially leading to cell death (Yoshida 2001).  
 Cytokeratin 14 has been documented to pair with cytokeratin 5 in basal 
epithelial cells during cell differentiation (Sun et al., 1984). Cytokeratin 14 is a type I 
cytokeratin and cytokeratin 5 is a type II cytokeratin. Cytokeratin 5 is also present in 
ameloblasts (Kasper et al., 1989; Domingues et al., 2000). Cytokeratin 14 and 
cytokeratin 5 pair via the N-terminal regions of both molecules. Similar to other type 
II cytokeratins, cytokeratin 5 carries GlcNAc at its N-terminal region (Omary et al, 
1998).  
 Ravindranath et al. (2003) hypothesised that if amelogenin bound to 
cytokeratin 5 it might define a role for both type I and type II cytokeratins in 
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amelogenesis. ATMP was shown to bind to cytokeratin 5 but not if the GlcNAc 
residues were removed. CLSM showed that cytokeratin 5 co-assembled with 
amelogenin in mouse molar ameloblasts separately from cytokeratin14-amelogenin 
complexes, and migrated to the apical regions of the ameloblasts on postnatal day 
1. Triple signals were noted between postnatal days 3-5, indicating the presence of 
cytokeratin14-amelogenin, cytokeratin 5-amelogenin and cytokeratin14-cytokeratin 
5 complexes. Accumulation of cytokeratin 14-cytokeratin 5 complexes in the 
Tomes’ processes were observed post-natal day 5. Secreted amelogenin was 
observed in the ECM adjacent to the Tomes’ processes, suggesting that following 
the secretion of amelogenin from the ameloblasts, cytokeratin 14 and cytokeratin 5 
formed a co-assembly. The co-assembly was first noted on post-natal day 3 and 
increased up to postnatal day 7, and disappeared thereafter. This was suggestive 
of degradation or cell death.  
 Even though cytokeratin 14 has the GMP motif and has been demonstrated 
within ameloblasts, it has not been identified in the enamel ECM. Ravindranath et 
al. (2004) suggested that ameloblastin may in fact be the preferred ECM binding 
target for ATMP in amelogenin as it has been suggested that the ameloblastin may 
bind to the amelogenins as well as interacting with the growing hydroxyapatite 
crystals (Deutsch et al., 1991). 
 Native ameloblastin is O-glycosylated, but has not been shown to carry a 
GlcNAc region to potentially interact with amelogenin (Uchida et al., 1997).  
Recombinant ameloblastin does not contain GlcNAc or NeuAc (since E.coli are 
unable to make these modifications) but paradoxically it is still bound via the 
amelogenin ATMP motif (Ravindranath et al., 2004). This is explained by the fact 
that ameloblastin carries a complete GMP sequence, interrupted by intervening 
residues. Even though the ameloblastin GMP sequence is fragmented, it might not 
need to be continuous sequence. The GMP binding sequence of cytokeratin 14 is 
also fragmented, yet Ravindranath et al. (2000, 2001) showed it to bind ATMP 
effectively. Folding and coiling of the polypeptide could bring the disparate 
fragments of the GMP peptide together resulting in the formation of an intact 
conformational binding site (Wright 1984, 1990; Murphy et al., 2000).  Ravindranath 
et al. (2004) further suggested a role for ameloblastin in amelogenin binding by 
demonstrating that anti-rM179 amelogenin antibodies detected amelogenin bound 
to recombinant ameloblastin in both western blots and ELISA experiments, that 
ATMP binds to recombinant ameloblastin and native amelogenin retrieved from 
enamel in a dose dependent manner, and that mutations of the third proline in 
ATMP abolishes binding to both recombinant and native ameloblastin.  
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In summary, the amelogenin ATMP domain has lectin–like properties in that it 
binds GlcNAc (a sugar). It also binds amino acid sequences that mimic GlcNAc. 
These so called GlcNAc mimicking peptide sequences (GMPs) are present in 
cytokeratins and ameloblastin and it is possible that amelogenin forms complexes 
with these proteins via the ATMP domain. Significantly single acid mutations in the 
ATMP domain lead to AI indicating the functional importance of this domain in 
amelogenesis and the production of functional enamel (see figure 9). 
1.3.4.1.2. Amelogenin and its role in mineral crystal formation in tooth 
enamel 
Amelogenins are rich in proline (25-30%), and with high levels of glutamine 
(13%), leucine (10%) and histidine (8%), making them hydrophobic (Eastoe 1964). 
This hydrophobic character appears to be responsible for driving the 
supramolecular assembly of amelogenin monomers into so called “nanospheres” 
which are assumed to be the functional form of the protein during amelogenesis 
(Fincham et al., 1995; Du et al., 2005). Amelogenin mutations giving rise to the 
human X-linked condition amelogenesis imperfecta (AI) have point mutations 
resulting in altered nanosphere dimensions and assembly kinetics (Lench et al., 
1994; Collier et al., 1997). Although amelogenin is hydrophobic, the C-terminal is 
rich in acidic amino acids resulting in the presence of a hydrophilic “C-terminal 
teleopeptide.” The teleopeptide enhances  amelogenin binding to hydroxyapatite in 
vitro (Aoba et al., 1987C), suggesting that the C-terminal region facilitates initial 
orientation of amelogenin along the forming enamel crystallites (Kirkham et al., 
2000).   
Protein function is determined by protein conformation and this in turn is 
driven by the interactions of the specific amino acid side chains; this gives the 
necessary stereochemical parameters required for function. Amelogenin has not 
been crystallised and appears to be devoid of secondary structural features such as 
beta pleated sheets and alpha-helices. The C terminal of full length amelogenin 
(teleopeptide) is highly conserved across all species and in contrast to the rest of 
the molecule is hydrophilic (Fincham et al., 1995; He et al., 2008). 
 Previous reports based on mechanical molecular modelling  have suggested 
the presence of beta-spiral in bovine amelogenin.  A central portion of the 
amelogenin molecule comprises a hydrophobic core of approximately 100 residues 
rich in leucine, proline, histidine and glutamine and theoretically in bovine species 
this core contains a repetitive beta-turn segment and beta-spiral between glutamine 
112 and leucine 138; this beta-spiral has been suggested to interact with calcium 
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ions (Margolis et al., 2006; Palmer et al., 2008). Calcium binding fits well with a role 
for amelogenin in enamel mineralisation. However, if we examine this critically, the 
significance of this proposed calcium binding beta spiral in amelogenin function is 
difficult to accept since amelogenin from non-bovine species lack the repetitive 
sequence and do not exhibit this beta spiral. On firmer ground, it is well 
documented that amelogenins self-assemble into nanospheres in vitro (Fincham et 
al., 1994; Moradian-Oldak, 2007). There are indications that similar structural 
elements exist in vivo in the developing enamel (Fincham et al.,1995B; Robinson et 
al., 1981). The conclusion that the charged C-terminus is exposed on the surface of 
the nanosphere was derived from the observed MMP-20 cleavage sites and a solid-
state NMR study using an alternative slice variant of amelogenin LRAP.  
Amelogenin self-assembly into nanospheres is driven by inter-molecular 
hydrophobic which maintains the hydrophobic end away from water, with the 
hydrophilic end is exposed on the surface. The pH, temperature and protein 
concentrations all affect the size of the assembled structures. (Beniash et al., 2005; 
Habelitz et al., 2006; Moradian-Oldak, 2001)., Aichmayer et al. (2005) have 
provided additional evidence to show that amelogenin nanospheres are composed 
of a hydrophobic and electron dense core surrounded by a less electron dense and 
hydrophilic corona of the charged C-termini by using small angle x-ray scattering 
(SAXS) and dynamic light scattering analyses 
 Studies have shown that the full length amelogenin nanospheres further 
connect into chains of connected nanospheres indicating a hierarchical self-
assembly into larger structures that could act as a template to drive the growth of 
hydroxyapatite crystals (Moradian-Oldak et al., 2006; Wiederman-Bidlack et al., 
2007) . Using solutions with high protein concentration in a hanging drop over 
extended periods of time, co-linear arrays of amelogenin nanospheres were 
observed suggesting that the full length amelogenin could possibly act as scaffold 
onto which hydroxyapatite crystals grow during enamel maturation (Moradian-Oldak 
et al., 2006). 
For effective enamel development, the cleavage and removal of proteolytic 
products in a timely manner are essential. The charged C-terminus of amelogenin 
has significant hydroxyapatite binding affinity with has been proposed to control 
morphology and organisation of the crystals (Moradian-Oldak et al., 2001; Beniash 
et al., 2005). It has been hypothesised that the hydrophilic region of amelogenin 
inhibits crystal growth and nucleation (Aoba et al., 1987B). Several studies have 
investigated this hypothesis further by  removing the C-terminal hydrophilic residue 
of amelogenin  and showing that it does not affect amelogenins ability to inhibit 
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crystal growth of calcium phosphates (octocalcium phosphate and hydroxyapatite) 
in directions perpendicular to the C-axis (Beniash et al., 2005; Iijama and Moradian-
Oldak, 2005).  It was also shown that the crystals that did form in the presence of 
the hydrophilic C-terminus were organised into parallel arrays, whereas the crystals 
formed in the absence of the hydrophilic C-terminus were randomly arranged under 
the same conditions (Beniash et al., 2005).  
Hydrophobic protein expression and secretion into extracellular space is 
commonly seen as a cell-directed activity to provide space for mineral formation 
(Addadi and Weiner, 1992). Hydrophilic proteins, in contrast, are generally regarded 
as molecules that have the potential to promote crystal nucleation and growth by 
defining the position and size of mineral crystallites (Addadi and Weiner, 1992). As 
described previously, Ravindranath et al. (2007) demonstrated that recombinant 
mouse amelogenin binds specifically to recombinant ameloblastin via its ATMP 
tyrosine rich domain (amino acids 33-45). This suggests the possible formation of a 
heteromolecular assembly.  Bouropolous and Moradian-Oldak (2004) examined the 
cooperative effects of amelogenin and a 32 kDa enamelin fragment on the induction 
of synthetic apatite crystals precipitated in 10% gelatine gel and proposed that the 
32 kDa enamelin bound to amelogenin serves as a potential nucleator for apatite 
crystals. These findings propose the idea of a cooperative role for enamel proteins 
to control mineral nucleation. Other studies introduced the idea of cooperative 
mineralisation, with the suggestion that the functional self-assembly of the organic 
matrix molecules can only occur with enamel crystal growth and alignment in situ 
and in a collaborative manner (Margolis et al., 2006). It can be confidently 
hypothesized that the protein components of the developing enamel matrix 
interactive with one another and may function synergistically to produce suitable 
template for biomineralisation and the production of highly ordered enamel tissue. 
 Changes in pH which can induce ionisation of the amine and carboxyl groups 
as well as the functional side chains can affect protein self-assembly. 
Intermolecular interactions of macromolecules are often enhanced at their 
isoelectric point pH, since electrostatic repulsion is minimal and molecules can 
approach each other closely (Aggeli et al., 2003; Zhao et al., 2003). The calculated 
isoelectric points (IPs) are close to physiological pH for monomeric 25 kDa 
amelogenin and the 23 kDa amelogenin being 6.62 and 6.85 respectively. The true 
IP may vary significantly from these theoretical values for these molecules 
depending on the protein higher order structure. When the cooperative assembly 
between two different proteins is required such as amelogenin and enamelin, the 
surface charges of the self-assembled structures becomes important. Electrostatic 
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attraction between different proteins may occur when either the dissolved 
macromolecules or the initially self-assembled nanostructures carry opposite 
charges, providing an opportunity for close protein to protein interaction that could 
stimulate a cooperative self-assembling behaviour. 
 Self-assembly of amelogenin into nanospheres which increase in size with 
increasing pH was observed by atomic force microscopy (AFM) (Wen et al., 2011). 
Elongated structures of 100 nm length and 25 nm widths formed over several days 
for 25 and 23 kDa amelogenins at pH values 6.5 and 7.5, respectively.  A mix of 
both proteins held at pH 7 for 24 hours resulted in self-assembled strings of 200-
300 nm length consisting of fused nanospheres. These protein nanostrings formed 
links and a continuous mesh after 7 days. Electrical conductivity data also showed 
gradual changes with mixed amelogenins, supporting the idea of elongated 
structures forming over extended periods. The idea was proposed that due to the 
difference in isoelectric point, self-assembled nanospheres composed of 23 and 25 
kDa amelogenin have opposite ionic charges at pH values around 7 and thus 
experience ionic attraction that enables cooperative self-assembly (He et al., 2008). 
 
1.3.4.2 Ameloblastin (Amelin/Sheathlin)  
 As mentioned previously ameloblasts secrete the ECM proteins involved in 
enamel development; both the amelogenin and the non-amelogenin proteins. 
Ameloblastin (also known as sheathlin and amelin) (Cerny, 1996) is the most 
abundant of the non-amelogenins, comprising 5-10% of all proteins present in 
secretory stage tooth enamel (Simmer et al., 2010) and like amelogenin and 
enamelin the 65 kDa nascent ameloblastin molecule is subjected to proteolytic 
processing immediately after secretion, with lower molecular weight fragments 
being identified by western blot analysis (Brookes et al., 2001). The ameloblastin 
gene (AMBN) in humans has been localised to chromosome 4q21 and contains 13 
exons (Krebsbach et al., 1996; MacDougall et al., 1997). Ameloblastin and 
amelogenin are sister genes and are believed to have evolved from the ENAM 
gene by gene duplication and neofunctionalisation (Sire et al., 2007). 
Ameloblastin is a glycoprotein that is anionic, rich in glycine, leucine and 
proline. Ameloblastin expression in ameloblast cells is highest during the secretory 
stage and diminishes in the maturation stage. However, ameloblastin expression is 
not exclusive to ameloblasts. It is also expressed in odontoblasts (Nagano et al., 
2003; Hao et al., 2005), osteoblasts (Tamburstuen et al., 2011) and cementoblasts 
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(Nunez et al., 2010). Expression has been noted in dentine and HERS cells (Fong 
et al., 1996; Bosshardt and Nanci, 1997).  
Ameloblastin is secreted from vesicles containing just ameloblastin or more 
usually a mixture of ameloblastin and amelogenin. The localisation of amelogenin 
and ameloblastin in the ECM layer is believed to reflect their individual functions. 
Similar to nascent amelogenin, nascent full length ameloblastin is restricted to the 
newly secreted enamel matrix immediately adjacent to the ameloblasts where the 
enamel crystals are undergoing elongation (Nanci et al., 1996A; 1996B).  
 Ameloblastin is cleaved upon secretion by MMP-20 (Uchida et al., 1997) and 
is processed in the deeper enamel to generate a range of peptides around 13-17 
KDa in size that aggregate (Brookes et al., 2001)  and accumulate around the prism 
peripheries  resulting in a ‘fishnet’-like or honeycomb patterning following 
immunohistochemical localisation (Uchida et al., 1991A) . The remaining C-terminal 
fragment is found in the outer superficial layer only and is rapidly degraded (Uchida 
et al., 1997).  The localisation of ameloblastin N-terminal fragments to the prism 
peripheries led to the suggestion that these molecules play some role in delineating 
the boundary between prismatic and interprismatic enamel (Iwata et al., 2007).    
Ameloblastin contains a number of binding sites for various components. It as 
has been found to contain binding sites for calcium (Yamakoshi et al., 2001), 
heparin (Sonoda et al., 2009) and fibronectin (Beyeler et al., 2010) which suggests 
that ameloblastin may have multiple roles.  
For example, ameloblastin may act as a linkage between ameloblasts and the 
enamel ECM (Cerny et al., 1996; Snead et al., 1996). Fukumoto et al., 2004 
proposed a role for ameloblastin as a cell adhesion molecule necessary for 
maintaining the differentiation state of ameloblasts. Ameloblastin null mice initially 
showed elongation of the dental epithelial cells comparable to wild type mice, but at 
the secretory stage the cells detached from the ECM and lost polarity. The 
ameloblasts eventually became smaller and rounder, and then resumed 
proliferation resulting in the formation of multicellular layers. Expression of 
amelogenin was also reduced in the ameloblastin null mice. Primary cell culture of 
dental epithelial cells with recombinant ameloblastin showed preferential binding of 
ameloblasts to ameloblastin over fibronectin or laminin (Fukumoto et al., 2004). 
Recombinant amelogenin also inhibited proliferation of ameloblastin null 
ameloblasts in culture (Fukumoto et al., 2004). These results were not noted with 
other epithelial cell types, indicating a role for ameloblastin in cell adhesion.  Paine 
et al., 2003 showed that mice over expressing ameloblastin exhibited an 
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amelogenesis imperfecta like phenotype. These results also indicate a role for 
ameloblastin in organising ECM proteins to initiate mineral crystal growth. 
Ameloblastin null mice were also shown to develop tumours with age in the 
Fukumoto et al., 2004 study. The tumour cells were shown to be expressing enamel 
ECM proteins implying that the source of the tumours is likely to be the 
ameloblastin defective ameloblasts.  The most common human odontogenic tumour 
is the ameloblastoma (Kramer et al., 1992) considered to be of dental epithelial 
origins due to similarities between the tumour and the developing tooth (Snead et 
al., 1992; Abiko et al., 2007; Yagishita et al., 2001). Perdigao et al., 2004 reported 
odotonogenic tumours resulting from ameloblastin mutations. The tumours are 
likely to form due to lack of ameloblastin regulation of ameloblast differentiation. 
Until recently, no ameloblastin mutations had been identified that give rise to 
an amelogenesis imperfecta phenotype, although ameloblastin’s chromosome 
location was linked to a local hypoplastic form of AI (MacDougall et al., 1994). 
However, Poulter et al., 2014B identified a deletion of ameloblastin exon 6 in a 
family displaying an amelogenin imperfecta phenotype. The teeth from the patients 
displayed a similar phenotype of a thin dysplastic layer of rough, pitted mineralised 
tissue lacking any discernible crystal structure comparable to a mouse model 
lacking ameloblastin exons 5 and 6 (Wazen et al., 2009; Hu et al., 2008). 
 
1.3.4.3  Enamelin 
 Enamelin falls into the non-amelogenin category along with ameloblastin, 
previously discussed above. Enamelin maps to chromosome 4q21 in humans and 
contains 9 exons (Hu et al., 2001).  It has been suggested that enamelin, 
ameloblastin and amelogenin all arose from a single ancestral gene from which 
gene duplication generated the amelogenin gene which then translocated to the X 
and Y chromosomes, while enamelin and ameloblastin remained on this original 
chromosome (Sire et al., 2007). Comprising less than 1% of all proteins present in 
developing tooth enamel, pig enamelin is secreted as a phosphorylated 186 kDa 
glycoprotein (Fukae et al., 1987). Like amelogenin, enamelin undergoes a series of 
proteolytic cleavages by MMP-20 once secreted (shown in figure 8). Fully mature 
and intact enamelin is present in newly secreted enamel at the mineralisation front 
perhaps suggesting a role for full length nascent enamelin in crystallite elongation 
(Hu et al., 2005; Kim et al., 2005A). Studies on enamelin biochemistry using 
enamelin proteins isolated from developing enamel have focused almost 
exclusively on the pig model due to the availability of pig developing teeth through 
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the meat industry and the thickness of the porcine enamel tissue.  The major 
enamelin protein in pig enamel is the 32 kDa processing product generated by 
proteolytic processing in the deeper enamel (Uchida et al.,1991B) and it is this 
species that is, without exception, used in biochemical studies relating to enamelin 
function due to its relative abundance. The 32 kDa enamelin is phosphorylated and 
glycosylated and has a high affinity for the mineral phase suggesting that its amino 
acid residues and/or the attached phosphate and sugar groups arrange 
stereochemically in a way that is complementary to the mineral surface in terms of 
binding potential.  The exact role of enamelin is unclear but the fact that the 32 kDa 
domain exhibits affinity for mineral surfaces suggests that interaction with mineral is 
an important function (Al-Hashimi et al., 2009; Bouropoulos and Moradian-Oldak., 
2004; Fan et al., 2008;  Fan et al., 2009; Fan et al., 2011; Ilijama et al., 2010; 
Uchida et al., 1991; Yamakoshi et al., 1995; Yamakoshi et al., 1998; Yamakoshi 
2006)  It is possible that this affinity is also directed towards initial clusters of 
mineral ions which provides sufficient stabilisation for nucleation to occur i.e. the 
domain acts as a template for mineral nucleation.   
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Figure 8.  Extracellular processing of porcine enamelin protein showing 
molecular weights of the breakdown products, from the parent 186 kDa 
protein to the 32 kDa, 25 kDa and 34 kDa fragments. The 32 kDa 
breakdown product retains the post translational modifications of 
phosphorylation and glycosylation. 
 
  Autosomal dominant hypoplastic amelogenesis imperfecta is linked to 
mutations in the enamelin gene.  In humans displaying the AI phenotype linked to 
enamelin mutations, those with single allele mutations had hypoplastic, thin, rough 
enamel resulting in yellow, temperature sensitive teeth. Those with both allele 
mutations had teeth with a complete lack of enamel (Ozdemir et al., 2005). A 
chemically induced mouse model (ENU) (Masuya et al., 2005) a gene targeted 
mouse model (Hu et al., 2008) and human gene mutations resulting in AI (Rajpar et 
al., 2001) have all been used to investigate enamelin mutations and indicate a 
fundamental role for enamelin in biomineralisation. The resulting thin enamel 
displaying disorganised mineral crystals seen in human and mouse AI models with 
ENAM null genotypes indicate that enamelin is necessary for optimal enamel 
thickness via crystal formation and prism organisation (Meredith et al., 2009). 
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 A recent study by Hu et al., 2014 describes investigations into the role of 
enamelin in enamel development. Using mice heterozygous and homozygous for 
enamelin mutations, the group aimed to characterise any resulting cellular and 
structural anomalies. They showed that no proper enamel formation occurred as 
there was no mineralisation along the ameloblasts distal membranes in affected 
mice. Β-galactosidase staining specific for enamelin expression showed expression 
in the developing tooth organ, and only in the secretory and early maturation stage 
ameloblasts. Unlike ameloblastin, enamelin expression was not noted in 
odontoblasts or osteoblasts.  In the homozygous Enam-/- mice, the ameloblasts 
were observed to become crowded and to lose contact with the ECM covering the 
dentine. The ameloblasts continued to secrete amelogenin but displayed enlarged 
endoplasmic reticulums. The ameloblasts were able to secrete an amelogenin-rich 
layer onto the dentine despite poorly formed Tomes’ process, but mineralisation of 
this protein layer did not occur and at the secretory stage, no mineral crystal 
ribbons were noted. In the heterozygous Enam+/- mice, the mineral crystals 
appeared to have the correct conformation but were more loosely packed together. 
  The above data show, that although enamelin is much less abundant than 
amelogenin, it is important for the formation and integrity of the enamel ECM and 
the mature mineralised enamel. 
 
1.3.4.4 Minor Enamel Matrix Proteins 
1.3.4.4.1 Kalikrein-4 (KLK-4) 
The human KLK-4 gene has been localised to chromosome 19q13.3-13.4 and 
consists of 6 exons and 5 introns (DuPont et al., 1999; Hu et al., 2000). It encodes 
a 254 amino acid protein with a conserved serine protease catalytic triad, and an 
amino-terminal prepropeptide sequence. In teeth, KLK-4 is secreted by the 
odontoblasts and by late-secretory and maturation stage ameloblasts. KLK-4 
expression correlates with the disappearance of enamel proteins, such as 
amelogenin, from the enamel ECM. KLK-4 is expressed in its latent proenzyme 
form. How it is activated has, as yet, not been fully defined (Lu et al., 2008). KLK-4 
appears to act upon protein fragments of amelogenin, ameloblastin and enamelin 
already created from proteolytic degradation by MMP-20. KLK-4 facilitates the 
removal of these fragments from the enamel layer as part of the maturation stage 
(Lu et al., 2008).  A KLK-4 mutation has been noted in a family with autosomal 
recessive hypomaturation amelogenesis imperfecta (Hart et al., 2004) which 
highlights the importance of proteolytic removal of matrix proteins from the 
- 54 - 
maturation stage enamel.  A KLK-4 null mouse model shows that the enamel 
produced is of normal thickness with the correct organisation of prisms and inter-
prism substructures seen in normal enamel. However, the maturation and 
hardening of the enamel is delayed in these animals, with a defect in the 
mineralisation near the DEJ, causing the enamel to be sheared from the surface of 
crowns during physical use. The teeth show abnormal wear patterns, with chipped 
incisor ends (Hu et al., 2009). 
The expression of proteolytic enzymes such as KLK-4 during enamel 
maturation is necessary for enamel to achieve its high degree of mineralisation. If 
KLK-4, or the other enamel proteinase, MMP-20, is absent or functionally defective 
during enamel secretion, the produced enamel is itself defective or of poor quality 
(Simmer and Hu., 2002; Hu et al., 2003; Hu et al., 2005). Recent studies have 
shown that MMP20 activates KLK4 by cleaving a propeptide. Hence, a MMP20 
mutation can indirectly compromise KLK4 function (Yamakoshi et al., 2013). 
1.3.4.4.2  Matrix Metalloproteinase-20 (MMP-20) 
The human MMP-20 gene has been localised to chromosome 11q22.3-q23 
(Llano et al., 1997) and consists of 10 exons and 9 introns (Caterina et al., 2002). 
Ameloblasts and odontoblasts of the dental papilla express MMP-20 (Hu et al., 
2002). MMP-20 is secreted during the secretory phase (Hu et al., 2002). MMP-20 is 
expressed in its latent proenzyme form. How it is activated has, as yet, not been 
fully defined (Ryu et al., 1999). MMP-20 is secreted into the enamel matrix 
appearing as  a doublet of 41 and 46 kDa on SDS gels following extraction, and 
MMP-20 activity accounts for all of the known cleavage sites in amelogenin that 
occur in the early stages of enamel development (Ryu et al., 1999). MMP-20 is also 
responsible for the cleavage of newly synthesised ameloblastin and enamelin 
(Yamakoshi et al., 2006, Simmer et al., 2009, Simmer et al., 2010). The Mmp-20 
null mouse displays a severely profound tooth phenotype as it is unable to process 
amelogenin correctly, so may possess and altered enamel matrix and crystal prism 
pattern, resulting in hypoplastic enamel that delaminates from the dentine (Caterina 
et al., 2002). The enamel that is present contains little, if any, prism and inter-prism 
substructure, and is very soft in texture (Bartlett et al., 2003; Bartlett et al., 2004). 
1.3.4.4.3 Amelotin 
Amelotin is the newest discovered enamel-specific protein and represents a 
novel component of the maturation stage basal lamina (Dos Santos Neves et al., 
2012).The Amelotin gene in humans has been localised to chromosome 4q13.3, 
has 9 exons and 8 introns, and gives rise to a 22 kDa protein.  Amelotin displays an 
N-terminal signal sequence typical of many secreted proteins, but appears to 
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undergo few, if any, post translational modifications. Investigations are underway to 
determine this restricted protein expression, and to decipher whether amelotin is 
indeed a structural protein of the enamel matrix or in fact, a proteolytic enzyme 
involved in enamel ECM degradation (Iwasaki et al., 2005). 
1.3.4.4.4 Biglycan 
The biglycan gene in humans has been localised to chromosome Xq28, and 
contains 8 exons (Fisher et al., 1991). Biglycan is a small cellular or pericellular 
matrix proteoglycan, and contains 2 glycosaminoglycan (GAG) chains (Iozzo, 1999) 
Biglycan in expressed by ameloblasts and is present in enamel ECM (Goldberg et 
al., 2003) 
 Biglycan expression is not unique to enamel, but it does play a significant role 
in amelogenesis and enamel biomineralisation due to biglycan null mice expressing 
a larger volume of developing enamel in molar teeth, but not incisors. This resulted 
from an increase in amelogenin expression. The mature enamel in biglycan null 
mice was morphologically comparable to wild type mouse enamel once fully 
mineralised.  Therefore, biglycan either directly or indirectly acts as a repressor of 
amelogenin expression during enamel secretion (Goldberg et al., 2002; Goldberg et 
al., 2005). 
1.3.4.4.5 Tuftelin and the tuft proteins 
The human tuftelin gene has been localised to chromosome 1q21. Tuftelin is 
an acidic protein shown to be present in the developing and mature enamel ECM. 
Tuftelin was originally described and classified as an enamel ECM protein, although 
it is not unique to ameloblasts or the enamel ECM (Deutsch et al., 1991). Tuftelin is 
a product of a wide range of cells including cells responsible for mineralising hard 
tissues (including enamel ECM) as well as cells responsible for non-mineralising 
tissues. In vivo localisation shows a minimal degree of amelogenin and tuftelin 
colocalisation in the cell cytoplasm (Deutsch et al., 1995). There is lack of evidence 
to suggest a physiological pathway from the cytoplasm to the ECM, but tuftelin has 
been repeatedly localised to the ECM, where its presence suggests a role in 
amelogenesis (Paine et al., 2000). It has been proposed that the tuftelins act to 
start the mineralisation process of the enamel ECM (Zeichner-David., 2001). 
 Tuftelin-interacting protein II (TFIP-II) has been immunolocalised to the 
Tomes’ processes and the enamel matrix (Paine et al., 2000), however TFIP-II 
appears to be a phosphorylated RNA splicing factor and is primarily localised within 
the cell nucleus (Beausoleil et al., 2004).  
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Previous studies have shown that cell membrane phospholipids accumulate in 
the dentine and enamel ECM during biomineralisation (Goldberg et al., 1999). One 
explanation for this in enamel is that the distal portions of individual Tomes’ 
processes are fragmented during the secretory stages of amelogenesis and the 
contents become trapped in the ECM. For a structure such as enamel with very 
specific matrix proteases that target tooth specific proteins, it is conceivable that 
non-secreted ameloblast-associated proteins can become trapped in the immature 
or mature enamel. This may explain the localisation of tuftelin and TFIP-II in the 
enamel matrix (Goldberg et al.,1998; Goldberg et al.,1999). 
Tuft protein, a different protein to tuftelin, was revealed during the complete 
dissolution of mature enamel from human molars. The presence of a considerable 
amount of insoluble material on the dentine surface was noted, and this material 
was not soluble even in mineral acids or EDTA (with or without 8M urea or 
guanidine chaotropic agents) (Hodson et al., 1952), or boiling in SDS or phenol. 
Analysis showed that this material was proteinaceous with a composition in excess 
of 80% amino acids (Weatherall et al., 1968; Robinson et al., 1975). Microscopy 
showed the material associated with the enamel tufts, blades of organic material 
along the enamel prism boundaries (Beust et al., 1932; Osborn et al., 1969). 
Amizuka et al., (1992) showed the presence of ‘tuft’ proteins in human molars 
with complex prism structures using electron microscopy. Tuft protein is not related 
to the other ECM proteins. Keratin has been identified in the tuft protein by 
immunohistochemistry staining (Robinson et al., 1989), and a fragment of 
ameloblastin has also been detected (Robinson et al., 2000). It is possible that this 
tuft protein material is a mixture of different proteins. Antibodies raised against a tuft 
protein suspension were used to probe sections of rat molar. This showed that the 
expression of the tuft protein followed the secretory pathway from ameloblasts 
(Robinson et al., 1989), and therefore was likely to be ameloblastin (Amizuka et al., 
1992; Robinson et al 2000). As described above N-terminal ameloblastin 
degradation products have been shown to be immunologically related to prism 
boundaries (Uchida et al., 1991B), which fits well with the notion that tuft protein 
contains ameloblastin as the tuft protein is associated with prism boundaries. 
The fact that this tuft protein is very resistant to chemical solubilisation implies 
chemical cross-linking such as that seen in keratin and collagen. Cross-links such 
as ε-γ-glutamyl-lysine occur between glutamine and a primary amine group such as 
lysine (Folk and Finlayson, 1977; Lorand and Conrad, 1984) and these have been 
reported to exist in tuft protein together with transglutamase enzyme responsible for 
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their formation (Robinson and Hudson, 2011). ECM proteins such as amelogenin, 
enamelin and ameloblastin all contain large quantities of lysine and glutamine. 
These cross-links are common in epithelial tissues, with a role in prevention of 
proteolytic degradation and promoting structural stabilisation. Enamel has epithelial 
origins, so it is tempting to speculate that these cross-links play a similar role in this 
tissue. However, enamel matrix proteins are not covalently linked during 
development (as evidenced by the fact that they can be isolated in their monomeric 
form) and considering the developing enamel matrix is designed to be 
proteolytically removed from the tissue, the formation of stabilising cross links  at 
this stage would be counterproductive. 
The effects of the proteinase Kallikrein-4 (KLK-4) on tuft protein are not 
known. Protein degradation such as that elicited by KLK-4 or MMP-20 at the 
dentine-enamel junction could be ruinous to the developing ECM, therefore the 
presence of chemical cross-links would provide a protective effect to the tissue and 
stabilise the interface. This is comparable to the cross-linking of keratin in layers of 
the skin tissue. Myoung et al (2009) proposed a role for the tuft protein in protecting 
the tooth under high functional stresses and in self-healing, consistent with cross-
linking. 
It is likely that tuft protein is a mixture of the degradation products of the 
enamel ECM proteins, along with a form of degradation resistant cross-linked 
material from the dentine. This tuft protein product in turn has a protective effect 
during tooth development, in strengthening and protecting the DEJ, and throughout 
the life of the tooth in acting as a cushioning layer between the prisms and dentine 
and enamel layers, to resist the stresses and strains of normal tooth wear.  
 
1.3.4.4.6 Sulphated Proteins 
A glycosylated and sulphated ‘non-amelogenin’ protein of 65 kDa has been 
identified in the developing enamel of rats by in vivo radiolabelling studies using 35S 
isotopes. The 65 kDa protein is rapidly degraded following secretion. It has been 
hypothesized that this protein may somehow interact with amelogenin, but this 
remains to be proven and no specific gene has been identified (Smith et al., 1995; 
Nanci et al., 1996A; Nanci et al., 1996B). It is possible that this protein is in fact 
nascent ameloblastin. 
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1.3.5 Non matrix proteins involved in enamel development 
Integral membrane proteins, calcium transport proteins, hard tissue 
mineralisation proteins and collagen were all identified during screening of a cDNA 
expression library to find enamel matrix proteins that interacted directly with 
amelogenin, enamelin or ameloblastin (Wang et al., 2005). These proteins included 
CD63 (LAMP-3), Annexin A2, α-2-HS-glycoprotein (Ahsg) and types I, II and IV 
collagen. CD63, LAMP1 and Annexin A2 are products of ameloblast cells 
(Fukumoto et al., 2004; Tompkins et al., 2006; Wang et al., 2005).  LAMP1 has also 
been identified as a membrane-bound receptor for amelogenin. CD63 and LAMP1 
are both found on the membrane of endosomes and lysosomes (Duffield et al., 
2003; Goldberg et al., 1990; Mayran et al., 2003). Annexin-2 is involved in the 
organisation and dynamics of the endosome membrane.  These interactions 
support the existence of signalling pathways through membrane bound receptors to 
allow the transfer of information from the enamel matrix to the ameloblast to 
influence gene transcription. Their presence also supports the theory of an 
anchoring mechanism for orientating the enamel matrix relative to the ameloblast 
Tomes’ processes and for receptor mediated removal of degraded ECM proteins 
during enamel biomineralisation. 
1.3.5.1 LAMP1 
Lysosomal associated membrane protein 1 (LAMP1) is a transmembrane 
protein expressed mainly by late endosomes and lysosomes and is often used as a 
marker for these organelles (Cook et al., 2004). It is involved in endocytosis, 
pinocytosis and phagocytosis. LAMP1 is present on the plasma membrane of 
presecretory, secretory, and post-secretory ameloblasts and is thought to act as a 
cell surface intermediary that can be shuttled to the lysosome through endocytosis. 
LAMP1 interacts directly with amelogenin (Tompkins et al., 2006) and has been 
shown to interact with the LRAP fragment of amelogenin and full length amelogenin 
on cementoblasts (Zhang et al., 2010). 
1.3.5.2 CD63 (LAMP3) 
CD63 is a member of the transmembrane 4 glycoprotein superfamily, known 
as the tetraspanin proteins. The majority of the family members are cell surface 
proteins, identified by four hydrophobic transmembrane domains. These proteins 
are involved in the mediation of signal transduction events associated with 
activation, growth, motility, and the regulation of cell development. CD63 forms 
complexes with integrins (Yunta and Lazo, 2003). CD63 is found in the cytoplasmic 
membranes of most cell types, and also in late endosomes, lysosomes and 
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secretory vesicles, trafficking between these different compartments. CD63 is 
immunolocalised to the Tomes’ processes of ameloblast cells, and is found 
throughout the cytoplasm of ameloblast cells and neighbouring cells. CD63 is able 
to interact directly with the secreted enamel proteins, and is perhaps likely to play a 
role in amelogenesis related to protein-protein interactions at the Tomes’ 
processes. (Zou et al., 2007). It may also play a role in amelogenin degradation by 
binding to the amelogenin and packaging the protein into vesicles, targeting it for 
removal from the cell cytoplasm (Xu et al., 2008). 
1.3.5.3 Annexin A2 
Annexin A2 is a 39 amino acid calcium and phospholipid binding protein. 
Annexin A2 acts as an autocrine factor to stimulate osteoclast formation and bone 
resorption and is also a necessary component in endosomal activity. Annexin A2 
has been located in the cytosol of ameloblast cells, close to the Tomes’ processes, 
and in the ameloblast secretory vesicles (Goldberg et al., 1990). Annexins are 
thought play a role in tooth development through exocytosis and endocytosis due to 
higher levels of Annexin 2 mRNA being identified in pre-and post-secretory 
ameloblasts, as opposed to secretory ameloblasts (Bartlett et al., 2006). 
1.3.5.4. Integrin 
 Integrins are cell-surface adhesion receptors with roles in cell-cell, cell-matrix 
and cell-pathogen interactions (Zhang and Chen 2012).  Integrins consist of non-
covalently linked α and β subunits. ITGB6 binds to integrin-α5 to form integrin-αvβ6. 
Integrin-αvβ6 is epithelial cell specific and binds to the arginine-glycine-aspartic 
acid (RGD) amino acid motif (Busk et al., 1992).  RGD motifs are often found in 
extracellular matrix proteins such as vitronectin, fibronectin and tenascin-C. The 
recent discovery of a missense mutation in the I-domain of integrin β6 (ITGB) 
resulting in hypomineralised amelogenesis imperfecta, has indicated a role for 
integrins in amelogenesis (Poulter et al., 2014A). The P196T mutation identified 
was in a family of Pakistani origin, presenting with pitted hypomineralised enamel 
with premature enamel failure. No other diseases were associated with this 
mutation.  The particular point mutation resulted in a phenotype similar to that 
observed in mice lacking a functional itgb6 gene. The authors proposed a potential 
mode of action being that the mutation in ITGB6 failed to allow the binding of the 
integrin to the latency associated peptide (LAP) of TGFβ, which resulted in the 
inhibition of MMP-20 expression. This would lead to failure to process the ECM in 
the enamel correctly and hypomineralisation as observed in the human family and 
mouse model (Poulter et al., 2014B). Enamel hypoplasia and skin blistering in 
patients with epidermolysis bullosa are also associated with integrin mutations. Six 
- 60 - 
novel mutations in all 10 genes of ITGBβ4 have been identified with patients with 
epidermolysis bullosa with pyloric atresia (Pulkkinen et al., 1998). 
 
 
1.4. Inherited diseases of enamel 
1.4.1. Amelogenesis Imperfecta 
Amelogenesis imperfecta (AI) is a disease of tooth enamel development 
where the biomineralisation process has failed. AI can cause teeth to be unusually 
small, discoloured, pitted or grooved and prone to rapid wear and breakage. The 
clinical appearance of AI can vary among affected individuals and can affect both 
primary and permanent teeth. AI is genetic in origin and presents as hypoplastic, 
hypomineralised and/or hypermineralised enamel. The prevalence of AI varies from 
1:700 people in Sweden to 1:14,000 people in the USA (Crawford et al., 2007) 
 Mutations in the enamel matrix proteins and in cellular proteins affecting 
ameloblast function underlie many cases of AI. These mutations alter the structure 
of the proteins or prevent protein secretion. Mutations in the following genes are all 
known to cause AI: enamelin (ENAM; chromosome 4 long arm position 21 – 4q21), 
amelogenin (AMELX; X chromosome short arm position 22.3 to 22.1 – Xp22.3-
p22.1), ameloblastin (AMBN; 4q21), tuftelin (TUFT1; 1q21), amelotin (AMELOTIN; 
4q13), kallikrein 4 (KLK4; 19q13.3-q13.4) and MMP-20 (MMP20; 11q22.3-q23). 
 AI can be X-linked, autosomal dominant or recessive. Four major 
manifestations of AI are described using the Witkop classification system; 
hypoplastic (enamel of reduced thickness), hypomaturation (enamel of normal 
thickness, but softer as mineralisation fails to mature), hypocalcified (enamel of 
normal thickness, but softer due to reduced mineral content) and hypomaturation-
hypoplastic with taurodontism (reduced enamel thickness with reduced mineral 
content and teeth present with enlarged and elongated pulp chambers (Witkop, 
1988).  These have been further subclassified into over 14 forms of AI as described 
in the literature (Aldred and Crawford., 1995). There are also cases of AI that 
appear to be sporadic, in people with no family history of the disease. 
Improvements in molecular genetics should help aid identification of further gene 
mutations. 
1.4.1.1 X-linked Amelogenesis Imperfecta 
X-linked AI usually manifests as hypoplastic AI. Five percent of AI is caused 
by mutations in the amelogenin (AMELX) gene. Males with X-linked AI have more 
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severe dental abnormalities than females. Males who inherit the AMELX defects 
have only a very thin layer of enamel, or poorly mineralised, discoloured enamel. 
Females have 2 X chromosomes, and those who inherit only one altered copy of 
the AMELX gene are less severely affected as they have a normal copy of the gene 
on the other X chromosome to produce amelogenin.  Their teeth show structural 
defects such as distinctive patterns of vertical ridges and grooves, or Lyonisation 
due to alternating bands of normal thickness enamel and reduced thickness enamel 
(Balmer et al., 2004). Mutations identified include deletions, single base alterations 
and premature stop codons. Figure 9 shows the amelogenin gene and the locations 
of known mutations that cause AI in humans. The gene mutation and resulting 
protein alteration are given. The resulting AI type is also given. 
Figure 9. Schematic of the amelogenin gene, showing the genetic 
location of the identified mutations (g), the resulting protein mutation 
(p), and the clinical enamel phenotype. 
 
1.4.2 The Y64H amelogenin mutation in mice 
1.4.2.1 Wild type and mutant (Y64H) mice teeth 
Human AMELX mutations include total loss of  protein secretion mutations 
causing loss of the C-terminal of amelogenin (Wright et al., 2003), and mutations 
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affecting the amelogenin N-terminal region that include a lectin-like tri-tyrosyl 
domain reported to bind to N-acetyl-D-glucosamine (Ravindranth et al., 1999). 
Mutations in the amelogenin gene are known to cause amelogenesis imperfecta, a 
genetic disease resulting in biomineralisation defects of tooth enamel.  For 
example, Collier et al. (1997) showed that a single amino acid mutation in the 
human amelogenin gene resulted in the substitution of proline at position 70 with 
threonine and is associated with hypoplastic amelogenesis imperfecta in affected 
individuals. The mutation lies in the conserved ATMP motif domain (as described 
previously Chapter 1 Section 1.3.4.1.1) shown below (the proline residue that is 
substituted by threonine in the mutation is highlighted in red):  
 
Human X Y P S Y G Y E P M G G W L H H Q 
Bovine X Y P S Y G Y E P M G G W L H H Q 
Porcine Y T S Y G Y E P M G G W L H H Q 
Murine Y P S Y G Y E P M G G W L H H Q 
Rat Y P S Y G Y E P M G G W L H H Q 
 
Studying human amelogenesis is difficult because unerupted teeth are required 
which invariably means obtaining post mortem material from children (which apart 
from the ethical issues involved results in tissues affected by post mortem changes 
unless unerupted wisdom teeth are available). Fortunately, a mouse model 
phenocopying human hypoplastic amelogenesis imperfecta was available 
(M100888 mutant from RIKEN Institute) and genetic analysis carried out as part of 
this research program (by Dr Martin Barron, University of Manchester) showed that 
the mutation involved the substitution of tyrosine 64 (shown in blue above) with 
histidine (Y64H substitution) (Barron et al., 2010). Given that the murine mutation is 
within the same ATMP domain as the proline 70 mutation reported in human 
amelogenesis imperfect, this mouse model would appear to provide a suitable 
model for study.  
 It is difficult to elucidate the underlying molecular mechanisms associated with 
amelogenesis imperfecta in humans due to the inability to obtain viable, developing 
(unerupted) teeth. Rodent incisors provide a workable alternative as they 
continuously erupt throughout the life of the animal and provide access to all stages 
of enamel development in one tooth. Mice models have been used in gene 
targeting experiments to define the roles of proteins in enamel development. An N-
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ethyl-N-nitrosurea (ENU-) induced mutation in mouse model (M100888 Riken 
Japan) has an x-linked enamel phenotype suggesting mutations in the amelogenin 
gene (amelx; the only ECM protein located on the X-chromosome. This mutation 
was identified by the Leeds-Manchester group as a single amino acid substitution 
involving the replacement of tyrosine 64 with histidine (Y64H mutation) (Barron et 
al., 2010).  The Y64H mutation lies in the highly conserved amelogenin ATMP 
domain (PYPSYGYEPMGGW mutated to PHPSYGYEPMGGW). A P-T mutation of 
the third proline results in hypomaturation amelogenesis imperfecta in humans 
(Collier et al., 1997). This mutation has been shown in vitro to inhibit normal 
amelogenin proteolysis and to abrogate the lectin-like binding by the tri-tyrosyl 
domain (Ravindranath et al., 1999; Li et al., 2001) (see section 1.3.4.1.1). M100888 
was identified during a large screen on mutated mice for dominant abnormal 
phenotypes (Masuya et al., 2005). C57BL/6J male mice (CLEA Japan) were 
administered with ENU [N-ethyl-N-nitrosurea (C3H7N3O2)], a highly potent mutagen, 
at 150-150 mg/kg, and crossed to DBA/2J female mice (CLEA Japan). ENU is an 
alkylating agent the transfers its ethyl group to the DNA nucleotides, preferentially 
to thymine (Coghill et al., 2002). ENU can induce one new mutation for every 700 
loci, but in too high a concentration can be toxic. It was first extensively used by Bill 
Russell for designing mouse strains for studies into the effects of toxins and 
chemicals (Russell et al., 1979). The M100888 ENU mutant was identified during a 
screen of F1 hybrids for dominant phenotypes at 8 weeks of age (Inoue et al., 2004; 
Masuya et al., 2005). Six mouse phenotypes were identified that exhibited 
abnormal incisor surfaces, of which M100888 was one. M100888 was obtained 
from the RIKEN Institute (http://www.gsc.riken.jp/mouse/) and maintained in a 
DBA/2J genetic background at the University of Manchester in accordance with the 
Animals (Scientific Procedures) Act, UK, 1986 (Barron et al., 2010). Gross 
morphology of the affected mice showed uneven, shortened incisors with chalky-
white, opaque, rough and pitted surfaces (figure 10 below). Examination of the 
lower jaw of the affected males shows a large, eroded, discoloured inferior border 
of the mandible. Dissection of the lower incisors showed that the mineralising 
enamel distal to the white opaque zone (where removal of the ECM normally 
occurs) was irregular and discoloured.  Genotypic analysis showed that the T to C 
transition at nucleotide 249 of the Amelx coding sequence resulted in a missense 
mutation Y64H. The Y64H is a mutation of the first tyrosine in the PYP SYG YEP 
MGGW sequence of amelogenin in the C-terminus of the TRAP domain. The 
mutation was present in all the affected males (n=72) and all the affected females 
(n=72) analysed, but was not detected in the wild type littermates (n=160) (Barron 
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et al., 2010). Affected males and homozygous females displayed a more severe 
phenotype that heterozygous females. 
 
Figure 10.  Images showing the wild-type and Amelx mice incisors. Wild-type 
maxillary (panel A) and mandibular (panel B) incisors show smooth 
enamel, opalescent and orange/brown in colour. Panels C and D show 
the maxillary (C) and mandibular (D) incisors for heterozygous female 
mutant mice (AmelxX/Y64H), illustrating patches of rough, chalky enamel.  
Panels E and F show the maxillary (E) and mandibular (F) incisors for 
hemizygous male mutant mice (AmelxY/Y64H), illustrating the whole of 
enamel surface as rough, opaque and chalky. The mutant mice teeth 
also show shortened incisors with irregular edges (C-F). Barron et al., 
2010. Reproduced under Creative Commons Attribution License.  
Modified from figure 3 published in:’A mutation in the mouse Amelx tri-tyrosyl domain 
results in impaired secretion of amelogenin and phenocopies human X-linked 
amelogenesis imperfecta’ by Barron et al 2010  Hum. Mol. Genet. (2010) 19 (7): 1230-
1247. Direct link: http://www. ncbi.nlm.nih.gov/pubmed/20067920  
 
How does this single amino acid mutation, from tyrosine to histidine at position 64 
of amelogenin give rise to the effects seen in amelogenesis imperfecta?  
 
1.4.2.2 Tyrosine and Histidine Biochemistry 
Amelogenin is secreted by specialist ameloblast cells prior to the tooth 
erupting into the mouth, and interacts with other secreted proteins to form an 
extracellular organic matrix, onto and in to which hydroxyapatite crystals nucleate 
and grow to form the enamel prisms (Moradian-Oldak, 2001; Hu et al, 2002). The 
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tertiary structure of amelogenin still remains to be defined. As described previously 
(section 1.3.4.1.1) the N terminus of amelogenin is a highly conserved region of 45 
amino acids, comprising the so called tyrosine rich amelogenin peptide (TRAP) 
containing 6 tyrosine residues, with the final 3 tyrosine residues lying at the C 
terminal of TRAP defining the ATMP region.  
The tyrosine to histidine change at amino acid 64 (Y64H) clearly has a huge 
impact on amelogenesis as evidenced by the dramatic clinical phenotype in 
affected animals (figure 10 above). Tyrosine can act as a receiver of phosphate 
groups transferred by receptor tyrosine kinases (serine and threonine) during signal 
transduction (Hanks et al., 1988) but there is no evidence that any tyrosine is 
phosphorylated in amelogenin. Tyrosine is most often found in beta-pleated sheet 
structures, as it is hydrophobic and prefers to be buried in hydrophobic protein 
cores (Farber and Mittermaier, 2008). The aromatic side chain in tyrosine is 
involved in protein stacking interactions with other aromatic side chains. Tyrosine 
contains a reactive hydroxyl group that can be involved with interactions with non-
carbon atoms. Tyrosine can be substituted by other aromatic amino acids (Betts 
and Russell, 2003). In contrast, histidine is a polar amino acid that does not 
substitute well with any other amino acid due to its unique biochemical properties.  
Histidine is highly hydrophilic and is most commonly found in alpha helical 
structures. The imidazole ring of the histidine side chain has a pKa near to 
physiological pH which means that subtle shifts in pH will change its net charge. 
This makes histidine the ideal amino acid for charge relay systems such as catalytic 
triads and cysteine and serine proteases (Wolfe et al., 2001). That the imidazole 
side chain changes from neutral to positive depending on pH, means that histidine 
may be hidden in a protein core or be exposed (Betts and Russell, 2003). In effect, 
histidine can act as a variable charge centre whose charge is controlled by pH and 
intuitively the insertion of such a disruptive residue into a protein is likely to affect 
both structure and function.  
In support of this contention, tyrosine to histidine mutations has been noted in 
several proteins. Tang et al., 1999 showed that a tyrosine to histidine mutation at 
position B5 of insulin changes the structure from an extended conformation (T 
state) to a stable alpha helix (R state). This R state is stabilised by non-polar 
interactions between the phenolic molecules and the B5 histidine.  Pegg et al., 
1999, showed that an alteration in the conserved tyrosine residue at position 158 to 
histidine in human O6 – alkylguanine-DNA alkyltransferase renders it insensitive to 
the inhibitor O6- benzylguanine. The presence of the charged residue in the active 
site pocket discourages the binding of hydrophobic residues. The charged residue 
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influences the steric effect, increasing resistance. Bobola et al., 2001, showed that 
a naturally occurring tyrosine to histidine replacement at residue 33 of human 
thymidylate synthase confers a 4 fold increase in resistance to 5-fluoro-2-deoxy 
uridine in mammalian and bacterial cells. 
A tyrosine to histidine mutation has also been shown to play a role in several 
diseases. 
Age related macular degeneration (AMD) has been shown to be caused  by a 
tyrosine to histidine mutation at position 402 located on C1q exon 9, and is located 
in the complement factor H (CFH) protein (SCR7) and contains overlapping binding 
sites for C-reactive protein, heparin and M protein (Giannakis et al., 2003). The 
T402H mutation causes increased inflammation in the outer retina. Subjects 
heterozygous for the mutation have a 2.5 to 4.6 fold increase in AMD. Subjects 
homozygous for the mutation have a 5.6 to 7.4 fold increase in AMD (Klein et al., 
2005). 
 Von Hippel Lindau syndrome results in benign tumours of blood vessels, 
central nervous system, eyes, adrenal glands and renal cell carcinoma. Tyrosine to 
histidine substitutions (Y112H and Y98H in von Hippel-Lindau tumour suppressor 
protein (VHL)) prevent the binding between VHL and the hypoxia inducible 
transcription factor (HIF), resulting in overexpression of angiogenic growth factors 
and local proliferation of blood vessels (Zbar et al., 1996; Ohh et al., 2000).  
It is clear that substitution of tyrosine with histidine can have great effects on 
the biochemistry and stereochemistry of proteins. In some substitutions, the 
stereochemical properties of the substituent may be sufficiently similar that protein 
function is maintained and not every point mutation leads to a noticeable 
phenotypic effect. However, due to its rather unique acid-base properties described 
above, histidine does not substitute particularly well for other amino acids (Betts 
and Russell, 2003). Not every site in a protein is equally vulnerable to mutations. 
Some areas of a protein will remain functional even with multiple sequence 
changes, while other areas cannot be altered at all without serious consequences. 
Active centres of enzymes and residues involved in protein stability are functionally 
important and evolutionary conserved and are especially vulnerable to the effects of 
any mutation (Steward et al., 2003). Although not an enzyme active centre, the 
amelogenin ATMP domain is believed to be functionally important (see section 
1.3.4.1.1) and substitution of tyrosine 64 (in blue below) with histidine adds a third 
histidine to the domain which could dramatically alter amelogenin structure and 
function as observed in Y64H mutant mice.       
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…..Y P S Y G Y E P M G G W L H H Q…… 
 
The discussion sections 4.2 and 4.4 will discuss the results showing the impact of 
the Y64H mutation on the potential of amelogenin (with and without 32 kDa 
enamelin) to nucleate mineral in vitro.  
 
The mutation in amelogenin investigated in the murine model occurs at amino 
acid 64, the third tyrosine in the amelogenin trityrosyl amelogenin peptide (ATMP) 
motif. This third tyrosine is mutated to a histidine amino acid. Figure 11 compares 
the structures of the two amino acids. 
 
Tyrosine                                                       Histidine 
Figure 11.  The structures of tyrosine and histidine amino acids at 
physiological pH. 
 
Tyrosine is partially hydrophobic so prefers to be buried in protein 
hydrophobic cores (Betts and Russell, 2003). Although essentially hydrophobic, the 
presence of the hydroxyl group allows tyrosine to participate in hydrogen bonding 
with other amino acids or ligands. This allows tyrosine to behave like a polar amino 
acid, such as arginine or lysine. However, tyrosine is overall less polar due to the 
presence of the non-polar C-C and C-H bonds in the phenolic side chain. This side 
chain allows tyrosine to be water soluble, even though it is partially hydrophobic. 
The aromatic side chain means tyrosine is involved in stacking interactions with 
other aromatic side chains. Tyrosine has a reactive hydroxyl group making it likely 
to be involved in interactions with non-carbon atoms. A common role for tyrosine 
(and serine and threonine) within intracellular proteins is phosphorylation. Protein 
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kinases frequently attach phosphates to these 3 residues as part of signal 
transduction pathways. 
Histidine is in fact an amino acid with an ionisable imidazole side chain having 
a pKa of 6.5.  Histidine is generally polar, but due to its chemical properties, it does 
not substitute particularly well with any other amino acid. Because its side chain  
pKa is near to physiological pH histidine is switched between the uncharged 
protonated and the charged un-protonated form on relatively small fluctuations in 
environmental pH. This flexibility has two effects; 1) ambiguity about whether it 
prefers to be buried in the protein core or exposed to solvent, and 2) histidine is the 
ideal residue to serve as a charge relay centre in a range of enzymes as the side 
chain can accept or donate protons.  
For example. in catalytic triads, the basic nitrogen of histidine is used to 
subtract a proton from serine, threonine or cysteine to activate it as a nucleophile. 
 The imidazole ring is aromatic at all pH values. It contains 6 pi electrons; four 
from 2 double bonds and 2 from a nitrogen lone pair. It can form pi stacking 
interactions but is complicated by the potential positive charge incurred when the 
side chain nitrogen is protonated.  
Tyrosine and histidine, along with phenylalanine and tryptophan, are aromatic 
amino acids in that they have aromatic side chains. Aromatic residues are proposed 
to participate in ‘stacking’ interactions (Hunter et al., 2001). Here numerous 
aromatic rings stack on top of one another such that their PI electron clouds are 
aligned. They can also play a role in binding to specific amino acids, such as 
proline. SH3 and WW domains use these residues to bind their polyproline-
containing interaction partners (Weisner et al., 2002).  
Looking at the genetic codes for tyrosine and histidine reveals that this amino acid 
mutation can actually be pin-pointed to a single base pair change. The mutation is a 
uracil to cysteine change in the first position of the RNA codon. Uracil and cysteine 
are both pyramidines, containing one small aromatic ring. 
 
1.4.3 Autosomal dominant amelogenesis imperfecta (ADAI) 
 Autosomal dominant forms of AI map to chromosome 4q11-q21. ENAM, 
AMBN and albumin all map to this same region (Hu et al., 2000; Dong et al. 2000). 
Autosomal dominant inheritance describes the route by which the mutation occurs.  
Two copies of the gene occur on the chromosomes, in this case chromosome 4, but 
autosomal dominant inheritance means that only one copy of the gene needs to be 
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altered for the associated phenotypic disease to manifest i.e. the mutated gene is 
dominant to the wild type gene. 
 Eight mutations have been identified in the ENAM gene which give rise to 
ADAI. These have a variety of phenotypic effects on the enamel. Some mutations 
decrease the amount of enamelin produced (Kida et al., 2002; Hart et al., 2003; Kim 
et al., 2005A) . Others result in a shortened or altered enamelin which results in 
shallow pits and horizontal grooves in the tooth enamel. Kida et al. (2002) identified 
a Japanese family with a single G deletion with a series of 7 G residues at exon 9 – 
intron 9 boundary of the enamelin gene. ENAM mutations result in hypoplastic 
enamel; thin enamel with spaced apart teeth. Figure 12 shows the human 
manifestation of this hypoplastic enamel. 
 
 
Figure 12. Hypoplastic enamel due to a mutation in the enamelin gene 
(photograph courtesy of Roger Shore). 
 
Figure 13 shows the enamelin gene and the locations of known mutations that 
cause AI in humans. The gene mutation and resulting protein alteration are given. 
The resulting AI type is also shown. Exon 2 is not found in humans, but is found in 
the rodent enamelin. 
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Figure 13. Schematic diagram of the enamelin gene showing the genetic 
location of the identified mutations (g), the resulting protein mutation 
(p), and the clinical enamel phenotype. and the resulting enamel 
phenotype. 
 
1.4.4 Autosomal recessive amelogenesis imperfecta (ARAI) 
 Kallikrein-4 maps to 19q13.4 and a mutation in the gene has been identified 
as causing autosomal recessive hypomaturation AI (Hart et al., 2004). Autosomal 
recessive inheritance means that both copies of the gene need to be  altered for the 
disease to manifest i.e. the wild type gene is dominant to the mutant gene. Three 
mutations have been identified in the MMP-20 gene that results in autosomal 
recessive AI (ARAI).  All three are single point mutations that prevent the secretion 
of functional MMP-20 protein (Kim et al., 2005B; Ozdemir et al., 2005; Kim et al., 
2006) . This results in other organic matrix proteins not being cleaved properly 
during amelogenesis, and results in soft enamel with abnormal crystal structure 
(hypomaturation AI). This causes teeth to be rough, discoloured and prone to 
breakage (Hart et al., 2004; Hu et al., 2005). 
The fact that these mutations in the genes for the enamel matrix proteins and 
proteases leads to defects in enamel formation underpins the importance of these 
5’ 3’1 2 3 4 5 6 7 8 9 10
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proteins in the biomineralisation process in tooth enamel development. Mutations in 
both the proteins and the proteases involved in amelogenesis lead to enamel 
defects, indicating that both the proteins and proteases are as important as one 
another in this finely orchestrated process. 
 
1.4.5 Other genes implicated in amelogenesis imperfecta 
Mutations in the ‘family with sequence similarity 20, member A’ gene 
(FAM20A) map to chromosome 17q24.2. FAM20 consists of 3 members. FAM20B 
is a kinase involved in phosphorylation and is expressed during the maturation 
stage of amelogenesis (Koike et al., 2009; O’Sullivan et al., 2011). FAM20C is 
essential for bone development (Hao et al., 2007). FAM20A is expressed in the 
enamel organ and gingiva (O’Sullivan et al., 2011). Mutations in the FAM20A gene 
are associated with hypoplastic AI and gingival overgrowth, resulting in the 
retention of primary dentition and delayed eruption of the permanent dentition 
(O’Sullivan et al., 2011). 
Mutations in the family with sequence similarity 83, member H gene 
(FAM83H) map to chromosome 8 (8q24.3) and code a protein associated with 
intracellular vesicles and trans Golgi organelles (Ding et al., 2009). FAM83H is 
expressed in developing teeth but is not limited to teeth and is expressed in other 
tissues of the body (Kweon et al., 2013). Mutations in FAM83H result in autosomal 
dominant hypocalcified AI (Lee et al., 2011). So far, 16 mutations have been 
identified that are non-sense or frameshift mutations in exon 5, causing premature 
translation termination between Serine 287 and Glutamine 674 (Lee et al., 2011) 
and resulting in a truncated protein (Kim et al., 2008; Lee et al., 2008; Hart et al., 
2009; Wright et al., 2009; El-Sayed et al., 2010; Lee et al., 2011). 
The WD repeat containing protein 72 gene (WDR72) encodes for an 
intracellular protein involved in protein-protein interactions. A point mutation in exon 
15 (c.2358C>G) results in a premature stop codon manifesting as autosomal 
dominant recessive AI (El-Sayed et al., 2009, 2011). El-Sayed et al., 2011 
hypothesised that the late stage of enamel maturation is affected by this mutation 
due to ultrastructural analysis of deciduous teeth revealing a reduction in mineral 
density in erupted teeth and a difference in electron density compared to normal 
enamel. 
Distal-less homeobox 3 gene (encoding DLX3) maps to chromosome 17 (q21-
q22). DLX3 is a homeodomain transcription factor expressed in dental epithelium 
and mesenchyme, as well as the neural crest, hair follicles, placenta and epidermal 
cells (Beanan and Sargent, 2000). A two base-pair deletion results in a premature 
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stop codon, causing an 88 amino acid truncated protein, manifesting as an unique 
syndromic AI known as amelogenesis imperfecta hypomaturation-hypoplastic type 
with taurodontism (AIHHT) displaying teeth with thin, hard enamel and enlarged 
pulp chambers (Dong et al., 2005). 
As more families present with amelogenesis imperfecta phenotypes, it is likely 
that more gene candidates for AI will be discovered. This will all assist with 
expanding the existing knowledge about amelogenesis and the complex blueprint 
for biomineralisation in enamel. 
 
1.4.6 Syndromic and non-syndromic disease of enamel 
Even though the enamel defects noted with AI are more often than not seen in 
isolation, some forms do have associated anomalies within the oral cavity or other 
regions of the body (Cobourne and Sharpe 2013). Hart et al 2013 noted that 
autosomal recessive AI due to an ENAM mutation is associated with open bite of 
the jaws. Dong et al 2005 noted a DLX3 mutation that resulted in autosomal 
dominant AI also resulted in taurodontism.  MacGibbon syndrome is an autosomal 
recessive form of AI, manifesting as hypoplastic, thin or absent enamel and 
nephrocalcinosis (deposition of calcium in the kidneys) (MacGibbon 1972). 
A number of conditions also result in enamel defects as one of the phenotypic 
presentations.  
Syndromes 
Kohlschutter-Tonz syndrome presents as AI, yellow teeth, spasticity and 
developmental delays (Kohlschutter et al., 1974). Tuberous sclerosis results in 
enamel hypoplasia and multiple organ hamatomas (benign tumours) (van 
Slegtenhorst et al., 1997). Focal dermal hypoplasia manifests as enamel 
hypoplasia, skin atrophy and pigmentation, fat herniation, papillomas and 
anomalies of the digits (Grzeschik et al. 2007). Smith Magenis syndrome present as 
enamel dysplasia, facial anamalies, hearing loss and delay in speech (Slager et al., 
2003). Vitamin D-dependent rickets type 1 manifests as enamel hypoplasia with 
yellow-brown discolouration, hypocalcemia, hypophosphatemia, and impaired bone 
formation (Kitanaka et al., 1998). Automimmune polyendocrinopathy is a syndrome 
that results in enamel hypoplasia, chronic mucocutaneous candidiasis and multiple 
autoimmune endocrinopathies (Perinola et al., 1998). 
Tricho-dento-osseus (TDO) syndrome has hypoplastic and hypomature 
enamel, taurodontism and defects of bone, nails and hair (Price et al., 1998; Wright 
et al., 2008). Jalili syndrome is a rare autosomal recessive disease caused by 
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mutation in the conserved domain protein 4 gene (CNNM4) that presents with 
hypoplastic and hypomineralised enamel, and conerod dystrophy of the retina 
(Parry et al., 2009; Polok et al., 2009). Morquio syndrome, also known as 
mucopolysaccharidosis type IV A, is an autosomal recessive lysosomal storage 
disease (Kirirons and Nelson, 1990). It is caused by the accumulation of GAGs, 
such as keratin sulphate and chondroitin-6-sulphate, intracellularly, due to a 
mutation in galactosamine-6-sulphate sulphatase (GALNS) (Fukuda et al.,1992). 
Patients present with dental anomalies akin to hypoplastic AI and widely spaced, 
flared maxillary incisors and pointed posterior teeth, skeletal dysplasia and opacity 
of the corneas (Barker and Welbury, 2000;  Levin et al., 1975). Type III 
Dentinogenesis Imperfecta was first identified in a population in Brandywine, 
Maryland, US. Teeth are opalescent with marked attrition. The pulps of developing 
teeth are larger than normal, but become almost completely obliterated. Scanning 
electron microscopy shows a significant reduction in the number of dentin tubules 
on fractured dentin surfaces. Enamel pitting is also noted in patients with type III DI 
(Levin et al., 1983). 
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Aims and Objectives 
The research carried out in this project complements a larger programme of 
work funded by the Wellcome Trust.  This work uses tooth formation as a paradigm 
to study biomineralisation - specifically the role of the extracellular organic matrix in 
this process.  
The specific objectives for this doctoral thesis were to investigate the in vitro 
hydroxyapatite nucleating potential of enamel proteins (amelogenin and enamelin) 
and how these proteins subsequently regulate crystal growth. Recombinant 
proteins were generated for use in these studies so as to compare the effects of a 
specific mutation in mouse amelogenin (Y to H substitution at positon 64) identified 
by the group.  The mineral produced during these in vitro studies was characterised 
chemically and by electron microscopy so that the relationship between the nature 
of the matrix protein components and resulting mineral chemistry and morphology 
could be explored.  
The main focus is on a Y64H mutation in mouse amelogenin that has 
similarities to a human amelogenin mutation, known to cause amelogenesis 
imperfecta. This mouse mutation was used to investigate whether amelogenesis 
imperfecta is caused by the secreted protein behaving differently to wild type 
amelogenin during nanosphere formation and mineralisation, or whether the 
mutation causes non-secretion of the protein. The latter possibility was explored 
using quantitative real time PCR to determine amelogenin biology at the 
transcriptomic level. 
Below is an outline of the thesis and the areas investigated. 
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A number of hypotheses will be explored as part of this thesis. 
Hypothesis 1: Is the 32 kDa enamelin breakdown product is conserved across all 
species? The majority of studies to date have used the porcine 32kDa enamelin 
product due to its ready availability. To investigate this hypothesis, western blot 
analysis of porcine and rat enamelin will be used, as  will a bioinformatics 
exploration of enamelin sequences across many species. 
Hypothesis 2: The AI phenotype generated as a result of the Y64H amelogenin 
mutation in mice is a result of the mutated protein behaving differently upon 
secretion. To investigate this hypothesis, in vitro nucleation studies will be 
performed to explore the effect of the mutation on the ability of amelogenin, and 
amelogenin in conjunction with enamelin, to nucleate hydroxyapatite mineral. In 
vitro binding studies will also be performed using the wild type and Y64H mutant 
amelogenin to investigate the effect of the mutation on protein-protein interactions. 
Hypothesis 3: The AI phenotype generated as a result of the Y64H amelogenin 
mutation in mice is a result of the mutated protein being retained in the ameloblast 
and not being secreted correctly. Similar mutations in other proteins have resulted 
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in endoplasmic stress in cells, resulting in transcription and translation 
downregulation and ultimately apoptosis of the secretory cells.  Quantitative PCR 
and SEM analysis of wild type and Y64H mutant mice incisors will be performed to 
probe whether ER stress and the unfolded protein response could be responsible 
for the AI phenotype in Y64H mutant mice. 
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Chapter 2 
 
General materials and methods 
This chapter describes the techniques and materials used throughout the 
research including the production and purification of recombinant proteins, gel 
electrophoresis, staining and antibody blotting, production of labelled proteins, and 
culture of cells in vitro. Specific experimental detail relating directly to the 
experiments conducted will be explained in detail in this chapter.  
All chemicals and reagents were from Sigma-Aldrich, Poole, Dorset, UK 
unless otherwise stated. 
2.1 Recombinant protein production 
2.1.1 Production of recombinant 32 kDa enamelin protein 
The sequence for the human 32 kDa enamelin protein (figure 14 below) was 
inserted into a pCepPU vector. This contains a BM-40 signal which allows the 
protein to be secreted. The vector was inserted in to human embryonic kidney cells 
(293-EBNA) which were then cultured in serum free medium (Rock et al., 2004; 
Marson et al., 2005). The use of eukaryotic cells maintains the post translational 
modifications of the proteins. Following intracellular transcription and translation, 
the protein was secreted into, and recovered from, the serum free media. The 
recovered protein was confirmed by mass spectrometry and western blot analysis. 
Protein production was performed by Dr J. Maycock at Manchester University. 
 
PWP IPQRPPTAF GRPKFSNEEG NPYYAFFGYH GFGGRPYYSE 
EMFEDEYEKPK EKPPKPEDP PPDDPPPEAS TNTVPDANA TQSOPEGGND 
TSPIGNTGPG PNAG 
Figure 14: The amino acid sequence for the 32 kDa recombinant mouse 
enamelin. The amino acids in red and underlined are the sites of the 
post-translational modifications. 
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2.1.2 Production of recombinant wild type and Y64H mutant 
amelogenin protein 
An overview for the production process for wild type and Y64H mutant 
amelogenin recombinant proteins is shown in figure 15.   
In brief, in Step 1 full length wild type and mutant Y64H mouse amelogenins 
were expressed using a pET28 expression vector (Novagen, Merck KGaA, 
Darmstadt, Germany) modified with a HRV 3C protease site  and HIS tag in 
Rosetta DE3 E.coli cells (Novagen, Merck KGaA, Darmstadt, Germany).  In Step 2, 
the cells were harvested by centrifugation and lysed using 6M guanidine-HCl. Step 
3, the proteins were purified using nickel affinity chromatography (His Trap Nickel 
column, GE Biosciences, Little Chalfont, Bucks, UK) in the presence of 8M urea. In 
Step 4 the histidine tag was removed by incubating the protein with HRV 3C 
protease (A.G. Scientific, Inc., San Diego, California) overnight in 50 mM tris buffer 
(pH 8.0) at a concentration of 25µg/mL. Step 5 was the further purification of the 
cleaved and uncleaved recombinant amelogenin proteins by preparative SDS-
PAGE (Bio-Rad Model 491 Prepcell, Bio-Rad, Hemel Hempstead, UK) using an 8 
cm 12% polyacrylamide gel run at a constant power of 1 Watt. Fractions were 
collected over 300 minutes at a flow rate of 70 µL/min and fractions containing the 
cleaved purified recombinant amelogenin protein were identified by standard SDS 
PAGE. This was step 6. In Step 7 the relevant fractions where the cleaved and 
uncleaved recombinant proteins were located were desalted against 125 mM formic 
acid using a Hi Prep 26/10 desalting column (GE Biosciences, Little Chalfont, 
Bucks, UK). This resulted in step 8; purified, cleaved and uncleaved recombinant 
amelogenin protein. The uncleaved protein was returned to step 4 for further 
cleavage. The cleaved protein was freeze-dried and protein identity confirmed by 
mass spectrometry and western blotting (step 9).  
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Figure 15:  Sequence for recombinant amelogenin protein purification. The 
same procedural steps were used for recombinant wild type and 
recombinant Y64H mutant amelogenin production. 
 
Step 1: The sequences for wild type and mutant amelogenin were inserted 
into a PET28 expression vector with a HRV 3C protease site (Leu-Glu-Val-Leu-
Phe-Gln-Gly-Pro), and transfected into Rosetta DE3 E.coli cells. This was spread 
onto an agar plate and incubated overnight at 37°C.  Resulting colonies were picked 
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with an inoculation loop and incubated in 10 mL tryptone soya broth for 7 hours at 
37°C with shaking (200-300 rpm). This resulting ino culant was used as a starter 
culture or for creating glycerol stocks for future use.  Glycerol stocks were created 
by mixing 0.5 mL starter culture with 0.5 mL 50% glycerol in a cryovial. These were 
stored at -80°C until needed.  
Cells were cultured in 5 x 50 mL culture medium in 2 L conical flasks. The 
medium consisted of 2.5 g yeast extract and 13.5 g tryptone soya broth in 450 mL 
distilled water. This was autoclaved before use and supplemented with 2.5% 1 M 
Na2HPO4, 2.5% 1 M KH2PO2, 5% 1 M NH4Cl, 0.5% 1 M Na2SO4, 0.4% 1 M MgSO4, 
0.1% CaCl2, 0.5% Glycerol, 0.2% Lactose, 0.25% 1 M Glucose, 500 µL of 30 mg/ml 
kanamycin and 500 µL 34 mg/mL chloramphenicol. All supplements were sterilised 
before use. One 10 mL starter culture was added to each flask, and the flask was 
incubated overnight at 37°C with shaking. 
Step 2: The following morning, the cultures were centrifuged at 10,000 rpm for 
10 minutes. The supernatant was discarded and the cell pellet lysed in 6 M 
guanidine hydrochloride-HCl buffer pH8.0 (15 mL of 10 x stock buffer (68.995 g 
NaH2PO4 and 6.0 g tris volumised to 500 mL with distilled water) plus 85.95 g 
guanidine hydrochloride, volumised to 150 mL with distilled water), containing 3 
protease inhibitor tablets per 150 mL buffer (Roche, Welwyn, Herts Uk). The pellets 
were vortexed to smash open the cells. The slurry was then centrifuged for 1 hour 
at 20,000 rpm. After centrifugation, the supernatant was filtered using a disposable 
filter (Nalgene, Thermo Fisher Scientific, Loughborough, UK). 
Step 3: Following centrifugation and filtration as described above, the filtrate 
was loaded onto a 5 mL Hi-Trap chelating column (GE Biosciences, Little Chalfont, 
Bucks., UK) primed with nickel sulphate. The protein attached to the column via the 
HIS tag, a series of 6 histidines. The protein was eluted with 8M urea buffer 
containing 0.4% imidazole (10 ml 10 x tris buffer (30.28 g tris plus 116.8 g sodium 
chloride, volumised to 500 mL with distilled water) plus 2.72 g imidazole and 48.08 
g urea, volumised to 1000 mL with distilled water and the pH adjusted to 8. The 
eluent was then run on the Hi-Prep 26/10 desalting column on the AKTA explorer 
FPLC (GE Biosciences, Little Chalfont, Bucks., UK), using degassed 125 mM 
formic acid as the buffer. 
Step 4: The protein fractions obtained from FPLC were freeze dried using a 
Christ freeze dryer (SciQuip, Shrewsbury, UK). To cleave the HIS Tag, the 
lyophilised protein was resuspended at 2 mg/mL in 50 mM tris-HCl pH 8. Cleavage 
occurred with the addition of HRV 3C protease (human rhinovirus 3C protease, a 
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cysteine protease that cleaves between Gln and Gly) (A.G. Scientific, San Diego, 
California) followed by overnight incubation at 4°C .  Confirmation of cleavage was 
performed by running a small fraction of the cleaved protein on a SDS-PAGE mini-
gel and staining with Coomassie Blue stain (Instant Blue ready to use Coomassie 
stain, Expedeon, Cambridge)(see below).  
Step 5: The cleaved protein was then run down the PrepCell 491 (Bio-Rad, 
Hemel Hempstead, UK) to separate cleaved and uncleaved protein. In order to 
prepare purified fractions from cleaved amelogenin, preparative SDS- 
polyacrylamide gel electrophoresis was used (discontinuous buffer system 
analytical SDS-PAGE). Separation of individual protein components was carried out 
on the basis of molecular size using SDS-PAGE according to the method of 
Laemmli (1970). The resolving gel (15% acrylamide containing 3% bisacrylamide in 
1.5 M Tris-HCl buffer, pH 8.8, 0.1% SDS) was cast in a 37 mm diameter tube using 
the model 491 Prep Cell (Bio-Rad, Hemel Hempstead, UK) according to the 
manufacturer’s instructions (total volume of gel used = 50 mL). The resolving gel 
contained 20% glycerol, allowing the stacking gel layer to be overlaid immediately. 
The stacking gel comprised of 10 mL 4% acrylamide (3% bisacrylamide in 0.5 M 
Tris-HCl, pH 6.8, 0.1% SDS) and was overlaid with water-saturated butan-2-ol. The 
gel was left to polymerise overnight at room temperature. Maintenance of the gel at 
room temperature during polymerisation of the gel was achieved by circulating 
water between a reservoir and the cooling core within the gel tube using a 
recirculation pump. This prevented excessive heat build up and assisted in the 
formation of uniform gels. The water-saturated butan-2-ol was removed and the top 
of the gel washed with SDS running buffer. Each 2 mL of HRV-3C treated 
recombinant amelogenin was mixed with 500 µL of 4 x SDS sample buffer 
(containing bromophenol blue) (see recipe below) and loaded onto the top of the 
gel. Electrophoresis was performed at 12 watts constant power at room 
temperature with running buffer circulating through the cooling core. Once the 
bromophenol blue dye front of the protein loading reached the bottom of the gel 
(approximately 6 hours) the elution pump was turned on and set to elute at 0.75 
mL/min with the fraction collector collecting samples every 10 minutes. A total of 80 
fractions were collected. After collection, every third fraction was re-electrophoresed 
by diluting 15 µL of the fraction with 5 µL of 4x SDS sample loading buffer 0.625M 
Tris-HCl, 10% glycerol, 2% SDS, 0.00125M bromophenol blue) and running on 
12% SDS-PAGE mini-gels. This allowed the specific fraction location of proteins of 
interest to be identified. Fractions with similar protein molecular weight size content 
were pooled together. These were then desalted using an AKTA explorer FPLC 
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system (GE Biosciences Little Chalfont, Bucks., UK) and a Hi-prep™ 26/10 
desalting column and 0.125 M formic acid. The desalted protein was then freeze-
dried and used for further experiments. 
 
 
Figure 16.  Schematic diagram of the Bio-Rad PrepCell 491 in action. 
 
 
Figure 17.  Schematic diagram of the flow inside the Bio-Rad PrepCell 491. 
 
Step 6: SDS-PAGE gels of the fractions were run and silver stained to 
visualise the proteins Separation of proteins was carried out on the basis of 
molecular size using SDS-PAGE based on the procedure described by Laemmli 
12 w
Power pack Prep cell Recirculation 
pump
Elution 
pump
Fraction 
collector
Recirculation 
pump
To 
fraction 
collector
Power 
pack
Circulation 
buffer
Polyacrylamide
gel
Dialysis 
membrane Cooling 
core
- 83 - 
(1970). Gels were cast in Protean Tetra mini gel rigs (Bio-Rad, Hemel Hempstead, 
UK) according to the manufacturer’s instructions. The resolving gel consisted of 
12% total monomer (acrylamide and N’N’-bis-methylene-acrylamide (bisacrylamide) 
of which 3% was bisacrylamide) in gel buffer (1.5M Tris-HCl, pH 8.8, 0.1% SDS) 
with a stacking gel of 4% total monomer (3% bisacrylamide) in gel buffer (0.5M Tris-
HCl, pH 6.8, 0.1% SDS). Once polymerisation was complete, the gel surface was 
washed well with 1 x SDS running buffer (25 mM Tris, 0.192 M glycine, 0.1% SDS, 
pH 8.3).  Recombinant amelogenin proteins were dissolved in SDS sample buffer 
(160 mM Tris-HCl, pH 6.8, 2% SDS, 26% glycerol, 0.1% bromophenol blue) to a 
concentration of 1 µg/µl and heated at 90°C for 2 m inutes prior to loading. 
Molecular weight markers covering the range 2 to 250 kDa (Precision protein 
standards, Bio-Rad) were loaded at 5 µL per lane. Gels were run at room 
temperature using 1 x SDS running buffer at 200 V constant voltage until the blue 
dye front reached the bottom of the gel (approximately 45 minutes). After removal 
from the glass plates, the gels were either stained in Coomassie blue R250 (Instant 
Blue Stain, Expedeon Ltd, Babraham Hall, Cambs., UK) or silver stained. 
Coomassie blue is a triphenylmethane dye that was first used to visual proteins in 
polyacrylamide gels by Meyer and Lamberts (1965). The Coomassie blue dye binds 
to proteins in the gels by a combination of van der waals bonds and electrostatic 
bonds to form strong non-covalent complexes. The formation of this dye-protein 
complex allows the blue colour to be visualised due to stabilisation of the negatively 
charged anionic form of the dye. The number of dye molecules binding to the 
proteins in the gel is semi-quantitative as the Coomassie blue dye binds more 
strongly to basic amino acids than acidic amino acids. InstantBlue Coomassie stain 
was provided ready to use. The gel was briefly washed with distilled water prior to 
placing into Coomassie stain, sufficient to cover the gel. The gel was incubated in 
Coomassie stain at room temperature with shaking for a minimum of one hour 
(overnight if applicable), Following incubation in Coomassie stain, the stain was 
decanted and the gel briefly washed in distilled water to remove any excess stain 
prior to scanning. For silver staining, the gel was placed into a solution of DL-
Dithiothreitol (DTT) (4 µL 1M DTT in 100 mL distilled water) for 20 minutes. The 
DTT solution was removed and the gel briefly washed in distilled water, before 
staining in a 0.2% solution of silver nitrate for 20 minutes. The silver nitrate solution 
was removed and the gel briefly washed in distilled water. A small amount of 
developer solution (3% sodium carbonate, 0.5% formaldehyde (37%)) was added to 
the gel and discarded when the solution turned black. Further developer was added 
until the bands became visible. The gel was stored in 10% acetic acid. 
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Step 7: The cleaved and uncleaved fractions were pooled separately and run 
down the desalting column. The resulting fractions were pooled and freeze dried. 
The uncleaved samples can be cleaved again with HRV 3C protease (back to step 
4). 
Step 8: The purified, cleaved recombinant wild type and Y64H mutant 
amelogenin proteins were then used in three ways. For confirmation of identity, 
samples of the recombinant amelogenin proteins were subjected to mass 
spectrometry and western blotting (step 9 below). Once the correct identity was 
confirmed, the recombinant amelogenin proteins were used in in vitro mineral 
nucleation studies (section 2.2) and in vitro protein- protein binding studies (section 
2.3). 
Step 9: The identification of the recombinant amelogenin proteins was 
confirmed by mass spectrometry and western blotting. 
2.1.2.1 Mass spectrometry 
The molecular weights of the recombinant proteins were identified by time of 
flight mass spectrometry. A small sample of purified lyophilised protein was sent to 
the mass spectrometry service within the University of Leeds. Dr James McNult ran 
the fractions on Q-TOF MS/MS – tandem electrospray time of flight mass 
spectrometry- to give an accurate molecular weight for the proteins. 
2.1.2.2  Western blotting 
Western blotting uses antibodies raised against specific proteins to permit a 
more specific protein identification following separation on SDS-PAGE. 
Recombinant amelogenin proteins were loaded and run on SDS-PAGE as 
described in step 6 above and transferred onto nitrocellulose membrane (Geneflow, 
Fradley, UK) using a transblot module (Bio-Rad) using Towbin’s transfer buffer 
(0.025M Tris, 0.192M glycine, 10% methanol, pH 8.6) (Towbin et al., 1979). 
Transfer occurred at 100 volts for 1 hour. The nitrocellulose membrane was then 
placed into 3% non-fat milk powder (Bio-Rad, Hemel Hempstead, UK) in tris 
buffered saline (TBS), and incubated overnight at room temperature. This blocks 
non-specific background proteins from reacting with the antibodies. The block was 
removed and the membrane thoroughly washed in TBS containing 0.05% Tween-
20 (TBS-T). Primary antibody (rabbit anti-amelogenin teleopeptide (Eurogentec)) 
was applied at 1:1000-1:3000 dilution in 1% non-fat milk in TBS, and incubated for 
1 hour at room temperature with shaking. The primary antibody was removed and 
the membrane thoroughly washed in TBS-T. The secondary antibody was applied 
at 1:3000 dilution in 1% non-fat milk in TBS. The secondary antibody was selected 
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on the basis of it being species specific to the primary antibody, e.g. goat-anti-rabbit 
secondary antibody.  All secondary antibodies used in this thesis were conjugated 
to horse radish peroxidise (HRP) to permit visualisation following reaction with a 
chromogenic substrate. The membrane was incubated for 1 hour at room 
temperature with shaking in the secondary antibody. The membrane was then 
thoroughly washed before applying the colour developer. One ml of 25 times 
concentrated alkaline phosphatase developer concentrate was mixed with 24 mL 
ddH20 and 0.25 mL reagent A (NBT – nitroblue tetrazolium) and 0.25 mL BCIP (5’-
bromo-4-chloro-3-indoyl phosphate). Cross reacting protein bands stained purple. 
2.2 In vitro mineral nucleation studies using recombinant 
amelogenin and enamelin proteins 
In order to determine the ability of the recombinant amelogenin proteins (wild 
type and Y64H mutant amelogenin) and recombinant 32 kDa enamelin protein to 
nucleate hydroxyapatite mineral, an in vitro steady state agarose gel system was 
used. The system used in this thesis was based on the system used by Hunter and 
Goldberg (1993), although several different methods have been used by 
researchers worldwide to investigate the mineral nucleating properties of 
recombinant ECM proteins (see discussion section 4.2 and appendix 1). The in vitro 
steady state agarose system was used by Hunter and Goldberg to investigate the 
mineral nucleating properties of bone extracellular matrix proteins.  In this particular 
steady state system, the recombinant protein(s) of interest was immobilised in an 
agarose gel plug in a central chamber. Either end of the gel was capped with a 
piece of dialysis membrane. Reservoir chambers were placed on either end of the 
central chamber and the whole block screwed tightly together to prevent leakage of 
buffer. Into one reservoir chamber, buffer containing a supersaturation level of 
phosphate was pumped at a constant rate, and into the opposite reservoir chamber 
buffer containing a supersaturation level of calcium was pumped. The calcium and 
phosphate ions diffused across the agarose gel and where they encountered 
protein, the potential for mineral nucleation occurred. If the recombinant protein was 
able to nucleate mineralisation, a white deposit was visible in the agarose gel. The 
identity of this mineral deposit was interrogated using quantification of phosphate, 
and energy dispersive X-ray spectoscopy (EDX), and the structure of the mineral 
crystals examined by scanning electron microscopy and transmission electron 
microscopy. 
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2.2.1 Steady state agarose gel system 
 Modified dialysis cells were used based on the system of Hunter and 
Goldberg (1993). The devices were constructed out of 1cm thick Perspex. The two 
reservoir chambers had in/out ports for buffer flow and a 1 mL capacity reservoir. 
The central chamber piece had a hole drilled all the way through it, with a 1.0 cm 
diameter and 0.95 mL capacity. All three pieces were held together with galvanised 
screws and wing nuts (figure 18). Each modified dialysis cell contained either a 
negative control (gel and buffer only), positive control (gel, buffer and PGA) or 
recombinant protein (gel, buffer and recombinant protein at certain concentrations). 
Triplicates of the negative controls, positive controls, and recombinant proteins 
(each concentration) were connected together to form the steady state agarose 
system. Each steady state system set up was incubated for 7 days at 37⁰C with a 
constant rate of calcium buffer pumping through one side of the dialysis cells, and a 
constant rate of phosphate buffer pumping through the opposite side of the dialysis 
cells. 
 
Figure 18.  Exploded view of the modified dialysis  cell used for the steady 
state agarose gel system.  The end buffer reservoir chambers show the 
in/out ports in blue. A buffer reservoir is visible in each end piece. The 
central gel chamber piece shows the hole through the middle into which 
agarose gel is poured. 
Buffer reservoirs 
Central gel         
chamber 
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 The system uses metastable, supersaturated (with respect to hydroxyapatite) 
conditions and is very sensitive to concentration changes. Prior to use, all Perspex 
components and glassware were washed in Decon 90 (Decon Laboratories, Hove, 
UK), rinsed with distilled water, acid washed (0.1 M HCl overnight) and further 
rinsed twice with distilled water. The central gel chambers were silinised by dipping 
in dichlorodimethylsilane (DCMS) for a few seconds in a fume hood. They were 
allowed to air dry and rinsed in distilled water. They were then wiped down with lint-
free tissue. Any dust or particles can cause nucleation, giving false positive results. 
 The reservoir of one buffer reservoir end piece was covered by a piece of 
1,000 Dalton molecular weight cut off dialysis membrane (Spectrapor 7 membrane, 
VWR 132105, VWR, Lutterworth, Leics., UK). The central gel chamber was placed 
over this and held in place with 2 screws/nuts. Low melting point sea plaque 
agarose (Bio-Rad, Hemel Hempstead, UK) was dissolved at 2% in distilled water, 
by microwaving, then cooled and maintained at 50-55°C.  It was important to 
maintain the temperature below 60⁰C or the recombinant proteins and PGA positive 
control would be denatured when added to the agarose gel. The 2% agarose 
solution was mixed with an equal volume of double concentrated steady state buffer 
(40 mM HEPES, 300 mM NaCl, pH 7.4), vortexed and maintained at 50-55°C. This 
was the negative control. The positive control was prepared in the same way as the 
negative control but contained 10 µg/mL Poly-L-glutamic acid (PGA – Sigma 
P4886). The test samples (recombinant 32 kDa enamelin at 10 µg/mL, 5 µg/mL, 2.5 
µg/mL and 1 µg/mL) were prepared as per the PGA positive control. Bradford assay 
analysis (Bio-Rad, Hemel Hempstead, UK) allowed the recombinant 32 kDa 
enamelin to be diluted to a stock solution of 100 µg/mL with distilled water. The 
recombinant 32 kDa enamelin was further diluted to the concentration described 
above with steady state buffer (20 mM HEPES, 150 mM NaCl, pH 7.4). For a 
description of the Bradford assay, see section 2.3.3 in the protein-protein binding 
assay section. 
 All samples were carefully sonicated to remove any air bubbles. Once 
prepared, 0.95ml of each sample was pipetted in triplicate into the  central gel 
chambers, so that the solution was slightly higher than the height of the cavity (to 
allow for contraction when cooled). Once cool, another piece of dialysis membrane 
was placed over the central piece and the other end piece place over. The devices 
were assembled with 4 screws/nuts per device and connected in series with 180 
PVC tubing (Saint-Gobain Performance Plastics, Bristol, UK). A calcium buffer (20 
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mM HEPES, 150 mM NaCl, 6.5 mM Ca (NO3)2.4H2O, pH7.4) was pumped through 
the devices on one side, and a phosphate buffer (20 mM HEPES, 150mM NaCl, 
3.9mM Na2HPO4.2H2O, pH7.4) was pumped through the devices on the other side 
counter currently. A peristaltic pump was used at a flow rate of 10 mL/hour (1 
mL/hour/cell). The entire apparatus was incubated at 37°C for 7 days. A schematic 
showing one of the modified dialysis cells is shown in figure 19. 
 
Figure 19. Diagram of a single steady state cell looking down onto the top of 
the cell Buffers containing calcium and phosphate are circulated 
counter currently. The agarose gel in the central gel chamber is 
separated from the buffer reservoir chambers by dialysis membrane. 
Agarose gel is present in the centre portion only. Diagram provided by 
Ashley Firth, Department of Oral Biology. 
 
2.2.2 Phosphate assay 
The phosphomolybdate method is a common technique for the analysis of 
inorganic phosphate  (Pi  or PO4-3). The assay is based upon the reaction of Pi 
with an excess of molybdic acid (generated by combining sulphuric acid with 
ammonium molydate) which produces the colourless phosphomolybdous acid 
complex. The colour generated is quite stable and follows Beer’s law (the 
absorbance measured is proportional to the concentration of the inorganic 
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phosphate). This method is restricted to measurement of inorganic phosphates. 
Organophosphates do not react with molybdic acid and do not produce colour in the 
assay (Smith and Ames, 1966).  
The degree of mineral deposition in the gels was determined by phosphate 
analysis. After incubation, the steady state system apparatus was dismantled and 
the agarose gels centres removed from the central chamber and photographed. 
Any presence of mineralisation (a milky white precipitate)  was noted. One of each 
triplicate gel sample (positive control, negative control or recombinant protein) was 
used for SEM/TEM studies and two ashed for phosphate analysis. For ashing, the 
individual agarose gels were placed into separate small conical flasks, 5 mL of 
concentrated nitric acid was added and the agarose gel in acid boiled gently until 
less than 1 mL remained. This was then made up to 10 mL with distilled water and 
stored at 4°C in air tight containers until needed.  
Phosphate standards of 0-100 µM were prepared from a stock solution of BDH 
phosphate standard (10 mM). Three hundred µL of blank/standard/sample was 
mixed with 0.7 mL of the colour developer (10% ascorbic acid mixed with 6 parts of 
0.42% ammonium molybdate.4H2O in 0.5M H2O) and incubated at 37°C for 2 
hours. Two hundred  µl aliquots, in triplicate, were placed into the wells of a 96-well 
plate and absorbance (minus blanks reading) read at 820 nm (Dynex plate reader, 
Dynex Technologies, Worthing, UK).  
The standards were used to construct a linear calibration curve from which 
phosphate content of the samples was determined. 
Figures 20 and 21 show the white mineral deposit in situ within the apparatus, 
after incubation of the steady state agarose gel system for 7 days at 37⁰C. 
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Figure 20.  Picture of a dialysis cell fully assembled, post steady state run. 
Gel is present in the centre and white mineral precipitate is visible.  
 
Figure 21. Side view of the fully assembled dialysis cell after a steady state 
run. A band of white mineral precipitate is clearly visible in the centre 
gel. 
 
2.2.3 Scanning electron microscopy (SEM) 
 To investigate the morphology of the mineral crystals nucleated in the 
presence or absence of recombinant proteins, electron microscopy (both scanning 
and transmission) was used. The areas of the agarose gels containing the visible 
mineral precipitation were excised using a razor blade, and was then cut in half. 
One piece of agarose gel containing the mineral deposit was prepared for SEM by 
Gel plug in situ 
Mineral   
precipitate 
in gel plug 
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washing with water taken to pH 10 with ammonium hydroxide. The agarose gel 
piece was then incubated in 6% sodium hypochlorite overnight or until the gel 
disappeared. The released mineral crystals were pelleted by centrifugation and 
washed again with water at pH 10. The crystals were finally resuspended in 
absolute ethanol. A 50 µL aliquot was placed onto a SEM stub and allowed to air 
dry before vacuum drying overnight. Samples were sputter coated with 5 nm of gold 
for SEM using a JEOL JSM35 Genie Scanning Electron Microscope (SEM), or 5 nm 
of platinum for SEM using a Leo 1530 field emission gun scanning electron 
microscope (FEGSEM – GEMINI, Oxford Instruments).  
 
2.2.4 Energy dispersive X-ray (EDX) spectroscopy 
The chemical composition of the recovered mineral crystals was analysed 
using energy dispersive X-ray (EDX) spectroscopy using the JEOL JSM35 Genie 
Scanning Electron Microscope. 
 
2.2.5 Transmission electron microscopy (TEM) 
To corroborate the morphologies of the mineral crystals nucleated by 
recombinant proteins seen by SEM analysis, TEM was also used. The second half 
of the agarose gel containing the mineral deposits excised as described in section 
2.2.3  was washed with water at pH 10 and fixed in 2% glutaraldehyde (buffered at 
pH 7.3 by 0.1M sodium cacodylate) for 2 hours at ambient temperature. The fixed 
agarose gel pieces containing mineral deposits were then rinsed four times in 0.1M 
sodium cacodylate buffer (pH 7.3). The fixed agarose gel pieces containing mineral 
deposits were then washed twice with pH 10 water, and dehydrated through a 
series of ethanol solutions; 30 minutes in each of 30%, 50%, and 70% ethanol , two 
times for 30 minutes in 90% ethanol, and three times for 30 minutes in 100% 
ethanol. The fixed agarose gel pieces containing mineral deposits were then 
embedded in LR white resin in beem capsules. 
 Ultra-thin sections of 50-70 nm were cut using an ultra-microtome and 
mounted onto 300-mesh carbon/formavar coated copper EM grids. The sections 
were viewed using a Philips E-400 transmission electron microscope at varying 
magnifications. 
 
- 92 - 
2.3 Protein- protein binding assays 
To investigate whether the Y64H mutation in amelogenin was a loss of 
function mutation, impacting on the ability of the protein to form the ECM for 
mineralisation, in vitro binding assays were used. The recombinant wild type and 
Y64H mutant amelogenin proteins were used in a modified ligand-binding platform 
(based on a FITC-FITC alternative system to ELISA, Harmer and Samuel., 1989) to 
determine the ability of the recombinant protein to bind to itself and other ECM 
proteins 
 
2.3.1 Production and labelling of recombinant proteins 
Amelogenin wild type and Y64H mutant recombinant proteins were produced 
as previously described (see general materials and methods section 2.1.2). Correct 
molecular weight was confirmed by mass spectrometry, and the nature of the 
protein was confirmed by western blot analysis. 
 Fluorescein isothiocyanate (FITC) labelling was performed on the 
recombinant proteins, as described in section 2.3.2 below. Analysis of fluorescence 
was performed by SDS-PAGE analysis. 
 Unlabelled and FITC labelled proteins were freeze-dried before use. 
Lyophilised proteins were stored at -20°C prior to use. 
 
2.3.2 Fluorescein labelling of recombinant amelogenin proteins 
Fluorescein isothiocyanate (FITC) (Sigma, Poole, Dorset, UK) was used to 
add a fluorescent tag to recombinant amelogenin proteins for use in protein binding 
experiments.  Protein was dissolved in 0.1M sodium carbonate buffer (pH 9) to give 
a final concentration of 4 mg/mL of protein. FITC was dissolved in anhydrous 
dimethyl sulphoxide (DMSO) to give a final concentration of 1 mg/mL. The FITC 
solution was prepared fresh for every reaction. For every 1 mL of protein solution, 
50 µL of FITC was added slowly in 5 µL increments, while continuously stirring. The 
mixture was then incubated in the dark at 4°C, stir ring continuously. After 6 hours 
incubation, ammonium chloride was added to give a final concentration of 50 mM. 
Incubation continued for a further 2 hours. The FITC-labelled protein was then 
dialysed against PBS for 72 hours at 2-8⁰C, changing the buffer every 24 hours. 
Slide-a-lyser™ cassettes were used for dialysis (Pierce, Thermo Fisher Scientific, 
Loughborough, UK). A 5 µL sample of labelled protein was run on an SDS-PAGE 
mini-gel, and viewed under dark light (dark light reader – Merck KGaA, Darmstadt, 
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Germany) to confirm fluorescence. The labelled protein was then freeze-dried prior 
to further use. 
 
2.3.3 Bradford assay to determine protein concentration 
The Bradford assay is a quick and sensitive method for determining 
microgram quantities of protein in a solution. It utilises the principle of protein dye 
binding by measuring the colour change of Coomassie Brilliant Blue G-250 dye in 
response to varying concentrations of protein. The dye binds primarily to basic 
(especially arginine) and aromatic amino acids in the protein sequence. The greater 
the concentration of protein, the more intense blue colour is seen in the reaction 
(Bradford, 1976). 
The Bio-Rad Quick Start Bradford assay (Bio-Rad, Hemel Hempstead, UK) 
was used to confirm the recombinant protein concentrations prior to use in further 
experiments using a 96-well plate format.  Seven concentrations of bovine serum 
albumin (BSA) were used as standards. Concentrations of 0.125, 0.25, 0.5, 0.75, 
1.0, 1.5 and 2.0 mg/mL BSA were used to produce a standard curve.  These, and 
the unknown concentrations of recombinant protein, were mixed 50:50 with the 
Quick Start Bradford reagent. This was incubated for 5 minutes before aliquoting in 
triplicate into the wells of a clear 96-well plate. The plate was read at 595 nm on the 
plate reader (Dynex Technologies, Worthing, UK) and the protein concentrations 
determined by interpolating the absorbance values for the unknown protein 
concentrations against the BSA standard curve values. 
 
 2.3.4  Binding assays 
Several combinations and concentrations of proteins were used to investigate 
recombinant amelogenin protein binding to recombinant amelogenin protein. The 
experimental procedure remained the same for all. Wild type or Y64H mutant 
recombinant amelogenin was dissolved in 0.1M sodium carbonate buffer (pH 9). 
One hundred microlitres of unlabelled protein was placed into the wells of the 
specialized plate in triplicate.  Microfluor 2 (7205 – Thermo Fisher Scientific, 
Loughborough, UK) polystyrene plates were used for all of the binding assay 
studies. These were a black plate to reduce background signal to noise, to improve 
assay sensitivity, to minimize crosstalk and prevent light piping between the wells. 
The plates have a slightly hydrophilic surface for increased binding of biomolecules 
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with a hydrophilic/hydrophobic character, such as proteins. The plates have a 96-
well format. 
The plates were incubated overnight at 4°C. The unb ound, unlabelled protein 
was removed and the plate was washed three times with TBS-T (tris buffered saline 
containing 0.05% Tween-20). The potential for non-specific binding was then 
blocked by applying 100 µL 1% BSA in TBS for 1 hour at room temperature. The 
blocking solution was removed and the plate washed three times with TBS-T. FITC-
labelled wild type or Y64H mutant amelogenin was dissolved in 0.1M sodium 
phosphate buffer (pH7). One hundred microlitres of the FITC-labelled protein was 
applied to the wells of the plate, and the plate was incubated for 2 hours at room 
temperature. The plate was read on an Ascent Fluoroskan plate reader (Thermo 
Fisher Scientific, Loughborough, UK) after washing three times with TBS-T to 
remove any unbound, FITC-labelled protein. After washing, 100 µl distilled water 
was placed into the wells prior to reading. Excitation of fluorescence was achieved 
at 488 nm and emission at 538nm. Ascent software was used to analyse the data. 
The system has sensitivity of 0.01 RFU (relative fluorescence units). 
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2.4 Enamelin breakdown studies  
The majority of studies into enamelin use the 32 kDa enamelin breakdown 
product. As described in the introduction (section 1.3.4.3) the major enamelin 
processing product is the 32 kDa enamelin, and due to the ready availability from 
the meat industry, the porcine 32 kDa enamelin is the most commonly used 
enamelin for enamel ECM studies. To investigate whether the 32 kDa enamelin 
processing product is the major enamelin product across species, the enamel 
organs from pig and rat teeth were extracted and the molecular weights of the 
breakdown products over time investigated by SDS-PAGE and western blotting. 
 
2.4.1 Extraction of the enamel organ from rat incisors 
Male Wistar rats of approximately 150 g were euthanized by CO2 inhalation 
and the lower incisors dissected from the lower mandibles. The enamel organ was 
gently wiped with damp tissue and left to air dry for one minute to expose the white 
opaque zone. This white opaque zone layer represents the start of the maturation 
stage in amelogenesis resulting from the hugely hydrated porous tissue drying out 
on exposure to air (Hillier et al., 1975). The developing enamel was carefully 
dissected with a scalpel in to the early secretory (S1), secretory (S2), transition (T) 
(all 1.5-2 mm sections apical to the white opaque zone), the white opaque zone 
(early maturation –M1), mid-maturation (M2) and late maturation (M3). All enamel 
sections were stored at ≤-65°C until needed. 
 
2.4.2 Extraction of the enamel organ from pig molars  
Pigs of approximately 6-months old were euthanized by anaesthetic overdose 
by the University of Leeds animal house. The lower mandibles were removed and 
the molar teeth removed from the lower mandibles. The enamel organ and pulp 
tissues were removed, and the tooth enamel wiped with damp tissue. The soft 
secretory stage enamel was scraped from the tooth with a scalpel, and stored at ≤-
65°C until needed. 
 
2.4.3 Preparation of enamel samples for enamelin breakdown 
studies 
The series of enamel samples from the rat incisor were extracted by grinding 
the samples with a glass rod in 500 µL of 10% acetic acid. The resulting extracts 
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were then centrifuged at 13,000 rpm for 5 minutes and the supernatants removed. 
The remaining pellet was then resuspended in a further 15 µL 10% acetic acid. The 
extract and supernatant were mixed and then centrifuged at 13,000 rpm for 5 
minutes in a centrifugal filter (Millipore Centricon) to concentrate. The filter was 
washed with 10% acetic acid, inverted into a clean tube and re-centrifuged at 
13,000 rpm for 5 minutes to remove the concentrated protein extracts. This double 
extraction technique solubilised all the ECM proteins effectively as all material was 
solubilised, being equivalent to protein extraction based upon acid demineralisation 
of the tissue. The proteins extracted were then mixed 1 to 1 (volume for volume) 
with 15 µL of doubly concentrated SDS-PAGE sample loading buffer (pH 6.8) 
(described in step 6 section 2.1.2).  Porcine secretory stage enamel was prepared 
in a similar way, using 500 µL of 10% acetic acid and double concentrated SDS-
PAGE sample loading buffer per mg of enamel. 
All samples were denatured by heating at 90°C for 2  minutes, and 10 µL per 
sample loaded per lane on to a 1 mm thick 12% resolving mini-gel (Mini-protean IV, 
Bio-Rad, Hemel Hempstead, UK). Gels were electrophoresed at 200 V until the 
blue dye front reached the bottom of the gel. Gels were stained with Coomassie 
blue G250 (Instant Blue, Expedeon, Cambridge, UK). Duplicate gels were trans-
blotted onto nitrocellulose membrane (Mini-trans blot, Bio-Rad, Hemel Hempstead, 
UK) at 100v for one hour. The membranes were blocked overnight in 5% non-fat 
milk powder in tris-buffered saline (TBS) pH 7. Electrophoresis was performed as 
described in step 6 in section 2.1.2 and western blotting as described in 2.1.2.2 with 
the exceptions noted below. 
 
2.4.4 Western blotting of enamel proteins 
Antibodies to the synthetic peptide EEMFEQDFEKPKEEDPPK, which 
corresponds to the sequence at the centre of the putative rat 32 kDa enamelin, 
were raised in rabbits (Eurogentec, Southampton, UK). There is sequence 
homology between the rat and pig enamelins so that the antibody should recognise 
enamelins from both species.  
The blocked membranes were washed and incubated for one hour at room 
temperature with shaking with 1:1000 anti-enamelin antibody in TBS containing 
0.05% TWEEN-20 (TBST). The blots were washed for 3x5mins TBST and then 
incubated in anti-rabbit IgG peroxidise conjugate (Sigma-Aldrich, Poole, Dorset, 
UK), diluted 1:750 for one hour with shaking at room temperature. The blot was 
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washed 3x5mins in TBST and developed using metal enhanced DAB substrate 
(Sigma-Aldrich, Poole, Dorset, UK) resulting in brown-black staining of the proteins.  
 
2.4.5 Comparison of rat and pig enamelin protein breakdown 
As described in the introduction section 1.3.4.3 and figure 8, the major 
breakdown product of enamelin is the 32 kDa fragment.  Most of the studies 
performed on enamelin using the 32 kDa breakdown product focused on the 
porcine product due to its ready availability. To investigate whether the 32 kDa 
enamelin breakdown product was produced in the rat secretory enamel with time, a 
proteolytic breakdown study was performed. 
A 150g male Wistar rat was euthanized by schedule 1 killing (CO2 inhalation) 
and the lower incisors removed from the mandible. The secretory zone of the 
enamel was removed from both incisors and placed into a sterile micro-tube 
containing 200 µL Dulbecco’s Phosphate Buffered Salt solution (DPBS – Lonza, 
Slough, UK) containing 130 mg/L calcium chloride. The enamel pieces in DPBS 
were immediately frozen at ≤ -65ºC. The next day, the enamel was thawed, 
crushed and sonicated to form a slurry. A further 200 µL of calcium enhanced 
DPBS was added to form a more diluted slurry. This was divided into six 50 µL 
aliquots in sterile micro- tubes. One tube was placed immediately into the freezer at 
≤ -65ºC, and the remaining tubes were placed into a 37ºC incubator. One tube was 
removed from the incubator and placed into the freezer at 4 hours, 8 hours, 16 
hours, and 32 hour time points. The samples were then run on 15% SDS-PAGE 
mini gels, and analysis performed by Coomassie staining and western blot.  Non-
specific binding was blocked by incubation with non-fat milk solution, followed by 
incubation with rat-specific anti-enamelin antibody (polyclonal antibody raised in 
rabbits – Eurogentec, Southampton, UK). Goat anti-rabbit secondary antibody was 
used, followed by incubation with streptavidin/biotin. The blot was then incubated in 
colour developer until bands appeared (Bio-Rad, Hemel Hempstead, UK). 
Two mg of secretory enamel from a pig molar (euthanized and extracted as 
previously described in section 2.4.2) was crushed into 400 µL of DPBS with 
calcium, and sonicated to form a slurry. The slurry was divided into six 50 µL 
aliquots and incubations and subsequent analysis performed as for the rat enamel 
samples described above.  
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2.5 Quantitative PCR studies to compare the gene profiles of 
mice teeth containing the wild type or Y64H Amelx gene 
To investigate whether the morphological changes expressed in mice with the 
Y64H amelogenin mutation were due to down-regulation of the amelogenin gene, 
non-secretion of the amelogenin protein or apoptosis of the ameloblasts, q-RT-PCR 
investigations of the gene expression profiles for mice expressing wild type 
amelogenin and mice with the Y64H amelogenin mutation were compared. 
 
2.5.1 Collection of mice teeth 
Mice containing the wild type amelogenin or mutant (Y64H) amelogenin genes 
were created by the RIKEN institute. The mice were bred, husbanded and 
phenotyped by our collaborators on the Wellcome Programme at Manchester 
University. Phenotyping was performed on ear samples from the mice by Dr Martin 
Barron at Manchester. Mice were culled and their lower incisors immediately 
extracted and placed into RNALater™ solution (Applied Biosystems, Warrington, 
UK). RNALater™ stabilises and protects the RNA in fresh specimens by rapidly 
permeating the tissue. It eliminates the need to immediately process or freeze 
samples. Tissue samples can be stored for extended periods in RNALater™ 
solution where normally RNA degradation would occur – 1 week at room 
temperature. Samples can be stored indefinitely in RNALater™ at -20°C or below. 
RNALater™ is fully compatible with the TRI-reagent used in the RNA extraction 
process. Samples were frozen in RNALater™ solution in Manchester, and 
transferred to Leeds using a cryocase (Starlabs, Milton Keynes, Bucks., UK) and 
stored at ≤-65°C prior to processing. 
 
2.5.2 RNA extraction 
RNA was extracted from whole mouse lower incisors or sections of mouse 
lower incisor, using the Ambion RiboPure RNA extraction kit (Applied Biosystems, 
Warrington, UK).  Samples were homogenised in TRI reagent, a monophasic 
solution containing phenol and guanidine thiocyanate, which rapidly lyses cells and 
inactivates nucleases. Bromochloropropane (BCP - Sigma) was added, which 
caused the separation of the homogenate into aqueous and organic phases.  RNA 
partitioned into the aqueous phase, while DNA and protein remained in the 
interphase and organic phase. The RNA was isolated from the aqueous phase by 
binding it to a glass fibre filter. The filter was washed twice to remove contaminants, 
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and the RNA was eluted from the filter with low salt buffer. The eluted RNA was 
stored at ≤ -65°C. 
RNA concentrations were determined using the 260/280 absorption method 
using a Shimadzu spectrophotometer (Shimadzu, Milton Keynes, UK). To 
determine the RNA concentration, 5 µL RNA was added to 495 µL distilled water. 
This was read on the spectrophotometer at 260 nm. To determine the RNA 
concentration in µg/mL, the following calculation was used:- 
 
A260 reading x dilution factor x extinction coefficient 
= A260 reading x 10 x 40 = RNA µg/mL 
 
 Genomic DNA contamination was removed using the Invitrogen Turbo DNase 
kit (Invitrogen, Paisley, UK). To 10 µg of RNA, 1 µL of Turbo DNase and 1 µL of 
Turbo buffer were added. The reaction mix was incubated at 37⁰C for 30 minutes. 
After incubation, 2 µL of DNase inactivation reagent was added, and the reaction 
mixture incubated for 2 minutes at ambient temperature, with gentle tapping of the 
tube to mix. The tubes containing the reaction mixture were then centrifuged at 
10,000 rpm for one minute and the supernatant removed to a clean, sterile 
microtube. 
 
2.5.3 Confirmation of RNA purity 
RNA purity was also confirmed by running RNA samples on an agarose gel.  
One g of agarose was dissolved in 72 mL water to which 10 mL of 10x MOPS 
running buffer (40mM 3-(N-morpholino) propansulfonic acid, 2mM sodium acetate, 
1mM EDTA, pH7) and 18 mL 37% formaldehyde were added. This was poured into 
gel caster trays cleaned with RNase Away. Three µg samples of RNA were mixed 
with RNA loading dye (Sigma R4268) and denatured at 65°C for 15 minutes. 
Samples were loaded on the gel and run with 1 x MOPS buffer at 100 V for 1 hour. 
RNA marker 0.28-6.6 KB (Sigma R7644) was also loaded. Gels were imaged on a 
UV light box (GelDoc, Geneflow, Fradley, UK). 
2.5.4 Transcription of RNA to cDNA 
 cDNA was produced from the treated RNA using the Ambion High Capacity 
RNA-to-cDNA kit (Applied Biosystems, Warrington, UK). The kit contents were 
removed from -20⁰C storage and thawed on ice.  A mastermix of the reagents was 
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prepared by mixing 200 µL of the RT buffer with 20 µL of 20 times enzyme mix and 
140 µL of nuclease free water. To 2 µL of the DNase treated RNA from section 
2.5.2, 18 µL of the mastermix was added. Each preparation was then incubated for 
60 minutes at 37⁰C. At the end of the incubation, the preparations were heated to 
95⁰C for 5 minutes. The preparation tubes were then centrifuged at 13,000 rpm for 
1 minute and placed on ice. 
 
2.5.5 Confirmation of cDNA purity 
cDNA purity was determined by performing conventional reverse transcription 
(RT) PCR using the Phire hot start PCR kit (New England Biolabs, Hitchin, Herts., 
UK) This is a hot start DNA polymerase, providing increased sensitivity, specificity 
and yield, and allow assembly of the PCR reactions at room temperature, as 
activation of the polymerase does not occur until the reaction has been heated at 
94°C. For the Phire hot start kit, 10 µL of 5x reac tion buffer was mixed with 1 µL of 
10 mM dNTP’s, 1µL of primer A (forward primer for gene of interest), 1 µL of primer 
B (reverse primer for gene of interest), 1 µL of Phire polymerase, 5 µL of cDNA 
(produced in section 2.5.4) and 31 µL of nuclease free water. These reaction mixes 
were placed into 0.2 mL sterile PCR tubes. The tubes were placed into a Techne 
MJ 100 thermocycler and the following protocol applied: 
Step 1: 98⁰C for 30 seconds 
Step 2: 98⁰C for 5 seconds 
Step 3: 65⁰C for 5 seconds 
Step 4: 72⁰C for 20 seconds 
Step 5: Repeat steps 2, 3 and 4 30 times 
Step 6: 72⁰C for 1 minute 
Step 7: 4⁰C hold 
A positive control cDNA and primers were provided with the Phire kit. 
Forward primer – 3’ ATG CCC CTA CCA CCT CAT C 5’ 
Reverse primer – 3’ ACT TCT TCC CGC TTG GTC TT 5’ 
These primers generated a product of 536 base pairs. 
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PCR products were run on a 2% agarose gel. One g of agarose was mixed 
with 1 x gel-red buffer (Biotium, VWR, Lutterworth, Leics. UK) and heated to 
dissolve. The molten agarose was poured into horizontal gel trays and allowed to 
set. The samples were mixed with gel-red loading buffer and loaded onto the gel. A 
100 base pair (bp) ladder was also loaded to aid identification of bands (Sigma 
P1473). The gel was run at 100v for 1 hour, and imaged on a UV light box (GelDoc, 
Geneflow, Fradley, UK). The gel-red system uses a fluorescent nucleic acid stain 
for visualization of DNA bands within the gel without the need for ethidium bromide, 
thereby providing a safe, non-toxic alternative to traditional DNA imaging.  
 
2.5.6 Quantitative real time polymerase chain reaction (Q-RT-
PCR) 
Conventional PCR detects the amplified DNA product by end point analysis, 
usually by running an agarose gel of the DNA products. Real-time PCR allows 
detection of the amplified product to be detected and measured as it occurs. The 
main advantage of real time over conventional PCR is the ability to accurately 
determine the starting template copy number with high sensitivity. Real time PCR 
can be evaluated without gel electrophoresis, allowing quicker reaction time and 
increased output (Bio-Rad Q-RT-PCR handbook). 
 Q-RT-PCR was performed on a Roche Lightcycler 480 (Roche, Burgess Hill, 
West Sussex, UK) using Taqman gene assays and Taqman master mix (Applied 
Biosystems, Warrington, UK catalogue number 4251372). Each reaction sample 
was prepared as follows: 27 µL of cDNA (prepared as section 2.5.4) mixed with 30 
µL Taqman mastermix and 3 µL Taqman probe (specific for each gene, catalogue 
code given below). All gene assays were set up in triplicate, with a blank (negative) 
control, where water replaces the cDNA in the assay. The assay assembly was 
performed on ice and assembly was performed in 0.2 mL sterile PCR tubes. The 
tubes were briefly centrifuged (1000 rpm for approximately 10 seconds) before 
transferring 20 µL in triplicate into the wells of a sterile 96-well PCR plate 
(StarLabs). The plate was covered with a plate seal to prevent evaporation and 
loaded into the Lightcycler instrument.  The following cycling conditions were used: 
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Step 1: 95⁰C hold for 10 minutes (4.4⁰C per second ramp rate) 
Step 2: 95⁰C for 10 seconds (4.4⁰C per second ramp rate) 
Step 3: 60⁰C for 30 seconds (2.2⁰C per second ramp rate) 
Step 4: 72⁰C for 1 second (4.4⁰C per second ramp rate) 
Step 5: Repeat steps 2, 3 and 4 44 more times 
Step 6: 40⁰C for 30 seconds (4.4⁰C ramp rate) 
Step 7: 4⁰C hold 
Gapdh was used as the endogenous control. Amelogenin (Amelx), Grp-94 
(HSP-90), Bip (HSP-5), Chop and Xbp-1 expression levels were all evaluated. The 
result was a value for the crossing threshold (CT). 
The gene product from the Q-RT-PCR assays resulted in an amplicon of a 
specific number of base pairs. This amplicon was run on agarose gel 
electrophoresis to confirm the expected size. This was performed as described in 
section 2.5.5 as for cDNA PCR product analysis. 
Amelx – Mm01166221_m1 = 74 amplicons 
Grp94 – Mm00441927_m1 = 72 amplicons 
Bip- Mm00517691_m1 = 75 amplicons 
Chop – Mm00492097_m1 = 82 amplicons 
Xbp1 – Mm01187751_m1 = 79 amplicons 
Gapdh – Mm99999915_g1 = 105 amplicons 
 
The perfect optimised Q-RT-PCR reaction would have a linear standard curve 
(R2 >0.98), high amplification efficiency (90-105%) and consistency between 
replicates. To determine if a Q-RT-PCR assay is optimised, it is good practice to 
run serial dilutions of template DNA and use the results to generate a standard 
curve. This is constructed by plotting the log of the starting quantity of template or 
dilution factor against CT values. The equation of the linear regression line, along 
with Pearson’s correlation coefficient (r) or the coefficient of determination (R2) can 
then be used to evaluate assay optimisation. 
Standard curves were performed for each gene assay and endogenous 
control for each cDNA sample. The standard curve was performed using a 1:10 
serial dilution of the cDNA. A 1 in 5 dilution of the ‘stock’ cDNA was performed to 
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give a starting concentration of 20 ng/µL cDNA. This was diluted further 1 in 10 to 
give 2 ng/µL cDNA. This was diluted further 1 in 10 to give 0.2 ng/µL. A further 1 in 
10 dilution was performed to give 0.02 ng/µL. This was diluted further 1 in 10 to 
give 0.002 ng/µL. Each dilution was used in the q-RT-PCR assay as described 
above. The result should be a linear increase in the CP (crossing point) values for 
the log of each dilution. All standard curves should be parallel to one another. 
Standard curves gave the efficiency of the gene expression (should be 2).  
Relative quantification was employed to compare changes in multiple 
samples. It compared the levels of two target sequences in a single sample, and 
expresses the final result as a ratio of gene levels. This number is only meaningful 
when compared between samples. 
 
           Relative ratio = Concentration target gene 
                                    Concentration reference gene 
 
The reference gene is usually a constitutively expressed gene or 
housekeeping gene. This is also known as an endogenous control and provides the 
basis for normalising sample-to-sample differences. Different experimental 
conditions should not affect the expression levels of housekeeping genes. For the 
Q-RT-PCR experiments in this thesis, two housekeeping genes were used; Gapdh 
and Actin B. Gapdh expression remained invariable with all experimental 
conditions, but Actin B expression varied. Due to this, Gapdh was selected as the 
housekeeping gene to normalise the data to. 
The Livak method (2-∆∆CT) is a widely used and easy to perform method for 
relative gene expression analysis (Livak and Schmittgen, 2001). . Firstly, the CT 
value of the target gene is normalised to the CT value of the reference 
(housekeeping) gene, for both the calibrator (wild type) and test (mutant) samples. 
 
∆CT (test/mutant) = CT (test gene) – CT (reference gene / Gapdh) 
∆CT (calibrator/wild type) = CT (test gene) – CT (reference gene/Gapdh) 
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Secondly, the ∆CT of the test/mutant is normalised to the calibrator/ wild type ∆CT. 
∆∆CT = ∆CT test (mutant) - ∆CT calibrator (wild type) 
Finally, the expression ratio is calculated:- 
2-∆∆CT = normalised expression ratio 
This is the fold increase or decrease of the test gene in the test (mutant) 
sample relative to the calibrator (wild type) sample. Normalising the expression of 
the test gene to a housekeeping gene compensated for any difference in the 
amount of sample tissue. The Livak method assumes a reaction efficiency of 2 for 
the equation 2-∆∆CT 
For the Q-RT-PCR analysis performed in this thesis, ∆CT was calculated by 
subtracting the CT value from the endogenous control away from the CT value of 
the gene of interest. 
e.g.  ∆CT = CT Amelx – CT Gapdh 
 
∆∆CT was calculated by subtracting the ∆CT value of the wild type (calibrator) 
away from the ∆CT value of the mutant (test) for the gene of interest 
E.g. ∆∆CT Amelx = ∆CT mutant Amelx - ∆CT wild type Amelx 
 
Changes in gene expression were calculated using the Livak method (2-∆∆CP).  
e.g. up or down regulation of Amelx = 2-∆∆CP Amelx 
This was normalised relative expression.  
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2.6 Scanning electron microscopy (SEM) of mice incisors 
Mandibular incisor teeth from wild type female, female mice heterozygous for 
the Y64H amelogenin mutation and male mice homozygous for the Y64H 
amelogenin mutation were dissected from the mandible following cervical 
dislocation. The enamel organ was removed using a lint-free tissue. The incisors 
were placed into polypropylene tubes to allow easier mounting onto SEM stubs. 
The incisors were ground with fine carborundum paper to obtain transverse 
sections through the incisor approximately 2 mm from the tip. The teeth were 
etched with 30% phosphoric acid for 20 seconds to remove any smear layer. The 
phosphoric acid was removed by thorough washing with distilled water and dried 
overnight under vacuum. The incisors were sputter coated with gold and imaged 
using a Hitachi S-3400N scanning electron microscope operate at an accelerating 
voltage of 20 kV and an emission current of 94 µA. The images were taken under 
backscatter conditions at 450 and 1600 times magnification. 
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Chapter 3 
Results 
3.1 Recombinant protein production 
Amelogenin and enamelin are both present in the developing enamel matrix 
and presumably may interact functionally. To investigate whether the Y64H 
mutation of amelogenin affects the interaction of the protein with enamelin, 
microplate based protein binding assays were used. To investigate whether the 
Y64H mutation of amelogenin affects the proteins ability to nucleate mineralisation, 
steady-state agarose gel assays were used. Recombinant human 32 kDa enamelin 
was provided courtesy of Dr J. Maycock and data arising from its production are not 
presented here. However, wild-type and Y64H mutant amelogenin were both 
produced for this thesis; the results of which are presented in the following  
sections. 
 
3.1.1 Recombinant amelogenin protein production  
Wild-type and mutant (Y64H) amelogenin were produced using a prokaryotic 
system using E.coli (section 2.1.1).  These recombinant proteins contained a HIS 
tag (a sequence of 6 histidines) to aid their purification from the bacterial proteins 
using a nickel affinity column in conjunction with FPLC (proteins with the His tag 
bind preferentially to the nickel column). Figure 22 shows how the recombinant 
amelogenin was purified from the crude E. coli lysate using nickel column 
purification and the removal of the HIS tag by HRV 3C protease enzyme. Cleavage 
of the HIS tag was not 100% efficient and preparative SDS-PAGE was carried out 
to separate the cleaved protein from uncleaved protein and the liberated HIS tag. 
Figure 23 shows the results of the preparative SDS-PAGE and isolation of the 
cleaved amelogenin from the uncleaved amelogenin still carrying the HIS tag. The 
fractions containing the cleaved amelogenin were subsequently pooled and 
desalted ready for use. See section 2.1.2. and figure 15 for a schematic of the 
production and purification process. 
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Figure 22. Coomassie stained SDS-PAGE gel of various fractions of 
recombinant amelogenin protein obtained throughout the protein 
purification process. Molecular weight markers are displayed in the left 
hand lane.  The cell lysate contained all the proteins recovered from the 
E.coli. The post His Trap column shows the protein recovered from the 
nickel chromatography His Trap column.  “Post desalt” shows the 
protein recovered from the desalting column.” Cleaved protein” shows 
the protein after it had been cleaved overnight at 4°C with HRV 3C. Note 
that cleavage was not 100% efficient with much of the protein remaining 
uncleaved.  
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Figure 23.  Silver-stained SDS-PAGE gel showing fractions of cleaved 
recombinant amelogenin obtained by preparative SDS-PAGE. MW is the 
molecular weight ladder and starting protein is the partially cleaved 
sample. Every third fraction obtained from the prep-cell was run on the 
gel allowing the fractions containing cleaved protein only to be 
identified and pooled.  Similar gels were obtained for the wild type and 
mutant amelogenin. 
 
Pooled fractions were desalted and freeze dried. A sample was provided for 
mass spectrometry analysis to confirm the removal of the HIS tag and the correct 
molecular weight. Figure 24 shows the mass spectrometry profile for wild-type 
amelogenin, with a molecular weight of 20590 Da (predicted molecular weight 
20590.65 Da), and figure 25 shows the mass spectrometry profile for Y64H mutant 
amelogenin, with a molecular weight of 20564 (predicted molecular weight 
20564.62 Da).
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Figure 24.  Mass spectrometry profile for recombinant wild type amelogenin showing a molecular weight of 20590 Daltons. 
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Figure 25.  Mass spectrometry profile of recombinant Y64H mutant amelogenin showing a molecular weight of 20564 Daltons. 
 
- 111 - 
3.2 The ability of recombinant amelogenin and recombinant 32 
kDa enamelin to nucleate mineral in vitro using a steady-
state agarose gel system 
The mineral nucleating properties of extracellular matrix proteins have already 
been demonstrated by Hunter and Goldberg using a modified dialysis cell system 
(Hunter and Goldberg, 1993; Hunter and Goldberg, 1994; Hunter et al., 1996). This 
system was used here to investigate the hydroxyapatite nucleating potential of 
recombinant human 32 kDa enamelin and recombinant mouse amelogenins (wild type 
and mutant), independently and in combination, given that they are both present in the 
developing enamel. Using both the recombinant wild type and Y64H mutant recombinant 
amelogenin proteins separately and in combination with the 32 kDa recombinant 
enamelin protein in the steady-state agarose gel system allowed the effects of the Y64H 
mutation in amelogenin on mineral nucleation to be investigated. 
 
3.2.1 Visual characterisation of nucleated mineral deposits at the 
gross level 
After 7 days incubation at 37°C, gel plugs retrieve d from the steady-state cells 
containing PGA or recombinant protein typically contained white bands of mineral 
precipitate. Figure 26 panels A, B and C shows three representative images of bands 
obtained when using 10 µg/mL recombinant 32 kDa enamelin as a potential nucleator.  
Panel A shows an instance where mineral seemed to have precipitated around the 
periphery of the gel. Panel B demonstrated the variability in band thickness seen within 
triplicates in the same experiment. Panel C shows a further instance where variability 
was less marked. Each panel consists of triplicate gel plugs for an experiment, with each 
panel representing an experiment performed on separate assay occasions. 
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Figure 26.  Panels A, B and C. Typical images of recovered agarose gel plugs 
showing recombinant 32 kDa enamelin nucleated mineral precipitation. Note 
the variability of mineral patterns obtained.  Each panel represents the 
triplicates from a different steady-state assay run. 
 
Any variations in colour in the photographs are due to different settings being used 
on the digital camera, and are not due to colour variations in the gels. It would have 
been preferable to standardise the digital photography but these photographs are for 
illustrative purposes only and are not presented as quantitative data.   
  
A B C 
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 Variability was also seen when using 10 µg/mL PGA (positive control) as the 
potential nucleator. Figure 26 shows representative images for gel plugs recovered after 
7 days incubation at 37⁰C in the steady state agarose gel system when 10 µg/mL PGA 
positive control was used as the mineral nucleator. Panel A shows very broad, 
somewhat diffuse bands of mineral. Panel B shows 2 separate bands of mineral and 
panel C shows bands that only extend partially across the gel plugs. 
   
Figure 27.  Panels A, B and C.  Images for bands of mineral precipitation obtained 
when using 10 µg/mL PGA positive control as the nucleating agent. Variation 
in band thickness and patterns are evident. Each panel represents the 
triplicates from a different steady-state assay run. 
  
A B C 
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Liesegang rings are precipitation geometries (Stern, 1954) that were previously 
seen when PGA was used in a gel-diffusion system (Hunter and Goldberg (1994). 
Likewise, Liesegang rings were periodically observed in the gel plugs recovered when 
10 µg/mL PGA positive control was used as the mineral nucleator in this study (figure 
28). Though in contrast, the mineral precipitates formed in the presence of recombinant 
32 kDa enamelin, or in negative controls, did not exhibit Liesegang rings.  
 
   
Figure 28. Images for agarose gels containing 10 µg/mL PGA positive control as 
the mineral nucleator. Liesegang rings are evident. 
 
 Figure 29 shows that mineral precipitation occurred to some degree even in the 
negative controls. Each panel shows the triplicate plugs form a single experimental run. 
The steady-state agarose gel system is a very delicately balanced system and any very 
slight changes in the buffer concentrations and ratios, or the presence of any 
heterogeneous nucleator such as lint or dust, can trigger spontaneous precipitation of 
mineral, as seen in the negative controls exemplified in figure 29. In the recovered gel 
plugs containing PGA or recombinant 32 kDa enamelin protein nucleated samples, 
however, the amount of mineral precipitation was visibly greater than the negative 
controls. 
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Figure 29. Panels A, B and C. Images obtained for negative control agarose gel 
plugs. It is clear that spontaneous nucleation occurred even in the absence 
of a nucleating agent. 
 
 
 
A B C 
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3.2.2 Quantification of mineral deposition in agarose gels containing  
recombinant 32 kDa enamelin 
The amount of mineral precipitation in the presence of various concentrations of 
recombinant 32 kDa enamelin was determined by measuring the phosphate content of 
the recovered agarose gel plugs following ashing (section 2.2.2). The phosphate content 
was calculated against standard curves prepared using known concentrations of 
phosphate that were run with each assay. Linear regression was then used to allow the 
back-calculation of phosphate concentration in the experimental samples. Figure 30 
shows a typical standard curve obtained with the phosphate assay. 
 
 
Figure 30. Typical standard curve data generated for phosphate analysis assay. 
Concentrations from 0 to 100 µM phosphate were used for the standard 
curve.  
 
The steady-state agarose gel system to assess the nucleating potential of 
10 µg/mL recombinant 32 kDa enamelin was performed on five separate occasions. The 
steady-state mineralisation assay to investigate the nucleating potential of recombinant 
32 kDa enamelin at concentrations of 5.0  µg/mL, 2.5  µg/mL and 1.0  µg/mL was 
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performed on three separate occasions. All assay occasions included duplicates of 
positive and negative controls. Results shown in figure 31 are for mean values. A 
students two-tailed T-test was performed on the data to test for statistical significance 
(p<0.05). 
Figure 31 shows the degree of mineral precipitation in the gel plugs in terms of the 
phosphate present. The positive control (10 µg/mL PGA), recombinant 32 kDa enamelin 
at 1 µg/mL and recombinant 32 kDa enamelin at 10 µg/mL were statistically significantly 
different to the negative control i.e. PGA and recombinant 32 kDa enamelin at 1.0 and 
10 µg/ml nucleate mineral. Recombinant 32 kDa enamelin at 2.5 µg/mL and 5.0 µg/mL 
were not significantly different to the negative control i.e. recombinant 32 kDa enamelin 
at 2.5 and 5 µg/mL did not nucleate more mineral above the borderline level of the 
negative control. 
The phosphate content of the mineral deposits recovered from the gel plugs using 
recombinant 32 kDa enamelin at 1.0 µg/mL, 2.5 µg/mL and 5.0 µg/mL as the mineral 
nucleating agent were all statistically significantly lower than the phosphate content of 
the gel plugs using 10 µg/mL PGA as the positive control. The phosphate content of gel 
plugs containing recombinant 32 kDa enamelin at 10 µg/ml was not statistically 
significantly different to the phosphate content of the gel plugs containing 10 µg/mL PGA 
as the positive control. 
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Figure 31. Graph showing mean levels of phosphate precipitation for 
negative control, positive control and recombinant 32 kDa enamelin at 
various concentrations in the steady state agarose gel nucleation assay. 
Negative control (no nucleating agent) and positive control (10 µg/mL PGA) 
n=28, 1 µg/ml, 2.5 µg/ml and 5 µg/ml recombinant 32 kDa enamelin n=6, 10 
µg/ml recombinant 32 kDa enamelin n=10. Statistical significance = p<0.05. 
Error bars for the standard deviations are also shown. 
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3.2.3  Quantification of mineral deposition in agarose gels containing 
wild type of Y64H recombinant amelogenin 
Figure 32 shows the data obtained from the steady-state agarose gel system when 
10 µg/mL recombinant wild-type amelogenin or 10 µg/mL recombinant mutant 
amelogenin was included in the agarose gels. Negative controls of agarose gel alone 
and positive controls of 10 µg/mL PGA were also included. Three separate experimental 
runs each including triplicates of each sample and controls were run. Duplicate gels 
were ashed to obtain phosphate assay data. 
 
Figure 32. Graph showing the phosphate content of gels containing no added 
nucleating agent (negative control), 10 µg/mL PGA (positive control),  10 
µg/mL recombinant wild type amelogenin or recombinant Y64H mutant 
amelogenin. Statistical significance = p<0.05. n=6. Error bars for the standard 
deviations are shown.   
 
This data showed that both 10 µg/mL recombinant wild type and Y64H mutant 
amelogenin were unable to nucleate hydroxyapatite crystal formation in vitro. The fact 
that the levels of phosphate detected were lower than the negative control containing no 
protein (p<0.05), suggested that amelogenin may in fact have suppressed nucleation.  
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3.2.4 Quantification of nucleating potential of either wild type or Y64H 
recombinant amelogenin in combination with recombinant 32 
kDa enamelin 
As amelogenin and enamelin do not occur independently in the ECM, the steady-
state agarose gel experiment was performed using samples comprising of a combination 
of recombinant amelogenin and recombinant 32 kDa enamelin together in the agarose 
gel. Ten µg/mL of recombinant wild type amelogenin or recombinant Y64H mutant 
amelogenin were mixed with 5 µg/mL recombinant 32 kDa enamelin and run in triplicate 
in the steady-state system. Controls of 5 µg/mL recombinant 32 kDa enamelin, 10 µg/mL 
PGA and negative controls of blank agarose gels were also run in triplicate. The 
experiment was performed on three separate occasions. 
Figure 33 shows the amount of phosphate recovered from mineral deposits 
recovered from the agarose gels in the presence or absence of amelogenin/recombinant 
32 kDa enamelin combinations for the three experimental runs. The results suggest that 
the presence of recombinant 32 kDa enamelin with either recombinant wild type 
amelogenin or recombinant Y64H mutant amelogenin reduced the apparent inhibition of 
nucleation shown by wild type or mutant amelogenin alone (figure 32). No significant 
differences were seen in the amount of phosphate recovered between recombinant wild 
type amelogenin in combination with recombinant 32 kDa enamelin or recombinant 
Y64H mutant amelogenin in combination with recombinant 32 kDa enamelin compared 
with the negative control. No significant difference was seen in the amount of phosphate 
recovered from the mineral deposits between the recombinant wild type amelogenin and 
recombinant Y64H mutant amelogenin, in the presence of recombinant 32 kDa 
enamelin.  
Together with the data presented in figure 32 (the effect of recombinant wild type 
amelogenin  and  recombinant Y64H mutant amelogenin alone on nucleation) the data 
implies that the Y64H mutation in the amelogenin protein does not affect the nucleation 
potential of amelogenin.  
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Figure 33. Graph showing phosphate precipitated in negative control gels (no 
nucleating agent), positive control gels (10 µg/mL PGA) , gels containing 10 
µg/mL recombinant wild type amelogenin + 5 µg/ml recombinant 32 kDa 
enamelin, 10 µg/mL recombinant Y64H mutant amelogenin + 5 µg/mL 
recombinant 32 kDa enamelin, and 5 µg/mL recombinant 32 kDa enamelin. 
N=6. Statistical significance = p<0.05.  Standard deviations are shown. 
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3.2.5 Characterisation of nucleated mineral deposits using scanning 
electron microscopy (SEM)  
SEM was performed on the mineral nucleated in the agarose plugs to investigate 
the morphology of the mineral crystals formed by recombinant 32 kDa enamelin alone 
and in conjunction with recombinant wild-type and recombinant Y64H mutant 
amelogenin. The following section presents representative images obtained using SEM.  
The top panel in figure 34 shows crystals nucleated in the presence of  10 µg/mL 
recombinant 32 kDa enamelin imaged at 24750 times magnification. This shows that the 
crystals exhibited a flat, planar morphology measured in the micron range, at 
approximately 6 µm in length. The bottom panel shows crystals nucleated in the 
presence of 10 µg/mL recombinant 32 kDa enamelin imaged at 66740 times 
magnification. The flat  crystal plates are clearly visible. 
The top panel in figure 35 shows crystals nucleated in the presence of  5 µg/mL 
recombinant 32 kDa enamelin imaged at 12950 times magnification. This shows that the 
crystals exhibited an oblate morphology measured in the micron range, at approximately 
6 µm in length. The bottom panel shows crystals nucleated with 5 µg/mL recombinant 32 
kDa enamelin imaged at 50000 times magnification. The flat crystal plates are clearly 
visible. 
Figures 34 and 35 for the SEM data for the crystals nucleated in the presence of 
10 µg/mL and 5 µg/ml recombinant 32 kDa enamelin display very similar morphology of 
the crystals, with large plates of mineral crystal of approximately 6 microns in length. 
This was in spite of the fact that when the agarose gels recovered from the steady state 
agarose gel system were analysed by the phosphomolybdate phosphate assay, the 
amount of mineralisation recovered for the 5 µg/mL enamelin gel plugs was not 
statistically significantly different to the negative controls. Therefore, although the levels 
of mineral nucleated were different for the agarose gel plugs containing either 10 µg/mL 
or 5 µg/mL recombinant 32 kDa enamelin protein, the crystal morphologies were 
comparable. 
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Figure 34. SEM data for crystals nucleated in the presence of 10 µg/mL 
recombinant 32 kDa enamelin. Panel A shows the crystal morphology 
imaged at 24750 times magnification. Panel B shows the crystal morphology 
imaged at 66740 times magnification. 
Panel A 
Panel B 
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Figure 35. SEM data for crystals nucleated in the presence of  5 µg/mL 
recombinant 32 kDa enamelin.  Panel A shows the crystal morphology 
imaged at 12850 times magnification. Panel B shows the crystal morphology 
imaged at 50690 times magnification. 
Panel A 
Panel B 
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 Although recombinant 32 kDa enamelin at 2.5 µg/mL did not nucleate mineral 
deposition in the steady state agarose gel system any better than negative controls 
(when analysed by the phosphomolybdate phosphate assay), the mineral crystals that 
were recovered are shown in figure 36. Mineral nucleated in the presence of 
recombinant 32 kDa enamelin at 2.5  µg/mL exhibited two distinct morphologies; both of 
them different to the flat crystals nucleated in the presence of 10 µg/mL or 5 µg/mL 
recombinant 32 kDa enamelin (as shown in figure 36). The upper two images (panels A 
and B) show the presence of small spherical clusters (approximately 10 nm in length). 
These are very similar in appearance to globular clusters of calcium phosphate seen by 
Wada et al (1996) during their investigations into in vitro mineralisation nucleated by 
dentine ECM proteins. In contrast, smaller, needle like crystals were also observed as 
shown in the bottom two images (panels C and D). 
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Figure 36. SEM data for mineral crystals from the steady state agarose gel system 
nucleated in the presence of 2.5 µg/ml recombinant 32 kDa enamelin.  Panel 
A shows the crystal morphology imaged at 24750 times magnification. Panel 
B shows the crystal morphology imaged at 89840 times magnification. Panel 
C shows the crystal morphology imaged at 25390 times magnification. Panel 
D shows the crystal morphology imaged at 65400 times magnification. Note 
the presence of clusters of small spheres in panels A and B. Panels C and D 
show smaller crystals exhibiting a different morphology. 
 
 Figure 37 shows crystals nucleated in the presence of 1 µg/mL recombinant 32 
kDa enamelin. Again the large plate like crystals of approximately 6 microns are visible 
that are more akin to the crystals nucleated with 10 µg/mL and 5 µg/mL recombinant 32 
kDa enamelin. When the gel plugs containing the mineral nucleated in the presence of 1 
µg/mL recombinant 32 kDa enamelin was analysed by the phosphomolybdate 
phosphate assay, these showed the mineral content to be statistically significantly 
increased compared to the negative controls. This was also true for the 10 µg/mL 
recombinant 32 kDa enamelin gel plugs and resulting mineral. 
A B 
C D 
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Figure 37. SEM data for crystals nucleated in the presence of 1 µg/mL 
recombinant 32 kDa enamelin. Panel A shows the morphology of the crystals 
imaged at 24600 times magnification. Panel B shows the morphology of the 
crystals imaged at 64410 times magnification. 
Panel A 
Panel B 
- 128 - 
Figure 38 shows SEM images of commercially available hydroxyapatite, not 
exposed to the steady state agarose gel system, for comparison of morphology. These 
mineral deposits were not obtained from the steady state agarose gel system. 
Commercial hydroxyapatite was mounted onto a SEM stub and sputter-coated with gold 
as for the mineral deposits obtained in the steady state agarose gel system (section 
2.2.3). Large plates-like crystals of approximately 18 µm in length are visible in the top 
image (panel A), but the surfaces of these large plates are covered in much smaller, 
needle like crystals. The bottom image (panel B), taken at higher magnification, shows 
these smaller crystals more clearly. These crystals are much smaller, approximately 0.3 
µm in length, than those obtained from the steady state agarose gel system and 
nucleated in the presence of recombinant 32 kDa enamelin, or indeed PGA. 
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Figure 38. SEM images for commercially available hydroxyapatite not exposed to 
the steady state agarose gel system. Panel A shows the commercially 
available hydroxyapatite imaged at 12850 times magnification. Panel B 
shows the commercially available hydroxyapatite imaged at 52850 times 
magnification. 
Panel A 
Panel B 
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Figure 39 shows crystals nucleated in the presence of the positive control (10 µg/mL) 
PGA. The crystals had a pointed appearance and appeared to radiate out of central 
areas. They were stellate in appearance. The bottom two images  (panels C and D) of 
the figure show large plate like structures, similar to those nucleated in the presence of 
recombinant 32 kDa enamelin. These were approximately 1200 µM in length. 
  
  
Figure 39. SEM data for the morphology of the mineral crystals nucleated in the 
presence of 10 µg/ml PGA recovered after 7 days exposure to the steady 
state agarose gel system. Panel A shows the crystals  imaged at 12850 times 
magnification. Panel B shows the mineral crystals imaged at 51250 times 
magnification. Panel C shows the mineral crystals imaged at 24750 times 
magnification. Panel D shows the mineral crystals imaged at 67150 times 
magnification. 
 
Figure 40 shows the images of crystals obtained for the negative controls, agarose 
gel without any additional nucleator. A much smoother, bubbly appearance was seen 
without any distinct crystal morphology. 
A B 
C D 
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Figure 40. SEM data for mineral crystals recovered from the negative control 
agarose gels. These were agarose gel plugs without the addition of any 
recombinant protein or PGA, but that had been exposed to the mineralisation 
solutions in the steady state agarose gel system. Panel A shows the mineral 
crystals imaged at 10010 times magnification. Panel B shows the mineral 
crystals imaged at 68530 times magnification. 
Panel A 
Panel B 
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3.2.6 Characterisation of nucleated mineral deposits by energy 
dispersive X-ray spectroscopy (EDX)  
EDX was used to determine the elemental composition of the nucleated mineral in 
the agarose gel plugs following their retrieval after the steady state run. Figures 41-44 
show the EDX results for commercially available hydroxyapatite; the agarose gel blank 
(agarose gel not exposed to mineralising solutions); the negative controls (agarose only, 
no nucleator added); PGA positive controls and samples containing recombinant 32 kDa 
enamelin at 10 µg/mL respectively.   
The  calcium to phosphate (Ca:P) ratios for material nucleated in the presence of 
PGA (figure 44) and recombinant 32 kDa enamelin (figure 45) were very similar to the 
EDX data obtained for commercial hydroxyapatite (figure 41)  – all exhibiting a Ca:P 
molar ratio typical of hydroxyapatite (1.66). The Ca:P ratio of 1.05 ± 0.32  obtained 
following EDX analysis of negative controls (figure 43) indicated that the bulk of any 
crystalline material deposited was unlikely to be hydroxyapatite. The Ca:P ratio of 0.60 ± 
0.12 obtained for the blank samples (figure 42) shows very little similarity to 
hydroxyapatite. This was expected as the blank was not exposed to mineralising solution 
and these figures represent the background ratio of calcium and phosphorus in the 
agarose gel.  
 
Figure 41. EDX data for commercially available hydroxyapatite (not exposed to the 
steady state agarose gel system). A Ca:P ratio of 1.52 was observed ( within 
10% of the theoretical value of 1.66 for pure hydroxyapatite). 
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Figure 42. EDX data for agarose blank (agarose gel not exposed to mineralising 
solutions).  Mean Ca:P from 5 steady state agarose gel runs  =  0.60 ± 0.12. 
 
 
 
Figure 43. EDX data for negative control agarose gels (gels exposed to 
mineralising solutions). Mean Ca:P from 5 steady state agarose gel runs = 
1.05 ± 0.32 . 
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Figure 44.  EDX data for the mineralised crystals nucleated in the presence of 10 
µg/mL PGA positive control for 7 days at 37⁰C under steady state conditions. 
Mean Ca:P from 5 steady state agarose gel assay runs = 1.73 ± 0.12 (within 
10% of theoretical value for hydroxyapatite). 
 
 
Figure  45. EDX data for the mineralised crystals nucleated in the presence of 10 
µg/mL recombinant 32 kDa enamelin protein for 7 days at 37⁰C under steady 
state conditions.  Mean Ca:P from 5 steady state agarose gel assay 5 runs = 
1.61 ± 0.03 (within 10% of theoretical value for hydroxyapatite). 
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3.2.7 Characterisation of nucleated mineral deposits by transmission 
electron microscopy (TEM)  
Transmission electron microscopy was used to investigate the morphology at high 
resolution of individual mineral crystals isolated from the agarose gel plugs containing 
recombinant protein or PGA positive control following incubation in the steady-state 
agarose gel system.  
Figures 46 and 47 below show TEM images of mineral crystals nucleated in the 
presence of 5.0 µg/mL recombinant 32 kDa enamelin protein. These crystals had a flat, 
planar appearance with a jagged edge. This crystal appearance is very similar to what 
was seen in SEM; that the crystals nucleated by recombinant 32 kDa enamelin have a 
flat, oblate  morphology.  
 
Figure 46.  TEM image of crystals nucleated in the presence of recombinant 32 
kDa (5 µg/mL). Note the large, flat planar appearance of the crystals. The 
crystal at the bottom of the screen measures approximately 4 µm by 0.7 µm. 
Image taken at 28,000 times magnification. 
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Figure 47. TEM image of 2 overlapping crystals nucleated in the presence of 
recombinant 32 kDa enamelin (5 µg/mL). The smaller crystal measures 
approximately 0.4 µm by 1.3 µm and the larger crystal 0.7 µm by 1.6 µm. 
Image taken at 60,000 times magnification. 
 
In comparison, the crystals nucleated in the presence of the 10 µg/mL PGA 
positive controls exhibited a much more ‘rosette’ like appearance. This can be seen in 
figures 48 and 49. The crystals appeared smaller (1 micron radius), more feather–like 
and to radiate around a central core. This also confirmed the SEM appearance of these 
crystals. 
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 Figure 48. TEM image of crystals nucleated in the presence of  PGA (10 
µg/mL) following incubation in the steady state agarose gel system. The 
crystal rosette has a diameter of approximately 2 µm. Image taken at 28,000 
times magnification. 
 
 Figure 49.  TEM image of crystals nucleated in the presence of PGA (10 
µg/ml) positive control recovered following incubation in the steady state 
agarose gel system.  The top crystal has a maximum diameter of 3.5 µm. 
Image taken at 60,000 times magnification. 
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Figure 50 shows a TEM image of commercially available hydroxyapatite crystals. 
These were not obtained from the steady state agarose system. Rather a solution of 
commercial hydroxyapatite was dried onto a TEM grid. These were far smaller than the 
crystals nucleated by recombinant 32 kDa enamelin or PGA, and had a much more 
needle-like appearance. 
 
Figure 50. Image of commercially available hydroxyapatite crystals. The crystals 
are more rod like with a length of approximately 0.2 µm. Image taken at 
60,000 times magnification. 
 
These nucleation studies showed that recombinant 32 kDa enamelin is capable of 
nucleating and supporting hydroxyapatite crystal growth at concentrations of 1 µg/mL 
and 10 µg/mL. The degree of nucleation of hydroxyapatite was highly variable between 
experimental runs using the steady state agarose gel system , even in the positive 
control (PGA). EDX analysis confirmed that the crystals nucleated by PGA and 10 µg/mL 
recombinant 32 kDa enamelin had a similar Ca:P ratio to that of commercially available 
hydroxyapatite and near to the theoretical value for the molar ration of this mineral. SEM 
analysis showed that both crystals nucleated in the presence of PGA and commercially 
available hydroxyapatite crystals have a similar rosette-like appearance with needle like 
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crystals radiating from a central core. SEM analysis showed that the crystals nucleated 
in the presence of recombinant 32 kDa recombinant 32 kDa enamelin were much larger 
with a flat, layered appearance. TEM analysis confirmed the crystal appearance seen in 
SEM. 
Recombinant wild-type and recombinant Y64H mutant amelogenin were both 
apparently unable to nucleate hydroxyapatite in vitro.  No significant difference was seen 
in the phosphate levels obtained for wild type or mutant amelogenin, alone or with 5 
µg/mL recombinant 32 kDa enamelin, suggesting that the Y64H mutation in the 
amelogenin protein does not affect the protein’s role in hydroxyapatite nucleation. 
 
3.3 Studies of 32 kDa enamelin biochemistry in the developing 
enamel matrix  
To date, most studies of enamelin biochemistry and function have used the 32 kDa 
porcine enamelin processing product due to the ready availability of pig developing 
enamel and the relatively high concentration of the 32 kDa species in the enamel matrix. 
There is a tacit assumption that the 32 kDa enamelin is the functional enamelin subunit. 
It is unclear how applicable this data is to other species since enamelin biochemistry is 
poorly described in non-porcine species. To investigate the hypothesis that the 32 kDa 
fragment of enamelin is the functional enamelin subunit in all species, the enamelin 
proteome in developing rat enamel was compared to the porcine enamelin proteome 
using SDS-PAGE and western blotting assays (see materials and methods section 2.4). 
Rat incisors were extracted from male Wistar rats as described in section 2.4.1.  Pig 
teeth were extracted from juvenile pigs as described in section 2.4.2. Developing enamel 
was removed and sectioned into secretory and maturation stage samples for SDS and 
Western blot analysis. In addition, a bioinformatics analysis was carried out to 
investigate the cross-species conservation of the proteolytic cleavage sites present in 
pig enamelin that are responsible for the generation of the 32 kDa enamelin cleavage 
product in pigs. 
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3.3.1 Characterisation of the enamelin proteome in secretory and 
maturation stage rat and pig enamel 
Rat incisor enamel samples from secretion (S1, S2) through to the maturation 
stage (M1, M2, M3 – early, mid and late maturation stage respectively) were subjected 
to SDS PAGE and analysed for enamelin content by western blot probing with an anti-
enamelin antibody. Pig secretory stage enamel was analysed in the same way for 
comparison. The resulting gels and blots are shown in figure 51. Protein bands (stained 
blue on the gels) migrating below 25 KDa correspond to the amelogenins, confirmed by 
the western blot analysis. In the case of the rat samples, the loss of the amelogenins 
from maturation stage samples was evident. Enamelin was present in the developing 
enamel matrix at very low concentrations and was only detectable on the blots; it was 
not detectable by Coomassie staining on the gels. In rat, the enamelin antibody cross 
reacted predominantly with a range of high molecular weight proteins centred around 70 
kDa. Critically, there was little staining in the 32 kDa region. In rat maturation stage 
enamel samples there was a shift in  cross reactivity to a slightly lower molecular weight 
(approximately 50 kDa) as enamelin shares the fate of amelogenin and is degraded and 
removed from the tissue but even here, no obvious 32 kDa processing product was 
present. In complete contrast, the predominant enamelin molecule present on the blot of 
pig secretory stage enamel was at the lower molecular weight of 32 kDa (marked by * in 
figure 51, pig blot) generated, as described widely in the literature, by proteolytic 
processing of a larger precursor enamelin.  
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Figure 51 Shows SDS-PAGE (top panels) of rat enamel from secretory through to 
the maturation stage and pig secretory enamel. The blue stained bands 
migrating below 25KDa are attributable to amelogenins. The corresponding 
western blots (bottom panels), probed with anti-enamelin antibody show 
higher molecular weight enamelin bands in the rat enamel samples. These 
bands migrate at around 70 kDa. In contrast, the pig secretory enamel 
contains a prominent enamelin band migrating at 32 kDa (marked *) .The 
results indicate that rat amelogenesis does not involve the generation of a 
predominant 32 KDa enamelin molecule.  
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3.3.2 The effect of continued proteolytic processing on the enamelin 
proteome in secretory stage rat enamel 
The results described above indicated that rat amelogenesis proceeds in the 
absence of a discrete 32 kDa processing product. To investigate whether the rat enamel 
matrix proteolytic enzymes could cleave rat enamelin with time to generate a 32 kDa 
enamelin homologue, rat secretory stage enamel was incubated in vitro for varying 
lengths of time. Secretory stage enamel from a rat incisor was removed and crushed in 
10% acetic acid. An aliquot was taken at time = 0, and the remaining enamel placed into 
a 37ºC incubator. Further aliquots were taken at 4, 8, 16 and 32 hours to investigate the 
proteolytic breakdown of the enamelin protein over time by the endogenous proteases in 
the enamel matrix. Figure 52 shows a Coomassie stained gel of these aliquots. The 
predominant bands are below 25 kDa, corresponding to the amelogenins as shown by 
the corresponding western blot. There was an obvious loss of full length parent 
amelogenin as it is degraded with time to lower molecular weight processing products. 
A corresponding western blot probed with anti-enamelin antibody showed that the 
enamelin proteins shifted to a slightly lower molecular weight with time consistent with 
limited proteolytic processing but again no 32 kDa enamelin was generated. 
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 Figure 52.  SDS PAGE and enamelin Western blot using anti-enamelin antibodies 
of rat secretory stage enamel matrix allowed to degrade over a period of 32 
hours.  Enamelin components shift to a lower molecular weight but no 
obvious 32 kDa species is generated. 
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3.3.3 Bioinformatics analysis of enamelin protein sequences across 
multiple species 
The data presented above strongly suggested that rat amelogenesis, unlike pig 
amelogenesis, does not involve the generation of a 32 kDa enamelin molecule. To 
investigate possible reasons for this, bioinformatics databases were scrutinised and the 
homology of the cleavage sites responsible for generating the pig 32 kDa enamelin 
component were identified and compared to the homologous site in other species.     
Figures 53 and 54 show the N-terminus cleavage site and C-terminus  cleavage 
site responsible for generating the 32 kDa enamelin in pig (Yamakoshi et al., 2006). In 
descending order, the homologous sequences for  human, mouse, rat, chimpanzee, dog 
and guinea pig are shown.  A full comparison of the enamelin sequences for 295 species 
is shown in Appendix 2 but this limited data below set illustrates the point that the 
combination of both cleavage sites responsible for generating the N and C-terminals of 
the 32 KDa enamelin in pig (as indicated by the blue line cutting between the amino 
acids P-L and R-S respectively) are absent in all other species. It appears therefore that 
the generation of the 32 KDa enamelin in pig amelogenesis may be unique as other 
species do not exhibit the specific cleavage sites present in pig that are responsible for 
the generation of the 32 KDa enamelin.  
 
Figure 53.  Bioinformatics analysis of the amino acid sequences around the 
cleavage sites for generating the N terminus sequence cleavage site of 
enamelin (shown by blue line).  
 
  
154 TQTPQAFPPFGNGLFPYQQP LWHVPHRIP-PGYGRPPTSNEEGGNPYFGFFGYHGFGGRP 212 PIG 
153 AQPPQAFPPFGNGLFPYQQP PWQIPQRLPPPGYGRPPISNEEGGNPYFGYFGYHGFGGRP 212 HUMAN 
158 AQPPQPFPPFGNGLYPYPQP PWPIPQRGPPTAFGRPKFSNEE-GNPYYAFFGYHGFGGRP 216 MOUSE 
228 AQPPQPFPPFGNGLYPYQQP PWPIPQTGPPTGFGRPKFSNEE-GNPYYAYFGYHGFGGRP 286 RAT 
153 AQPPQAFPPFGNGLFPYQQP PWQIPQRLPPPGYGRPPMSNEEGGNPYFGYFGYHGFGGRP 212 CHIMP 
155 GQPPQAFPPFGNGLFLYQQP PWQVPHRVP-PGYGRPPASNEEGGNPYFGYFGYQGFGGRP 213 DOG 
155 AQPPQPFPPFNNGLFPFQQP PWPIPQRMPPPGYGRPPLSNEDGGNPYFGFFGYPGFGGRP 214 GUINEA PIG 
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Figure 54.  Bioinformatics analysis of the amino acid sequences around the 
cleavage sites responsible for generating the N C terminals of the 32 kDa 
enamelin in pig. The relevant cleavage sites in pig appear to be unique and 
are not shared by other species.  
 
3.4 Recombinant wild type and Y64H mutant amelogenin protein 
binding/aggregation studies 
In vitro experiments were performed to determine whether the Y64H mutation in 
recombinant amelogenin affected its aggregative properties (the basis of nanosphere 
formation). Wild type and Y64H mutant recombinant amelogenin proteins were used to 
coat 96-well microtitre  plates and act as a ‘bait’ to capture wild type or Y64H mutant 
recombinant amelogenin proteins, labelled with the fluorescent tag fluorescein (FITC). 
BSA bait protein was used as a control to examine non-specific amelogenin binding. The 
level of binding interaction (i.e. aggregation) was assessed by reading the fluorescence. 
 
3.4.1 Adsorption and blocking of recombinant amelogenin proteins to 
microtitre plates 
Binding experiments were performed by adsorbing a bait protein of interest 
(unlabelled amelogenin or BSA) onto microtitre plate wells. Any remaining exposed well 
surface was blocked with a blocking protein and then the binding partner (labelled 
amelogenin) added (section 2.3). Blocking was essential to prevent the labelled 
amelogenin simply adsorbing to the wells and giving a false positive result. It was 
equally important that the binding partner did not bind to the blocking protein.   Several 
different blocking solutions were initially investigated with 1% BSA in TBS proving to be 
the most suitable (data not shown).  
264 NDTSPTGTSGQGPNPR SNPTGQNGP----AVNVSGQGVPRSQSPWGPRQTIIHENYPNPN 319 PIG 
265 NDTSPTGNSTPGLNTG NNPPAQNGIGPLPAVNASGQGGPGSQIPWRPSQPNIRENHPYPN 324 HUMAN 
269 NDTSPIGNTGPGPNAG NNPTVQNGVFPPPKVNVSGQGVPKSQIPWRPSQPNIYENYPYPN 328 MOUSE 
342 NDSSPVGNTGPGPNAG NNPTVLNGVFPLPKVNVSGQGVPKNQIPWRPSQPNIYENYPYPN 401 RAT 
265 NDTSPTGNSTPGLNTG NNPPAQNGIGPLPAVNASGQGGPGSQIPWRPSQPNIRENHPYPN 324 CHIMP 
266 NDTSPTGNSGPGPNTV SNPTAQNGVISPATVNISGQGVPRTQISWGPNQPNIHENYPNPN 325 DOG 
262 NDTGPTLNSIPGLNTG NNPTVQNGIFPLPTVNFSGQVIPGSQIPWKPNQPNIYGSYPKPN 321 GUINEA PIG 
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3.4.2 FITC-labelled protein binding 
Following bait protein adsorption, the wells were aspirated, washed and blocked. 
FITC labelled binding partner (either labelled wild type or labelled Y64H mutant 
recombinant amelogenin) was then added and allowed to bind to the bait protein. The 
wells were aspirated and washed to remove unbound FITC labelled protein and the 
degree of binding determined by reading the fluorescence on a fluorimeter.  
The results are shown in figure 55. Reading left to right the first column shows the 
fluorescence associated with FITC labelled wild type recombinant amelogenin binding 
with unlabelled wild type recombinant amelogenin bait initially bound to the well (WT-
WT). The second column shows the fluorescence associated with FITC labelled Y64H 
mutant recombinant amelogenin binding with unlabelled wild type recombinant 
amelogenin bait initially bound to the well (WT-MUT). From this data it was clear that the 
Y64H mutant recombinant amelogenin apparently showed a greater binding affinity 
(approximately 3 times greater) to wild type recombinant amelogenin than wild type 
recombinant amelogenin did to itself. The next two columns show the fluorescence 
associated with FITC labelled wild type recombinant amelogenin binding with unlabelled 
Y64H mutant recombinant amelogenin bait initially bound to the well (MUT-WT) and the 
fluorescence associated with FITC labelled Y64H mutant recombinant amelogenin 
binding with unlabelled Y64H mutant recombinant amelogenin bait initially bound to the 
well (MUT-MUT). From this data it was clear that the Y64H mutant recombinant 
amelogenin apparently showed a greater binding affinity (approximately 3 times greater) 
to Y64H mutant recombinant amelogenin than wild type recombinant amelogenin does.  
Binding of either FITC labelled wild type or Y64H mutant  recombinant amelogenin to the 
BSA bait showed no fluorescence, indicating that binding of either amelogenin type to 
BSA did not occur; this indicated that specific amelogenin-amelogenin interactions were 
being detected. Interestingly, the interaction shown in column 3 (between FITC-Y64H 
mutant recombinant amelogenin to unlabelled wild type recombinant amelogenin bait  
(MUT-WT)) was much less than FITC-wild type recombinant amelogenin to unlabelled 
Y64H mutant recombinant amelogenin (WT-MUT shown in column 2). Both columns 
represent interactions between wild type and mutant proteins; the difference being in 
which protein (wild type or Y64H mutant) that was initially bound to the well to act as bait 
protein.  When Y64H mutant amelogenin acted as bait, the resulting binding was 
reduced compared to the results obtained when wild type amelogenin acted as the bait. 
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Figure 55.  Results of FITC binding experiments showing 100 µg/mL of unlabelled 
wild type amelogenin, Y64H mutant amelogenin or BSA bound to a 96-well 
microtitre plate and interrogated with 100 µg/mL of either wild type or mutant 
FITC-labelled amelogenin. N =6. Standard deviation error bars are shown 
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      3.5 Q-RT-PCR of ER stress genes and amelogenin in wild type 
and Y64H mutant mice incisors  
3.5.1 Comparison of the expression of ER stress genes in enamel 
organs of wild type and Y64H mutant amelogenin mice. 
Immunocytochemical investigation of ameloblasts expressing the Y64H mutant 
amelogenin (carried out by Dr Martin Barron, University of Manchester) revealed the 
presence of abnormal vesicles packed with amelogenin protein. Figure 71 (Discussion 
section 4.7) shows a typical TEM image of affected ameloblasts including following 
probing with anti-amelogenin antibodies. This abnormal retention of protein in the ER 
can lead to the phenomenon of ER stress which raised the possibility that the 
mechanism underpinning amelogenesis imperfecta in the Y64H mutant mice was based 
on cellular ER stress rather than functional failure of mutant amelogenin in the 
extracellular enamel matrix.  To investigate this radical hypothesis further q-RT-PCR 
was used to determine levels of amelogenin and proteins known to be expressed by 
cells attempting to combat ER stress in wild type and Y64H mutant mouse incisor 
enamel organs.  
 
3.5.2 RNA extraction from mice enamel organs 
Mice expressing the Y64H amelogenin mutation were bred by our Wellcome Trust 
collaborators at the University of Manchester (Materials and Methods Section 2.5). The 
mandibular incisors from five male animals carrying the Y64H amelogenin mutation and 
four male animals carrying wild type amelogenin were extracted. Each tooth was treated 
as a separate entity. The enamel organ was dissected from the incisors and the RNA 
extracted as described in Section 2.5.2. 
Figure 56 shows an image of an agarose gel of the RNA extracted from two wild-
type and two mutant mice incisors. The 28S and 18S subunits were visible indicating 
successful RNA extraction. 
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Figure 56. Image of an agarose gel of the extracted mouse tooth RNA. RNA 
markers are shown on the left, then the RNA for two wild-type mouse incisor 
enamel organs and then the RNA for two mutant mouse incisors. 
 
This RNA was treated to remove any genomic DNA contamination and transcribed 
into cDNA using a commercially available kit as per Section 2.5.4. Figure 57 shows an 
image of an agarose gel for the cDNA created using the extracted RNA using reverse 
transcription PCR (RT-PCR) for two wild type and two Y64H mutant extracted enamel 
organs. 
 
 
 
28S subunit 
18S subunit 
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Figure 57. Image of an agarose gel showing the cDNA PCR product achieved after 
performing RT-PCR on the RNA extracted from mice enamel organs using 
the Phire Hot-Start PCR kit from New England Biotech. Full-length 
amelogenin product at 540bp can be seen for both the wild type and Y64H 
mutant amelogenin cDNA. 
 
3.5.3  Quantitative real time PCR of the transcribed cDNA 
 
cDNA obtained as described above was used as the template for quantitative real time 
PCR (q-RT-PCR) analysis. Primers for the amelogenin gene (Amelx), marker genes for 
ER stress proteins (Bip, Grp94, chop, Xbp1) and a housekeeping gene (Gapdh) were 
used determine the effects of the Y64H mutation on gene expression of amelogenin and 
proteins associated with ER stress. Following DNA amplification, each gene was 
expected to produce DNA of a particular size, known as an amplicon. This is shown in 
figures 57 and 58 after horizontal agarose gel electrophoresis of the q-RT-PCR products 
(amplicons) and the differences in molecular weights (base pairs). Figure 58 is a 
representative gel for a wild-type mouse enamel organ and figure 59 is a representative 
gel for a Y64H mutant mouse enamel organ. Figure 60 shows the amplicons for Amelx 
across all the mice enamel organs, both mutant and wild type, investigated. 
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Figure 58. Horizontal gel electrophoresis of q-RT-PCR amplicons from Wild-type 
amelogenin mice incisors enamel organs. BP= base pairs for the New 
England Biolabs low molecular weight DNA ladder. 
 
Figure 59.  Horizontal gel electrophoresis of q-RT-PCR amplicons from Y64H 
amelogenin mice incisors enamel organs. BP= base pairs for the New 
England Biolabs low molecular weight DNA ladder. 
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Figure 60. Agarose gel stained with Biotium Gel-red stain and viewed under UV 
light on GelDoc, showing RT-PCR product for extracted RNA with 
amelogenin forward and reverse primers. 
 
Standard curves were performed for each gene using a dilution series of cDNA. A linear 
response is required to show efficiency of amplification. Figure 61 shows a standard 
curve for GAPDH housekeeping control gene, as generated by the Lightcycler 4800. 
 
 
Figure 61. Standard curve for Gapdh control. This curve is typical of the data 
obtained from the Light Cycler 4800 (see appendix for an example of the data 
obtained). The curve has an efficiency of 1.892 (expected value is 
approximately 2), a slope of -3.610, a Y Intercept of 31.52, with an error of 
0.0203. 
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Standard curves were run for each gene of interest and with each cDNA sample, 
using a 1 in 10 dilution range. Plotting the log of concentration against the CP values 
resulted in a linear fit comparable to the Gapdh control in figure 61.  
 
Figure 62 shows the amplification curves for Gapdh extracted from mice enamel 
organs containing wild type Amelx. This is a typical example of the amplification curves 
obtained throughout the study. The cycle number at which the amplification increases is 
known as the crossing point or CP. This is the point at which the levels rise above 
background/threshold. The graph show that the negative controls (concentration 0) stay 
at threshold. A representative q-RT-PCR report from the Lightcycler is shown in 
Appendix 3. 
 
 
Figure 62. Typical graph generated by the LightCycler 4800 to show the CP values 
and amplification of samples. In this case, cDNA transcribed from mice 
carrying wild type Amelx is amplified for Gapdh. 
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Table 1 Shows the CT values for all 11 Y64H amelogenin mutant mice enamel 
organs and the 6 genes investigated. Where no data is shown, no data was generated. 
Figures 62 shows representative fold changes in gene expression for each individual 
Y64H mutant amelogenin mouse enamel organs for each of the 6 genes. 
 
Table 1. CT values for all Mutant (M) and wild-type (WT) AMELX mice incisors for 6   
genes. N/D = not detected. 
  
Gapdh Amelx Grp94 Bip Chop Xbp1 
1A M 35.16 29.31 33.86 34.37 40.00 34.77 
1B M 34.20 27.72 33.50 33.53 40.00  35.19 
2A M 33.59 27.48 34.49 34.93 40.00 35.19 
2B M 32.75 25.84 31.06 32.71 25.88 33.62 
3A M 34.07 28.87 33.83 35.75 40.00 39.20 
4B M 33.14 28.63 33.38 34.25 40.00 35.25 
5A WT 35.81 29.49 35.35 36.88 40.00 39.78 
5B WT 31.81 23.29 30.93 32.73 40.00 32.63 
6A WT 34.62 28.59 34.01 35.34 N/D 36.01 
6B WT 31.78 24.22 31.75 32.94 39.51 33.20 
7A M 33.93 27.16 33.97 34.53 40.00 33.69 
7B M 32.87 24.56 33.68 33.40 40.00 35.65 
8A WT 32.17 25.00 31.65 33.74 40.00 33.39 
8B WT 38.59 30.46 36.05 37.58 40.00 35.49 
33A WT 34.48 26.81 32.60 34.19 40.00 35.93 
33B WT 32.38 24.92 33.19 33.04 40.00 34.90 
34A M 36.39 30.35 31.07 35.87 40.00 39.68 
34B M 34.73 28.05 36.00 36.22 39.27 32.13 
 
 
Figure 63 shows a graph representing the crossing point data for all the mice 
incisor enamel organs examined with the panel of 6 genes, represented as a fold 
difference compared to Gapdh housekeeping control. Each gene is the mean of 11 
replicates.  From this data it is clear to see that Amelx is statistically significantly down-
regulated in Y64H mutant mice enamel organs, while Chop is statistically significantly 
up-regulated. 
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Figure 63. Overall fold change (∆∆CT) for Y64H mutant amelogenin enamel organs 
compared to wild type amelogenin enamel organs (n=10) Grubbs outlier test 
applied. Student’s two-tailed T test applied to determine upregulation and 
down-regulation to gapdh housekeeping control. 
 
Several statistical methods were employed to investigate any upregulation or 
downregulation of the CT levels of the genes of interest, comparing gene expression in 
the enamel organs of wild type mice and mice carrying the Y64H amelogenin mutation. 
Non-parametric analysis was performed using SPSS (IBM) software. The student 2-
tailed T test performed on the ∆∆CT values (Y64H amelogenin mutant compared to wild 
type) showed that Amelx was statistically significantly down-regulated in the Y64H 
amelogenin mutant enamel organs and Chop statistically significantly up-regulated in the 
Y64 amelogenin mutant enamel organs (p<0.05 in both cases). However, the Chop data 
should be viewed with caution as the difference observed is accounted for by the results 
obtained from a particular sample which skewed the mean values (sample 2BM, table 
1). In general Chop was at very low levels in most samples as evidenced by the CT 
value of 40 obtained. 
In summary, the q-RT-PCR data showed that amelogenin expression was 
significantly down regulated in Y64H mutant amelogenin ameloblasts. Down regulation 
of general protein synthesis is a classical UPR survival response.   Chop (a marker for 
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apoptosis) was also significantly upregulated although the reliability of this data is 
questionable as this result is based on a single sample exhibiting a high expression of 
chop.  
3.6 SEM analysis of Y64H mutant amelogenin mouse incisors 
In an attempt to better understand the mechanism by which the Y64H mutation 
affects amelogenesis, the micro-ultrastructure of the resulting affected mature enamel 
was investigated using SEM.    
Wild type female mouse incisors, Y64H mutant amelogenin heterozygous female 
mouse incisors and male Y64H mutant amelogenin homozygous mouse incisors were 
prepared as described in Chapter 2 section 2.6 and imaged using a Hitachi S3400N 
scanning electron microscope using backscatter mode. 
Figure 64 shows a typical wild type female mouse incisor in transverse section. 
The characteristic decussating interlocking weave pattern of the enamel prisms 
emanating from the dentine layer is clear. Figure 65 shows a higher magnification of the 
enamel layer, displaying the ordered disposition of the enamel prisms.  
 
Figure 64. SEM image of a female wild type mouse incisor imaged at 450 times 
magnification. The decussating interlocking weave pattern of the enamel 
prisms emanating from the dentine layer is clear. The enamel layer is even in 
thickness at approximately 75 microns (shown with red arrow). 
Enamel 
Dentine 
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Figure 65. Higher magnification SEM image of the wild type female mouse incisor 
enamel layer shown in figure 63.  The decussating interlocking weave pattern 
of the enamel prisms emanating from the dentine layer is clear. 
Figure 66 shows a typical SEM image of a female mouse incisor that is 
heterozygous for the Y64H amelogenin mutation in transverse section. The 
characteristic decussating interlocking weave pattern of the prisms is evident in the inner 
enamel adjacent the dentine. However, in contrast to wild type enamel, the ordered 
enamel structure is disturbed in the mature outer enamel tissue layer.  
 
Figure 66. SEM image of a section through an erupted mouse incisor of a female 
animal heterozygous for the Y64H amelogenin mutation. Imaged at 450 times 
magnification. The decussating interlocking weave pattern of the enamel 
prisms emanating from the dentine layer is clear in the inner enamel, but is 
lost in the outer enamel layer, shown by the red arrow. 
Enamel 
Dentine 
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Figure 67 shows a higher magnification of enamel layer of the section through the 
incisor from the female mouse heterozygous for the Y64H amelogenin mutation with the 
loss of enamel structure clearly visible at the interface between the normal inner enamel 
and structurally abnormal outer enamel layer.  
 
Figure 67.   Higher magnification SEM image of the section through the incisor 
from the Y64H mutant amelogenin heterozygous female mouse incisor 
enamel layer shown in figure 65.  Note the interface between the normal 
decussating interlocking weave pattern of the enamel prisms and the 
abnormal outer enamel layer. 
Figure 68 shows the outer edge of the enamel layer of the section through the 
mouse incisor from a female mouse heterozygous for the Y64H mutant amelogenin 
where pieces of enamel at the outer edge are absent suggesting that the outer abnormal 
enamel is mechanically inferior to the underlying enamel and has sheared off in the 
mouth has retained a normal structure. However, it is also possible that the enamel was 
missing prior to eruption i.e. the enamel was never present to begin with. 
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Figure 68. SEM image of a section through an incisor from a Y64H mutant 
amelogenin heterozygous female mouse. This image shows the pieces of the 
outer enamel structure have broken away leaving an uneven edge (shown 
with white arrows) suggesting the abnormal enamel is mechanically 
compromised during mastication. 
 
Figure 69 shows a SEM image of a section through an incisor from a male mouse 
homozygous with respect to the Y64H amelogenin mutation, imaged at 450 times 
magnification. The mature enamel layer is thin, at approximately 30 microns or less, and 
lacks the characteristic decussating prism structure. Figure 70 shows a higher 
magnification of the enamel layer, clearly showing that the normal prism structure is 
missing.  
 
 
 
Uneven enamel 
edge 
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Figure 69.  SEM image of a section through an incisor from a Y64H mutant 
amelogenin homozygous male mouse imaged at 450 times magnification. 
The enamel layer (thickness shown with white arrows) is shown above the 
darker dentine layer, but the characteristic prism structure is not visible. 
 
 
Figure 70.  SEM image (times 1600 magnification) of the enamel layer for the male 
homozygous Y64H amelogenin mutant mouse incisor. The characteristic 
prism structure is not visible. 
 
Enamel 
Dentine 
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In summary, the SEM analysis revealed that heterozygous female mice carrying 
the Y64H mutation appeared to secrete an initial enamel layer that was normal in 
appearance. However, with time, the ability of the ameloblasts to secrete a visually 
normal enamel layer was lost and the final outer enamel layer secreted was structurally 
abnormal. In contrast, the ameloblasts in affected male mice were only able to secrete a 
thin enamel layer that was devoid of normal structure. 
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Chapter 4 
General discussion 
This chapter will discuss the results presented in the previous chapter, and how 
these results fit with and expand our current understanding of the processes involved in 
amelogenesis. 
The research presented in this thesis was undertaken as part of a larger 
multicentre research program and the discussion will explain how the research 
presented here contributed to the overall project outcomes. It is difficult to discuss the 
results presented here without reference to the work of other members of the research 
group and particular attention will be paid to  acknowledging the work of others where it 
is included in order to better contextualise the results presented in this thesis.   
The overall aim of the larger research project was to use amelogenesis as a 
paradigm for biomineralisation. A major focus of the research was to understand the role 
of amelogenin in amelogenesis by studying the effects of an amelogenin mutation in 
mice that resulted in an obvious biomineralisation defect.  Initially, the hypothesis was 
that any amelogenin mutation would disrupt amelogenin function in terms of mineral 
nucleation/crystal growth including how any protein-protein interactions may be affected, 
potentially allowing the affected amelogenin domain to be linked to a specific function. 
To this end, the effect of the Y64H mutation on the ability of amelogenin to nucleate 
mineral de novo and in vitro was investigated using recombinant wild type and mutated 
amelogenin in isolation or in combination with the 32 kDa enamelin  (previously reported 
to cooperatively enhance the nucleation potential of amelogenin (Bouropoulos and 
Moradian-Oldak, 2004)). An unexpected outcome of this work was the realisation that 
the 32 kDa enamelin used almost exclusively for enamelin biochemical and functional 
studies worldwide may be unique to pig amelogenesis and not play as large a role in 
amelogenesis in other species as previously thought.  During the course of the research 
it became clear that the Y64H amelogenin was actually blocking the intracellular 
secretory pathway in ameloblasts and that ER stress driven ameloblast apoptosis was a 
major factor in the disease mechanism operating in affected mice. This section 
discusses the existing literature and how the present results relate to these previous 
studies and also develops hypothesis to be tested in future studies. The thesis map in 
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the aims and objectives section provides a summary to the content and structure of the 
Discussion.      
 
4.1  Effect of the Y64H mutation on the nucleating potential of 
amelogenin 
 
This effect of the Y64H mutation on the nucleation potential of amelogenin in the 
presence and absence of 32 kDa enamelin was investigated using a steady-state 
agarose gel based in vitro nucleation system.  The interpretation of data in this area is 
difficult to appraise due to the fact that the same protein can exhibit opposite behaviors 
(i.e. promote nucleation or inhibit nucleation) depending on the experimental conditions 
used The situation was best summed by Hunter et al 1996 who in their Discussion 
section admitted that:  
“….the diversity of experimental systems used [to study promotion/inhibition of 
nucleation] makes any overall conclusions very difficult to find.”        
That aside, it is clear that certain biochemical features are associated with proteins 
thought to control skeletal biomineralisation. The steady-state agarose gel system was 
first used by Hunter and Goldberg in 1993 to investigate the nucleation of hydroxyapatite 
by bone sialoprotein (BSP) and later extended to other proteins which at least allows 
comparisons to be made against a fixed experimental baseline.  
BSP is a major phosphorylated protein in mammalian bone and has been 
proposed to have a role in mineral initialisation (Hunter and Goldberg, 1993). Mature 
BSP is a 33 kDa protein and is predominantly made up of glutamic acid and glycine 
residues (32% of all residues). The glutamic acid residues occur in clusters of up to 10 
consecutive repeats. BSP is highly acidic (pKa approximately 3.9) and contains no α 
helices or ß sheet, or structural domains. BSP has extensive post-translational 
modifications amounting to approximately 50% of the native protein. Tye et al., (2003) 
used the steady state agarose gel system to identify which regions of BSP are required 
for hydroxyapatite nucleation. The conformation of the wild type and mutant proteins 
were studied by circular dichroism and X-ray scattering which revealed that a sequence 
of at least 8 contiguous glutamic acid residues are required for the nucleation of 
hydroxyapatite by BSP. Hunter and Goldberg drew the conclusion that polycarboxylate 
- 164 - 
sequences (i.e. glutamate and aspartate) represent a general site for growth modulating 
interactions between proteins and biological crystals. The carboxyl groups that terminate 
the side chains of both glutamate and aspartate are negatively charged (see figure 71 
below) at physiological pH and when linked by peptide bonds into long chains (as they 
appear in BSP) can provide a negatively charged array that could potentially bind 
calcium ions through ionic interactions in a suitable stereochemical arrangement to 
trigger mineral nucleation. 
 
 
Figure 71. Structure of glutamate and aspartate polycarboxylate sequence 
 
 Like BSP, dentine phosphoprotein was found to promote nucleation in the agarose 
gel system (though less potently) (Hunter et al 1996). Dentine phosphoprotein is 
extremely acidic due to its very high content of polyaspartic acid residues (Richie and 
Wang, 1996), again supporting the notion that polycarboxylic acids are a feature of 
nucleating proteins.   
 However, it is clear that the presence of polycarboxylic acids per se is not enough 
to give a protein nucleating potential. The acidic phosphorylated bone protein 
osteopontin is a phosphorylated sialoprotein similar to BSP but in contrast exhibits 
domains of polyaspartic acid rather than polyglutamic acid. Although these amino acids 
are structurally and chemically similar, osteopontin proved to be a potent inhibitor of 
mineral nucleation in the agarose gel system (Hunter et al 1996).     Desphosphorylation 
and chemical modification of osteopontin showed that the ability of osteopontin to inhibit 
nucleation required phosphate and carboxylic acid groups, and possibly the conserved 
sequence of contiguous aspartic acid sequences (Hunter and Goldberg 1994). 
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Another acidic bone protein, osteocalcin, contains three gamma carboxyglutamic 
acid residues that participate in the binding of calcium ions. On calcium binding a major 
conformational change occurs that greatly increases the ά helical content of the protein 
(Hauschka 1986). Using the steady-state agarose gel system osteocalcin was found to 
delay nucleation (Hunter et al 1996).   
It is clear that predicting the mineral nucleating behaviour of a protein from its 
amino acid sequence is difficult. It is clear that polycarboxylic acids and phosphorylation 
are common features associated with bone and dentine biomineralisation; regardless of 
whether the protein in question promotes or inhibits nucleation. The potency of 
polyglutamic acid sequences as a nucleator is evidenced by the now common use of 
long chains of glutamic acid synthesised chemically for use as a positive control in 
mineral nucleation experiments.   PGA at 10 µg/mL was used as the positive control for 
assessment of mineral nucleation in the steady state agarose gel system used in this 
thesis. 
How do enamel proteins compare in terms of phosphorylation and polycarboxylic 
acid content?  Enamelin contains 2 phosphorylated serine residues and 3 glycosylated 
asparagine residues which are located in the domain that forms the 32 kDa fragment in 
pig enamelin following cleavage of the full length protein. Like the mineralised tissue 
proteins described above, the 32 kDa enamelin is acidic (isoelectric point of 5.27) but 
contains only two examples of diglutamic acid units (Hu and Yamakoshi. 2003). The 32 
kDa enamelin protein used in the experiments presented in this thesis was produced in a 
eukaryotic system and the resulting protein should have all the appropriate post-
translational modifications such as phosphorylation and glycosylation (Hu and 
Yamakoshi, 2003). Given these modifications, the 32 kDa enamelin has the potential 
capacity to interact with mineral and influence growth (Robinson et al., 1998; 
Bouropoulos and Moradian-Oldak, 2004; Fan et al., 2008; Fan et al., 2009B; Al-Hashimi 
et al., 2009). 
Table 2 shows a comparison of the key features of extracellular matrix proteins that have 
been used to investigate hydroxyapatite nucleation potential. 
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Table 2. Table to show comparison of common features of proteins that have been 
examined for hydroxyapatite nucleating potential. Note that the frequency of aspartic 
acid and glutamic acid invertebrate proteins is on average around 6% (Mann, 2001) 
 
Protein 
(Porcine) 
PKa MW 
kDa 
PTM Tertiary 
Structure 
Aspartic 
Acid 
Glutamic 
Acid 
 
Shown to 
nucleate 
HAP? 
Bone 
sialoprotein 
21 
3.91 331 50%1 No1 5.4%1 19%1 Yes2 
Phosphoryn3 Acidic 33 yes Yes with 
Ca2+ 
20% 5% Yes 
Osteocalcin3 5.5 6 Yes Yes 4% 8% No 
Osteopontin 
(Bone 
sialoprotein 
1)2 
Acidic 32.6 Yes Yes 15% 9% No 
Osteonectin3 5.9 44 Yes Yes8 8% 11% No 
32 kDa 
Enamelin 
5.3 325 Yes5 No (Mainly 
ά helices)6 
3%4 9.4%4 No 
Amelogenin 6.57 25 Yes Β sheet 
(bovine) 
 
1.5% 2.5% No 
1
 Oldberg et al., 1988; 2 Hunter and Goldberg, 1993; 3 Hunter et al., 1996; 
4
 Hu and Yamakoshi 2003; 5  Yamakoshi, 1995; 6 Fan et al, 2008; 
 
7
 He et al., 2008; 8 Fujisawa et al., 1996 
 
 In contrast to enamelin, which exhibits at least some similarities with the 
mineralised tissue proteins discussed above; amelogenin is not particularly acidic 
(isoelectric point 6.5) and has a low glutamic and aspartic acid content.  Indeed, Hunter 
et al (1999) reported that recombinant mouse amelogenin in agarose gels failed to 
induce or inhibit in vitro nucleation at protein concentrations ranging from 1-300 µg/mL. 
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However, Tarasevich et al. (2007) tested recombinant mouse amelogenin, rM179 in vitro 
and found that the protein nucleated mineral up to a protein concentration of 6.5 µg/mL 
in free solution.  At higher concentrations the nucleating potential decreased until at 130 
µg/mL nucleating potential was essentially zero. However, higher concentrations of 
amelogenin are not necessarily inhibitory because on close examination of the 
Tarasevich’ s 2007 publication it is apparent that the mineralising solutions remained 
metastable and did not nucleate mineral in the absence of protein; in other words this 
experimental system was not suitable for determining whether higher concentrations of 
amelogenin are able to inhibit nucleation simply because even in the absence of 
amelogenin, nucleation does not occur. To show if these higher concentrations of 
amelogenin are able to inhibit nucleation they would need to be added to a system that 
is able to induce nucleation in the absence of the added amelogenin. Previous studies 
have shown that proteins may inhibit mineralisation by the sequestering of mineral ions.  
The binding of calcium ions to proteins and proteoglycans lowered the concentration of 
calcium in solution and inhibited nucleation ([Hunter and Szigety, 1985; Hunter et al., 
1994). Protein concentration in vitro being able to influence mineralisation suggests that 
amelogenins function in vivo may be dependent on concentration, with roles such as 
nucleator being promoted at low concentration and other roles such as growth modifier 
occurring at high concentration. The concentration of recombinant amelogenin protein 
used in the steady-state agarose gel system in this thesis was 10 µg/mL, above the limit 
of 6.5 µg/mL amelogenin shown by Tarasevich et al., (2007) where amelogenin switches 
from a nucleator to an inhibitor. The experiments in section 2.2 agree with this theory, 
with 10 µg/mL recombinant amelogenin eliciting an inhibitory effect on mineral nucleation 
in the steady state agarose gel system. 
Bouropoulos and Moradian-Oldak (2004) showed that crude amelogenin extracts 
(comprising nascent amelogenin and its processing products) added to gelatine gels in 
amounts far exceeding 6.5 µg/ml (i.e. 0.75 or 1.5% (w/w)= 7.5-15 mg/mL) had an  
inhibitory effect on in vitro hydroxyapatite nucleation. They also tested the nucleation 
potential of the 32 kDa enamelin at 18 µg/mL in the same system and reported that it too 
inhibited nucleation. However, when amelogenin at 1.5% (w/w) was used in conjunction 
with 32 kDa enamelin, nucleation was accelerated. This striking result suggested a 
synergistic role for amelogenin and the 32 kDa enamelin in terms of hydroxyapatite 
nucleation.    
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Based on this, the nucleating potential of wild type and Y64H mutant recombinant 
amelogenin was tested in the absence and presence of recombinant 32 kDa enamelin. 
When deciding on relevant amelogenin concentrations to use in the present work 
several things needed to be considered:  
1) How the concentrations used in the in vitro system compare to those in vivo:  
Secretory stage enamel is approximately comprised of equal volumes of protein 
(mostly amelogenin), water and mineral meaning that in vivo amelogenin concentration 
approaches 100% (v/v) or 1350 mg/mL (assuming an average density of 1.35g/cm3 for 
protein (Fischer et al 2004)). Researchers studying amelogenin have been frustrated 
by the low solubility of amelogenin at physiological pH which is around 200 µg/mL in 
calcium-phosphate solution (Tan et al 1998). This explains why Tarasevich et al. (2007) 
used amelogenin concentrations of only up to 130 µg/mL in calcium-phosphate 
solution. Bouropoulos and Moradian-Oldak (2004) used amelogenin at much higher 
concentrations of 7.5 and 15 mg/mL but here amelogenin was added to gelatine gels 
and presumably the amelogenin was only partially solubilised in these gels and as such 
closer to the situation found in vivo where the amelogenin must exist as a hydrated 
protein gel.  In general, amelogenin experiments are conducted using solutions that are 
orders of magnitude more dilute than in vivo concentrations but dispersing the 
amelogenin in gelatine or agarose (as is the case in this thesis) may be a better 
approximation to in vivo conditions compared to experiments conducted with 
amelogenin free in solution.    
2) The availability of amelogenin to use in in vitro mineralisation experiments: 
 In vitro mineralising experiments, including the system described in this thesis, have to 
be designed with the knowledge that amounts of recombinant protein available are 
likely to be a limiting factor. Scaling down the experimental mineralising system helps 
to some extent, but this is countered by an increase in measuring error as volumes 
decrease. Using amelogenin at in vivo-like concentrations was simply not practical due 
to limited availability of protein and the solubility issues described above. An 
amelogenin concentration of 10 µg/mL dispersed in agarose gel was used in this study 
as this was the maximum amount that could be sustained in terms of recombinant 
protein production that also aligned with concentrations used previously in the 
literature, enabling the results to be interpreted with reference to what has gone before.  
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4.2 Nucleation potential of wild type and Y64H mutant 
recombinant amelogenin  
 At 10µg/mL both wild type and Y64H mutant recombinant amelogenin significantly 
inhibited nucleation of hydroxyapatite mineral in vitro compared with a PGA positive 
control with no significant difference in levels of inhibitory activity between the two 
amelogenin forms. Under these experimental conditions at least, Y64H mutation did not 
alter the nucleating potential of amelogenin in the agarose gel based system used here; 
both proteins significantly inhibit nucleation relative to the negative control by 
approximately 50%. This inhibitory effect was consistent with previous reports for wild 
type amelogenin studied in a gel based experimental system (Bouropoulos and 
Moradian-Oldak 2004 - see above) but conflicts with Hunter et al (1999) who as 
described above examined the nucleating potential of recombinant amelogenin and 
found it neither nucleated nor inhibited in their agarose gel based system (similar to the 
system used in this thesis).  
Bouropoulos and Moradian-Oldak (2004) also reported that wild type amelogenin 
and 32 kDa enamelin at 18 µg/mL inhibited nucleation in isolation. However, together 
they synergistically promoted nucleation. To test if the Y64H mutation disturbed this 
synergistic relationship, the nucleating potential of the 32 kDa enamelin alone and in 
combination with either WT or Y64H amelogenin was determined. 
 
4.3 Nucleation potential of recombinant 32 kDa enamelin 
Initially, the nucleating potential of 32k Da enamelin alone was determined in the 
present study. Recombinant 32 kDa enamelin was available in limited amounts due to 
the relatively inefficient expression system used. For that reason its nucleating ability 
was tested at concentrations between 1-10 µg/mL. In contrast to Bouropoulos and 
Moradian-Oldak (2004), the 32 kDa enamelin used here induced significant nucleation at 
1 and 10 µg/mL compared to the negative control whereas 32 kDa enamelin at 2.5 and 5 
µg/mL was not significantly different to the negative control (figure 30 Section 3.3.2). 
This apparently conflicting phenomenon, where protein concentration can reverse 
nucleation behaviour is well known. For example dentine phosphoprotein at 100 µg/mL 
inhibited mineral formation but promoted it at <1 µg/mL (Boskey et al., 1990).   
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Increasing the protein concentration could conceivably reduce nucleation due to calcium 
binding by the protein causing a drop in supersaturation levels but it is difficult to 
reconcile this with the parabolic-like response exhibited by the 32 kDa enamelin in this 
thesis. Furthermore, the steady state agarose gel apparatus used is designed to provide 
constant composition conditions and any enamelin calcium binding sites would be 
saturated and levels of supersaturation would remain fixed at the predetermined level. 
One possible explanation for this parabolic response is that any quaternary structure 
existing between two or more 32 kDa enamelin monomers varies with concentration 
which in turn affects the conformation of the 32 kDa enamelin and its ability to nucleate. 
However, there is no evidence to date that supports this hypothesis. 
The Ca:P molar ratio of enamelin nucleated mineral was 1.61±0.03 (see figure 43 
Section 3.2.6); close to the theoretical value for hydroxyapatite(1.66). Polyglutamate, the 
positive control nucleated mineral with a Ca:P of 1.73±0.12; again close to the 
theoretical value for hydroxyapatite of 1.66. In complete contrast any mineral deposits 
formed in the absence of protein (agarose only) had a non-apatitic ratio of 1.05±0.32 
which clearly shows the potential of both 32k Da enamelin (at permissive concentrations 
of 1 and 10 µg/mL) and polyglutamate to nucleate apatitic mineral. Brushite has a Ca:P 
of 1.0 though this information alone does not allow this phase to be identified as brushite 
unequivocally.  Brushite is dicalcium phosphate dehydrate (CaHPO4.2H2O) is a phase of 
calcium phosphate that is relatively soluble in simulated physiological solutions (Kumar 
et al., 1999). However, brushite in solution is only stable in acidic solutions less than pH 
6.5 (Cheng and Pritzker, 1983). Below pH 4.3, brushite is more stable than 
hydroxyapatite. In theory, brushite should form at pH 7.4 at 37⁰C when the 
concentrations of the total calcium and phosphate ions exceeds 5 mM (Koutsoukos et 
al., 1980), such as the conditions used in the steady state agarose gel system in this 
thesis. 
It is clear from the SEMs that the crystal morphology of mineral nucleated is 
affected by the recombinant 32 kDa enamelin.  As described in section 3.2.5, the 
morphology of the crystals was affected but the  concentration of the recombinant 32 
kDa enamelin in the agarose gel plugs. Recombinant enamelin at 1 µg/mL, 5 µg/mL and 
10 µg/mL nucleated mineral crystals with a  large plate like appearance of approximately 
6 microns. Mineral crystals nucleated in the presence of recombinant enamelin at 2.5 
µg/mL exhibited two morphologies, both different to those seen for the crystals nucleated 
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in the presence of recombinant 32 kDa enamelin at 1 µg/mL, 5 µg/mL or10 µg/mL. 
These two morphologies were small spherical clusters of approximately 10 nm in length 
or needle like crystals. TEM images of the mineral nucleated in the presence of 5 µg/mL 
recombinant 32 kDa enamelin showed the crystals to be large (approximately 4 microns 
in length) and flat. Mineral crystals nucleated in the presence of PGA (10 µg/mL) were 
shown by both TEM and SEM analysis to be rosette like in appearance, radiating from a 
central area. Individual crystals were smaller, approximately 1 micron in radius, than 
those nucleated in the presence of recombinant 32 kDa enamelin. 
4.4 Nucleation potential of 32 kDa enamelin in combination with 
either wild type or Y64H mutant recombinant amelogenin  
 When recombinant 32 kDa enamelin at 5 µg/mL was combined with either wild 
type or Y64H mutant amelogenin the inhibitory effects previously observed for all the 
amelogenin proteins observed in isolation (relative to precipitation in the negative 
control) were lost. This result does not support  the results obtained by Bouropoulos and 
Moradian-Oldak (2004) where 18 µg/mL enamelin + 15 mg/mL amelogenin accelerated 
nucleation but at least the trend was the same in that  32 kDa enamelin combined with 
either WT or Y64H synergistically reduced inhibition of nucleation in the system used 
here. In explaining the difference in results obtained by Bouropoulos and Moradian-
Oldak (2004) attention can be drawn to the fact that they used higher concentrations of 
32 kDa enamelin (18 µg/mL compared to 1-10 µg/mL used here) and the amelogenin 
was a crude guanidine-HCl extract containing several amelogenin processing products 
and probably other non-amelogenin contaminates such as ameloblastin that would have 
been co-extracted with the amelogenins.  
In summary, the crucial finding here is that the results obtained with 32 kDa 
enamelin combined with either WT or Y64H amelogenin were not significantly different 
i.e. within the limits dictated by the in vitro nucleation system used to be able to discern 
any effect of the Y64H mutation on the nucleating behaviour of amelogenin (in the 
presence or absence of 32 kDa enamelin).  
The overall conclusion to be drawn from these in vitro nucleation experiments is 
that the amelogenin imperfecta phenotype observed in mice carrying the Y64H 
amelogenin mutation is not due to the Y64H amelogenin behaving differently from the 
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wild type molecule in terms of its behaviour with respect to mineral nucleation (in the 
presence or absence of 32 kDa enamelin). 
 
4.5 The assumed role of the 32 kDa enamelin in amelogenesis  
The calcium binding constant of amelogenin is estimated to be significantly lower 
than other enamel ECM proteins (Ka= <4.5 x 102 M-1 versus Ka = 1.0 x 104 M-1) 
(Yamakoshi et al., 2001). This suggests that an interaction between amelogenin and the 
non-amelogenins such as enamelin may be necessary for enamel mineralisation 
Historically enamelin has been regarded as the non-amelogenin most likely to play 
a role in mineral nucleation (Robinson et al., 1998; Bouropoulos and Moradian-Oldak, 
2004) and as such is a candidate molecule that may act in tandem with amelogenin to 
promote nucleation; a contention supported by the results obtained by Bouropoulos and 
Moradian-Oldak, (2004) using 32 kDa enamelin in combination with amelogenin as 
described above.  Enamelin is a phosphorylated glycoprotein, specific to enamel. It 
constitutes only 1-5% of the ECM, but plays a key role in enamel formation, evidenced 
by enamelin mutations resulting in amelogenesis imperfecta (Rajpar et al., 2001; Mardh 
et al., 2002; Kida et al., 2002;  Hart et al., 2003; Kim et al., 2005A; Gutierrez et al., 2007; 
Gopinath et al., 2008; Simmer et al., 2013). The gene sequences for many species 
including mouse (Hu et al., 1998), pig (Hu et al. 1997) and human (Hu et al., 1998) 
enamelin are known (Al-Hashimi et al 2009). However, studies at the protein levels have 
focused almost exclusively on porcine enamelin owing to the ready availability of porcine 
developing enamel from the meat industry. Upon secretion, the porcine 186 kDa 
enamelin protein is subjected to extensive proteolytic cleavage. Enamelins with 
molecular weights of 155, 142, 89, 45, 32, and 25 kDa have been isolated from 
developing porcine enamel (Fukae et al., 1996).  The 32 kDa fragment extends from 
Leu174 to Arg279 of the full length enamelin molecule, and its carbohydrate moieties have 
been elucidated (Fukae et al., 1996; Dohi et al., 1998; Yamakoshi, 1995). The 32 kDa 
enamelin is hydrophilic, has an acidic PI of 5.3 is rich in proline, glycine, threonine and 
glutamic acid (Hu and Yamakoshi, 2003), has 2 phosphorylated serines (Ser191 and 
Ser216) and 3 glycosylated asparagines (Asn245, Asn252 and Asn264) (Yamakoshi, 1995). 
This is the most abundant enamelin product found in the developing tissue and the most 
stable, accumulating in the deeper, older layers of the developing porcine enamel. 
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Immunohistochemistry studies have shown that the porcine 32 kDa enamelin 
accumulates in the inner layer of crystallite-containing prism and interprismatic areas of 
the enamel matrix (Uchida et al., 1991B).  The 32 kDa enamelin also caused elongation 
of hydroxyapatite crystals in vitro in agarose gels, indicating a role in controlling crystal 
nucleation and/or growth (Hu et al., 2008). Crucially, Bouropoulos and Moradian-Oldak 
(2004) showed that the combination of the 32 kDa enamelin with amelogenins promoted 
the nucleation of hydroxyapatite crystals. Fan et al. (2008) applied circular dichroism 
(CD) and Fourier transform infrared (FTIR) spectroscopy to study secondary structural 
preferences of the porcine 32 kDa enamelin in the presence and absence of calcium 
ions. In the absence of calcium, 32 kDa enamelin showed a high content of α-helix 
(81.5%). Although the 32 kDa enamelin had a calcium association constant of 1.55 (± 
0.13) x 103 M-1 (which is a relatively low affinity) CD showed that with increasing calcium 
ion concentration, the enamelin undergoes a conformational change to β-sheet. This 
may allow a preferable interaction of the 32 kDa enamelin with hydroxyapatite crystal 
surfaces.  
Fan et al. 2009A used the extracted 32 kDa enamelin fragment from developing 
porcine enamel, along with a recombinant amelogenin (rP172 – analogous to full-length 
porcine amelogenin, only lacking the first methionine and a phosphate on Ser16) to 
elucidate the role of  protein interactions in vivo. Dynamic light scattering showed that 
the 32 kDa enamelin caused partial dissociation of amelogenin nanospheres in a dose-
dependent manner at pH 8.0. If this data is examined critically, attention should be 
drawn to the fact that the full length amelogenin is only present in newly secreted 
surface enamel while 32 kDa enamelin is generated with time in the deeper enamel by 
proteolysis of larger precursor proteins (Uchida et al. 1991B). In other words the full 
length amelogenins are unlikely to interact with the 32 kDa enamelin in vivo because 
they are temporally and spatially separated in the developing tissue. However, Fan et al 
later repeated their work using the 20 kDa amelogenin processing product (P148) which 
does co-localise with the 32 kDa enamelin. In this case they reported that the 32 kDa 
enamelin increased the size of amelogenin nanospheres indicating a conformation 
change that may influence interactions with the mineral interface (Fan et al., 2011).  
These data  emphasise the volume of research already conducted using  the 32 
kDa enamelin molecule and the 32 kDa enamelin continues to be the enamelin of choice 
in experiments designed to study the role of enamelin in amelogenesis.   
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However, one unexpected finding arising from this thesis forces us to completely 
revaluate the role, if any, of the 32 kDa enamelin as a discrete entity in amelogenesis. 
This controversial finding is discussed in detail next section. 
4.6 Is the 32 kDa enamelin required in amelogenesis?  
One of the aims of this study was to see whether enamel matrix proteins (enamelin 
and amelogenin) nucleate crystal growth in vitro and how mutations in amelogenin might 
affect any nucleating potential exhibited.  In the case of enamelin, several nucleation and 
protein–protein interaction studies have been carried out using the 32 kDa enamelin 
processing product purified from developing pig enamel (Uchida et al., 1991A and B; 
Dohi et al., 1998; Bouropoulos and Moradian-Oldak, 2004; Habelitz et al., 2006; Fan et 
al., 2008; Hu et al., 2008; Iljima et al., 2010). The 32 kDa enamelin is the most abundant 
enamelin-derived protein in pig secretory stage enamel and although still present as a 
tiny fraction of the total protein is the obvious target for purifying enamelin protein for use 
in in vitro studies. The focus on the 32 kDa enamelin is also linked to widespread belief 
that the 32 kDa moiety is functionally important. This perception was most emphatically 
stated by Al-Hashimi et al in their 2009 publication:  
“Evolutionary analysis of mammalian enamelin, the largest enamel protein, 
supports a crucial role for the 32-kDa peptide and reveals selective adaptation in rodents 
and primates.” 
 They noted that the amino acid sequence comprising the 32 kDa enamelin peptide 
was highly conserved across 36 species especially in terms of its phosphorylation, 
glycosylation and “proteolytic sites”. On this basis a recombinant peptide corresponding 
to the human 32 kDa enamelin sequence was constructed and used in the nucleation 
studies described in this thesis. However, during the course of these studies it became 
apparent that there is a crucial difference between the amino acid sequences of pig 
enamelin and enamelin in other species. Although cleavage sites within the 32 kDa 
sequence are well conserved between species, the cleavage sites that are cleaved to 
release the 32 kDa fragment from its larger precursor are not well conserved at all. 
Critically, Al-Hashimi focused their attention on internal cleavage sites that are 
hydrolysed during the degradation of pig 32 kDa enamelin but neglected the fact that the 
cleavage sites required to release the 32 kDa enamelin (i.e. cleavage between proline 
and leucine to generate the new N terminus, and arginine and serine for generating the 
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terminals of the 32 kDa enamelin) are absent from non-porcine species. The sequence 
alignment of 290 enamelin sequences shown in Appendix 3 shows that the residues 
comprising the cleavage sites responsible for generating the N and C terminals of the 
pig 32 kDa enamelin are only present in the pig. It is believed that MMP20 is responsible 
for liberating the 32 kDa moiety in porcine enamel (Yamakoshi et al., 2006). MMP20 
does not cleave all peptide bonds as evidenced by the fact that it generates a spectrum 
of discrete processing fragments from amelogenin and enamelin and it is unclear how 
flexible MMP20 might be in terms of releasing the 32 kDa enamelin fragment from 
enamelins that do not exhibit the specific cleavage sites used to liberate the porcine 32 
kDa enamelin. The amino acids corresponding to the pig 32 kDa cleavage sites (proline/ 
leucine and arginine / serine) are proline / proline and glycine / asparagine in rat. 
Assuming narrow specificity for the protease that releases the pig 32 kDa enamelin, it is 
reasonable to assume that rat amelogenesis does not involve the participation of a 
discrete 32 kDa enamelin since the specific cleavage sites responsible for its generation 
are absent. To test this, developing rat enamel matrix was compared to developing pig 
enamel matrix by SDS PAGE and western blot probing with a rabbit anti-enamelin 
antibody recognising a region within the 32 kDa enamelin sequence.                     
The anti-enamelin probed Western blots of rat and porcine developing enamel 
(Chapter 3 Section 3.3.1 figure 51) showed that rat amelogenesis does not involve the 
generation of a 32 kDa enamelin molecule. This supports the hypothesis outlined above, 
that based on sequence analysis, only the pig enamelin molecule contains the specific 
cleavage sites required to generate the 32 kDa enamelin.    
The different kinetics of enamel production in the rat and the pig may cause this 
difference in the predominant enamelin species produced. Rat enamel takes 
approximately one week to progress through the secretory stage, at which point the 
matrix is removed at the maturation stage. It could be possible that the proteases 
present at the secretory stage are not active enough to process the rat enamelin to the 
32 kDa level. As the enamel is much thicker in pig teeth, and remains in the secretory 
stage for much longer, the proteases have longer to interact with, and breakdown the 
enamelin. To test this, rat enamel matrix proteins were homogenised and incubated for 
various time periods to encourage enamelin proteolysis. However, no 32 kDa enamelin 
molecules were generated.   
The data strongly indicates that rat amelogenesis occurs without the generation of 
a discrete 32 kDa enamelin processing product. The sites of porcine 32 kDa enamelin 
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post translational modifications (N-linked glycosylation and phosphorylation) are well 
conserved among all species (including pig, mouse, rat and human) indicating a 
functional role for these modifications  (Al-Hashimi et al., 2009). The larger enamelins of 
non-porcine species will of course contain the 32 kDa sequence domain, and these post 
translational modifications, and the biochemical activity associated with these 
modifications may be critical in terms of the function of enamelins larger than 32 kDa. 
However, the functional behaviour of the phosphorylated/glycosylated 32 kDa domain 
may be quite different when it is within larger enamelins due to the influence of the 
additional sequences flanking the 32 kDa domain.   
Given that the generation of the 32 kDa enamelin processing product is not 
essential for amelogenesis in rat, and that its production in pig appears to be an 
anomaly, the use of discrete 32 kDa moieties in enamelin functional studies should be 
viewed with caution and results interpreted with the caveat that the 32 kDa enamelin 
processing product is not common to amelogenesis in non-porcine species. In fact, the 
anomalous production of the 32 kDa enamelin in pig amelogenesis may explain why pig 
enamel only attains a mineral content of ~60% by volume which is significantly lower 
than other species (Kirkham et al., 1988). The pig 32 kDa enamelin has the highest 
affinity for hydroxyapatite of all enamel proteins and is a potent inhibitor of 
hydroxyapatite crystal growth following its adsorption (Tanabe et al., 1990).  Pig 
amelogenesis may therefore be compromised to some degree due to the release and 
accumulation of 32 kDa enamelin from its larger enamelin precursor. Pig enamel 
remains perfectly functional even though it exhibits a reduced mineral density compared 
to other species and therefore there is little evolutionary pressure to eradicate the 
production of the 32 kDa enamelin during pig amelogenesis.  
The above discussion questions the validity of using 32 kDa enamelin (either 
purified from pig tissues or produced as a recombinant protein as in this thesis) in 
studies designed to explore the function of enamelin. An obvious criticism of the work 
examining the effect of recombinant 32 kDa enamelin in the nucleation assays reported 
in Chapter 3 section 3.2 is that the 32 kDa enamelin may not be relevant in 
amelogenesis in general and the enamelin function is associated with enamelin(s) with 
molecular weights greater than 32 kDa. Isolating sufficient amounts of full length 
enamelin from developing enamel is not practical due to its very low concentration in the 
matrix and as yet no one has managed to produce a recombinant full length enamelin 
presumably due to the technical issues related to producing large recombinant DNA 
molecules.   Given these limitations, studying the functionality of discrete enamelin 
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domains such as the 32 kDa sequence may be the only option at present but clearly the 
caveat must be made that the behaviour of this domain may be different when it is a 
component part of larger enamelins.  
4.7 Intracellular effect(s) of the Y64H amelogenin mutation on 
the ameloblast secretory pathway  
 
 The in vitro nucleation data presented in Chapter 3 section 3.2 and discussed 
above would indicate that the wild type and Y64H mutant amelogenins behave in a 
similar fashion in terms of mineral nucleation/inhibition. During the course of the wider 
research program it became clear that it was the ameloblasts themselves that were 
affected by the mutation; i.e. the disease mechanism underpinning amelogenesis 
imperfecta in Y64H mutant mice appeared to be related to a deleterious effect of 
amelogenin on ameloblast cell biology rather than the dysfunctional behaviour of 
mutated protein in the enamel matrix. SDS PAGE and western blotting data obtained 
within the research group showed that the enamel matrix of male Y64H mutant mice 
exhibited a paucity of full length amelogenin (Barron et al., 2010). The obvious 
conclusions from this data are that full length amelogenin was not expressed or the 
normal secretory pathway was stalled in ameloblasts carrying the Y64H amelogenin 
mutation, resulting in a failure to secrete amelogenin.  In the present study, the question 
was posed as to whether or not failure to detect Y64H full length amelogenin in the 
developing enamel matrix of affected teeth was due to a failure in protein trafficking out 
of the cell or a failure in gene transcription. Quantitative RT PCR was therefore carried 
out to determine levels of amelogenin transcript in affected animals. The PCR data 
presented in figure 64 section 3.5.3 suggested that amelogenin is expressed (albeit at 
lower levels) in Y64H mutant mice leaving the possibility that Y64H amelogenin is not 
secreted correctly.  Figure 72 shows an electron transmission micrograph of Y64H 
mutant mouse ameloblasts labelled immunochemically for amelogenin (courtesy of Dr 
Martin Barron Manchester) of displaying abnormally engorged vesicles packed with 
amelogenin which suggested that that amelogenin is accumulating in cells; i.e. the 
secretory pathway is indeed blocked.    
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Figure 72.  This figure shows the secretory ameloblast cells of a male Y64H mouse 
as seen by immunoelectron microscopy. The cytoplasm is abnormally 
engorged with vacuoles strongly immunoreactive for amelogenin (see black 
dots in the top right insert). The scale bar is 2 µm; N = nuclei. (Barron et al., 
2010). Reproduced under Creative Commons Attribution License.  Modified 
from figure 3 published in:’A mutation in the mouse Amelx tri-tyrosyl domain results in 
impaired secretion of amelogenin and phenocopies human X-linked amelogenesis imperfecta’ 
by Barron et al 2010 Hum. Mol. Genet. (2010)19 (7): 1230-1247. Direct link: http://www. 
ncbi.nlm.nih.gov/pubmed/20067920  
 
It is well known that mutated proteins can misfold and undergo abnormal 
aggregation as they transit the endoplasmic reticulum (ER) in a range of cell types 
(Steward et al., 2003).  The ER is an organelle where newly synthesised proteins begin 
their journey on the secretory pathway out of the cell. During ER trafficking, proteins are 
modified as any post translational modifications are carried out and proteins fold 
(assisted by chaperone proteins) to attain the correct conformation.  The abnormal 
retention of proteins in the ER results in ER stress which triggers the so called unfolded 
protein response (UPR) (Ron and Walter. 2007). The UPR attempts to restore 
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proteostasis, but if unsuccessful, will eventually direct the cells towards apoptosis and 
ultimately cell death. Mutant proteins can therefore lead to disease due to reduced 
secretion of protein or in extreme cases, death of cells and tissues.  ER stress and the 
UPR is associated with diseases such as Huntington’s disease, Alzheimer’s, diabetes 
(type 2), cystic fibrosis, atherosclerosis, connective tissue disease and cancer (reviewed 
by Schroder and Kaufmann 2005). Given the evidence presented in this thesis together 
with that of the wider group, it appeared that ameloblast ER stress, due to retention of 
Y64H mutant amelogenin, could also be the driver for amelogenesis imperfecta in the 
affected mice. One possible reason for retention of Y64H amelogenin in the ER might be 
that amelogenin carrying the mutation is more highly aggregative than its wild type 
counterpart. 
To explore this possibility, the interaction of Y64H amelogenin with other Y64H 
amelogenin molecules and with wild type amelogenin molecules was investigated. This 
would indicate if Y64H amelogenin is more prone to aggregation.  
 
4.8 Effect of the Y64H mutation on amelogenin-amelogenin 
interactions 
The amelogenin binding studies reported in Chapter 3 section 3.4 shows the 
binding of solubilised FITC labelled wild type and FITC labelled Y64H mutant 
amelogenin to unlabelled wild type and Y64H mutant amelogenin and BSA (control) 
immobilised to cell culture plates.  To aid discussion of these results the data is 
reproduced here along with an additional cartoon figure that represents the results 
pictorially (figure 73).  
The first thing to note was that neither labelled mutant or WT amelogenin bound to 
immobilised BSA which was included as a control protein to test if amelogenin bound 
other proteins non-specifically under these experimental conditions (figure 55 section 
3.4.2). In contrast, labelled mutant amelogenin and labelled WT bound to immobilised 
Y64H and WT amelogenins (columns A & B in figure 55 section 3.4.2). This immediately 
indicated that both of these amelogenins have the ability to interact specifically and we 
are not just observing a general protein binding phenomenon. FITC- labelled Y64H 
mutant amelogenin appeared to bind to both immobilised WT and Y64H amelogenin to a 
greater extent than free labelled WT (with fluorescence readings being approximately 2-
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3 times higher in all cases).  Interestingly, labelled WT amelogenin did not show any 
increase in binding to Y64H mutant amelogenin immobilised on the plate whereas in the 
reciprocal case, solubilised labelled Y64H amelogenin showed increased binding to 
immobilised WT amelogenin. The reasons for this are unclear but may be related to the 
higher affinity that the mutant protein appears to have for itself. The data can be 
explained if we assume that bait (immobilised) proteins are adsorbed to the wells as 
monolayers.  Adsorption is carried out at pH 9.6 which favours binding of protein to the 
plastic well but inhibits protein-protein interactions. This is illustrated in figure 73 below 
where the adsorbed unlabelled WT and unlabelled Y64H mutant bait proteins are 
depicted as monolayers bound to the wells. In well 1, labelled WT amelogenin from 
solution is binding unlabelled bait (bound) WT but the affinity is such that a relatively 
small amount binds; illustrated here pictorially as a monolayer. In well 2 we have the 
same bait binding to labelled mutant amelogenin. The greater binding affinity of the 
mutant amelogenin to itself means that labelled mutant proteins build up by mutant-
mutant interaction; illustrated pictorially as a thicker layer which would give rise to a 
greater fluorescence signal. In well 3, we have the same binding partners as in well 2 but 
here the mutant is the bait protein and the binding partner is the labelled WT amelogenin 
in solution. The fluorescent signal is about 3 times less than well 2 and comparable with 
well 1. This is simply explained by the lower affinity that WT amelogenin has for itself. An 
initial layer of labelled WT amelogenin binds the mutant bait amelogenin but no more 
labelled WT binds to this initial partnership.    Finally, in well 4 in which unlabelled mutant 
bait protein is binding labelled mutant protein a large fluorescent signal is returned 
(comparable to well 2). Again this is explained by the high affinity of the mutant for itself. 
An initial layer of the labelled mutant binds the bait followed by further growth of the layer 
ad more labelled mutant protein binds the initially bound material.          
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Figure 73. Results of FITC binding experiments showing 100 µg/mL of unlabelled 
wild type amelogenin or Y64H mutant amelogenin bound to a 96-well 
microtitre plate and interrogated with 100 µg/mL of either wild type or mutant 
FITC-labelled amelogenin. N =6. Standard deviation error bars are shown. 
The cartoon below the graph depicts the hypothesis of the protein-protein 
interactions. 
 
That the Y64H amelogenin mutation increases amelogenin-amelogenin binding 
may be important in terms of pathogenic mechanisms. Previous studies have indicated 
that wild type amelogenins interact prior to secretion and form complexes containing up 
to 6 monomers (Brookes et al 2006). Following secretion, amelogenins assemble (i.e. 
aggregate) further to generate nanospheres comprising 100 or more amelogenin 
nanospheres (Fincham et al 1998), which represent the normal extracellular habit for 
amelogenin  as described in the Introduction (section 1.3.4.1.2). In Y64H amelogenin 
mutant mice, the mutant amelogenin accumulates in the ER and the ameloblasts 
become engorged with vesicles packed with amelogenin. Given that Y64H amelogenin 
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appears to exhibit a greater propensity to interact with other Y64H amelogenin 
molecules, the obvious hypothesis is that Y64H amelogenin molecules interact 
inappropriately during their passage through the ER, by aggregating and blocking the 
secretory pathway, triggering the UPR and thus exposing the ameloblasts to the 
possibility of apoptosis.  
 
4.9 ER stress, UPR and apoptosis in Y64H ameloblasts 
Genetic information required to generate proteins from the 20 amino acids is stored 
in the chromosomes in the nucleus of the cell as DNA. This information is transcribed 
into messenger RNA (mRNA) which carries the information to the ribosomes which 
translate the mRNA into a protein containing the specified amino acids in the specified 
order. Ribosomes synthesising proteins destined for import into intracellular organelles 
(e.g. mitochondria) or proteins destined for secretion into the extracellular medium 
associate with the outer membrane of the endoplasmic reticulum (ER) and as the protein 
chain is synthesised it is translocated into the ER where, as it is trafficked through the 
ER lumen, it undergoes further modification (e.g. glycosylation, phosphorylation etc.) 
and 'quality control' checks (Ellgaard and Helenius., 2003).  Once proteins are ready to 
exit the ER they are packaged into vesicles known as transition vesicles, which bud off 
from the ER and travel to the Golgi apparatus. The vesicles fuse with the Golgi and 
proteins are sorted and packaged into new vesicles which bud off and carry the cargo to 
the correct destination (Pfeffer and Rothman, 1987).  In the case of secretory proteins 
such as amelogenin, vesicles migrate to the cell membrane and release the protein to 
the outside of the cell (figure 74).   
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Figure 74.  Schematic diagram of protein synthesis, intracellular trafficking and secretion.
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 Newly synthesised proteins entering the ER undergo a series of post-translational 
modifications such as N-linked glycosylation, signal peptide cleavage, and di-sulphide 
bond formation (Bateman et al., 2009). These modifications dictate how the proteins fold 
and direct the protein to attain the correct secondary and tertiary structures. 
 Protein folding is assisted by chaperones, co-chaperones, foldases and 
oxidoreductases. These assistant proteins prevent misfolded proteins from aggregating 
via exposed hydrophobic sequences and provide and environment conducive to correct 
protein folding. Enzymes such as protein disulphide isomerases (PDI) catalyse 
disulphide bond formation and exchange. Other ancillary proteins are involved in 
securing and delivering the energy requirement for protein folding and in maintaining the 
correct redox state to permit the reversible formation of disulphide bonds in the ER 
lumen (Boot-Handsford and Briggs, 2010). 
 The ER quality control mechanisms ensure that misfolded proteins do not 
accumulate or progress along the secretory pathway. Instead they are kept in the ER 
and targeted for degradation (Anelli and Sitia, 2008). This occurs by two mechanisms. 
Firstly, the protein can be returned to the cytoplasm where it is ubiquinated which targets 
it for degradation by proteasomes during ER-associated degradation (ERAD) (Brodsky, 
2007). Alternatively, portions of the ER become engorged with misfolded protein and are 
budded off to become an autophagosome. This fuses with a lysosome and the contents 
are degraded. This usually occurs with proteins that have aggregated or become 
multimers, and are unable to undergo ERAD (Bernales et al., 2007). This quality control 
system is operative in all cells at all times as up to 30% of proteins fail to attain their 
correct conformation (Shubert et al 2000) and must be disposed of by the systems 
described above.  
Proteins abnormally accumulating in the ER trigger so called ER stress; a condition 
also caused by many different stimuli including heat shock, energy deprivation, hypoxia, 
metabolic dysfunction and drugs such as tunicamycin, which inhibits N-linked 
glycosylation, and thapsigargin which disrupts ER calcium ion balance. When ER stress 
is due to accumulating unfolded or misfolded protein within the ER, ER stress goes on to 
trigger the so called unfolded protein response (UPR) in an attempt to restore protein 
folding homeostasis (Boot-Handsford and Briggs, 2010). The UPR is a conserved 
cellular mechanism that protects cells against accumulation and aggregation of 
misfolded proteins during synthesis. It achieves this by stopping protein translation and 
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upregulating the expression of chaperones that drive protein folding (Hetz, 2012). When 
the aggregation of misfolded or damaged protein exceeds the capacity of the UPR, it 
can no longer protect the ER from stress and activation of apoptosis is triggered 
(Gardner et al., 2013). 
 The level of ER stress experienced by a cell is related to the amounts of protein 
passing through the cell’s ER. Professional secretory cells such as hepatocytes, insulin 
producing beta cells of the pancreas, and antibody-producing lymphocytes are 
particularly susceptible to ER stress, as are other strongly secretory cells such as 
chondrocytes, osteoblasts, and fibroblasts (Rutkowski and Kaufman, 2007). It is logical 
therefore, to assume that ameloblasts, the specialised ECM secreting cells in tooth 
enamel development, are also highly susceptible to ER and in fact secretory ameloblasts 
in wild type mice have been shown to ubiquitously express genes characteristic of an 
activated UPR (Tsuchiya et al., 2008). The UPR triggers a number of cell responses with 
the aim of relieving ER stress and restoring proteostasis; typical responses include; 
increasing the volume of the ER, increasing chaperone synthesis and damping down 
transcription of client proteins transiting the ER (Ron and Walter, 2007).  Under 
persistent exposure to ER stress, the cells may reduce the stress to acceptable levels 
via the UPR, though this is not without consequence. In fact, if the levels of ER stress 
become unacceptable a signalling cascade is triggered by IRE-1 mediated JNK 
phosphorylation and through the activity of Chop, and may result in the cell undergoing 
apoptosis, which may have pathogenic consequences. This can occur in metabolic 
diseases such as type II diabetes, where ER stress is crucial in insulin resistance. This 
increases demand on the insulin-producing beta cells of the pancreas. The increased 
insulin load causes elevated and persistent ER stress which can result in beta cell 
apoptosis and the subsequent need for insulin therapy (Lin et al., 2008; Zhang and 
Kaufman, 2008). 
 The unfolded protein response (UPR) has developed to counteract any stresses 
that occur in the ER due to the misfolding of proteins. The UPR is a complex 
homeostatic mechanism that has developed in mammalian cells to maintain the protein 
folding equilibrium within the ER (Boot-Handford and Briggs, 2010).  
 In order to overcome the problems associated with ER stress, a four-pronged 
response pathway has developed. This is discussed below with reference to the data 
presented in this thesis and obtained elsewhere in the research program.   
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1) Transcriptional and Translational attenuation 
The first response to ER stress is to reduce the general secretory load by 
transcriptional (Wu and Kaufman. 2006) and translational attenuation (Scheuner et al., 
2001). The synthesis of new protein is decreased to prevent further accumulation of 
unfolded protein in the ER. Interestingly, the data present in section 3.5.3 suggests that 
amelogenin transcription is significantly attenuated in Y64H mice which appears to be an 
attempt to reduce the secretory load. However, as evidenced by the intracellular 
accumulation of Y64H amelogenin in affected ameloblasts, this strategy in not sufficient 
to relieve the ER stress. The issue may be that amelogenin is synthesised in huge 
amounts (it is the major secretory product of ameloblasts) and though transcription is 
reduced the amount of protein translated is still evidently enough to overcome this initial 
line of defence against ER stress.  
2) Upregulation of ER chaperone proteins 
The second response to ER stress is the upregulation of ER chaperone protein 
genes such as binding immunoglobulin protein (BiP) (also known as 78 kDa glucose-
regulated protein (GRP-78) or heat shock 70 kDa protein 5 (HSPA5)) and enzymes (e.g. 
protein disulphide isomerase, sarco/endoplasmic reticulum calcium ATPase) to increase 
the protein folding capability of the ER (Harding et al., 2003).  
BiP is multifunctional; it is a classic chaperone molecule whose expression is 
increased when proteins misfold. BiP binds exposed hydrophobic regions on the 
misfolded proteins in an attempt to direct them towards the normal folding pathway by 
reducing the potential for aggregation driven by interactions between exposed 
hydrophobic regions on the misfolding proteins (Bertlotti et al., 2001). In respect of this 
thesis, the question asked was: is BiP expression upregulated in ameloblasts affected by 
Y64H amelogenin mutation, as the UPR attempts to relieve ER stress? To answer this, 
BiP mRNA expression levels from wild type and Y64H affected ameloblasts were 
compared by quantitative RT-PCR. The results shown in figure 62 show that BiP 
expression was elevated but this did not reach statistical significance in this set of 
experiments. However, the qualitative detection of BiP mRNA on sections of early 
secretory stage ameloblasts from wild type females and female Y64H mice 
heterozygous for the mutation (using in situ hybridisation) showed very obvious 
increased levels of BiP mRNA in Y64H ameloblasts. This work was carried during the 
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research program by Dr Martin Barron and is reproduced in figure 75 to emphasise the 
result. 
Figure 75. In situ hybridisation: BiP protein in early secretory stage 
ameloblasts from wild type and Y64H affected female mice. The darker blue 
staining, indicats clear upregualted BiP expression in affected ameloblats 
(arrowed).  Reproduced under Creative Commons Attribution License.  
Modified from figure 3 published in:  “Endoplasmic reticulum stress in amelogenesis 
imperfecta and phenotypic rescue using 4-phenylbutyrat”e; by Brookes et al 2014 
Hum. Mol. Genet. (2014) 23 (9): 2468-2480. Direct link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976337/)      
 
The in situ hybridisation results in figure 75 suggested that BiP expression was 
indeed increased in ameloblasts affected by the Y64H amelogenin mutation indicating 
that affected ameloblasts were upregulating chaperone production in an attempt to 
increase the probability of correct protein folding in the ER. An obvious question here is: 
why is the increase in BiP mRNA levels so much more convincing using in situ 
hybridisation compared to quantitative RT PCR?  The likely answer is due to the fact that 
quantitative RT PCR is carried out on dissected tissue samples; i.e. the secretory stage 
mouse incisor enamel organs, measuring a few millimetres in length and a couple of 
hundred microns in thickness. The levels of BiP mRNA were measured relative to the 
Gapdh gene, a so called “housekeeping” gene we assume is expressed at constant 
levels in all cells. The ameloblasts are a single monolayer of cells within the enamel 
organ and are therefore a minority of the total cell population. Hence, any increase in Bip 
expression occurring in affected ameloblasts is lost to some extent (i.e. diluted/ 
averaged out) against the lower levels of Bip expression in the non-ameloblast cells of 
the enamel organ. This demonstrates a potential pit fall when using quantitative RT PCR 
to measure gene expression in a sub population of cells within a larger tissue or organ 
and emphasises why it is important to support the PCR data by using a technique such 
as in situ hybridisation which is more sensitive to changes in gene expression within 
single cells.         
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 It is worth noting that not all ameloblasts in the Y64H amelogenin affected female 
mouse shown in figure 75 are stained heavily for BiP (this further reinforces the point 
made above how quantitative RT-PCR can only provide ensemble gene expression data 
that are averaged over all cells present in the sample). This staining pattern is to be 
expected since as described in the Introduction (section 1.3.4.1); the amelogenin gene is 
present on the sex chromosomes. Thus females heterozygous for the Y64H mutation 
have 2 copies of the amelogenin gene; one on each chromosome. During early 
embryogenesis one of the X-chromosomes is randomly inactivated so that 50% of the 
ameloblasts present in an affected heterozygous female are totally normal (expressing 
wild type amelogenin) while the remaining 50% are affected as they express Y64H 
mutated amelogenin. This is a very important point and will be referred to later.  
Later in the UPR there is an increase in the transcription of ERAD components to 
increase the ability of the cell to eliminate misfolded proteins via the ubiquitin-
proteasome pathway (Zhang and Kaufman, 2008). However, this was not investigated in 
the Y64H amelogenin mutant mice.  
From the above discussion it is clear that the UPR attempts to relieve stress by 
reducing general protein synthesis, increased the cell’s ability to dispose of misfolded 
protein and has increased the ability of the ER to direct proteins away from misfolding 
via hydrophobic interactions towards the correct folding pathway via the increased 
production of chaperones. If these measures fail to relieve stress the UPR switches from 
a pro-survival mode and directs the cell towards death via apoptosis (Fribley et al 2009).  
3) NFκβ activation 
The third response is NFκβ activation for the mediation of immune and anti-
apoptotic responses (Baeuerle and Baltimore; 1996). This is known as the ER overload 
response (EOR) as it is triggered by accumulation of membrane proteins in the ER. 
NFκβ activation was not investigated as part of this thesis with regards to the Y64H 
amelogenin mutation, as amelogenin is not a membrane protein. NFκβ activation is a 
highly complex situation with differing and opposing effects dependent on the cell type. 
4) Apoptosis  
If the UPR cannot relieve ER stress, it goes on to drive cells towards apoptosis 
which protects the organism by removing damaged cells that are expressing the problem 
mutation (Ron and Walter; 2007). Naturally, if the stressed cells comprise a significant 
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bulk of the tissue or organ then the effects can be catastrophic. Apoptosis is important in 
tissue homeostasis maintenance (Zhang et al, 2002). Dysregulation of apoptosis has 
been implicated in many diseases such as increased apoptosis in neurodegenerative 
disease, diabetes and AIDS, and altered apoptosis in cancer and autoimmune disease 
(Boot-Handsford and Briggs, 2010; Tsai and Weissman, 2010).  
There are 3 molecular signalling pathways known to be involved in modulating the 
various UPR responses described above and these will now be discussed with reference 
to data presented in this thesis and obtained elsewhere in the research program.   
 
4.9.1 Modulation of the UPR  
 The ER responds to increases in misfolded protein levels via three pathways 
activated respectively by the transmembrane ER-stress inducing proteins inositol 
requiring enzyme-1 (IRE1), pancreatic ER eukaryotic initiation factor (eIf)-2a kinase 
(PERK), and activating transcription factor - 6 (ATF-6). These three proteins are all 
associated with the luminal side of the ER inner membrane and continually monitor the 
status of the ER cargo as it transits the ER (Boot-Handsford and Briggs, 2010). Figure 
76 is a schematic for the proteins involved in the unfolded protein response in their 
unstressed state. The multifunctional nature of the folding chaperone BiP is exemplified 
again because BiP also plays a key role in detecting misfolded proteins in the ER. Under 
normal conditions with basal levels of misfolded proteins entering the ER, BiP is found 
associated with the 3 transmembrane receptors IRE1, PERK and ATF-6. While BiP 
remains bound to these receptors they are dormant and the UPR is not active. However, 
as levels of misfolded protein increase BiP binds to the exposed hydrophobic domains of 
the misfolded protein and the transmembrane receptors are activated (Bertolotti et al., 
2009). The consequences of activating these receptors are described next.       
Figure 77 shows a schematic for the proteins involved in the UPR in the stressed 
state, when the UPR is activated. BiP is removed from the cell surface receptors to act 
as a chaperone for the unfolded protein. The results from Q-RT-PCR analysis of wild-
type and Y64H mutant amelogenin mice incisors showed an increase in Chop and a 
decrease in Amelx expression. This suggests that the PERK pathway has been 
activated, 
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Figure 76. Diagram to show the protein receptors of the unfolded protein response (UPR) when the cell is in an unstressed 
state – UPR not activated. 
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 Figure 77.  Diagram to show the activation of the protein receptors in the unfolded protein response when the cell is in a 
stressed state – UPR activated.
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4.9.1.1 The IRE1 Pathway  
Dissociation of BiP (HSPA5/GRP78), the resident HSP70 orthologue in the 
ER, from IRE1 (figure 77) due to detection of unfolded or misfolded protein initiates 
the splicing of XBP1. Spliced XBP1 is a potent transcriptional activator that 
increases expression of a subset of UPR genes involved in the efficient protein 
folding, maturation and degradation in the ER (Lee et al., 2003; Schroder and 
Kaufman., 2005). This is described in more detail below, but the main outcome from 
this pathway is to switch off translation of protein in the ER lumen and reduce ER 
stress. 
 Once the binding equilibrium between BiP and IRE1 is disturbed by the 
presence of misfolded protein in the ER, IRE1 oligomerises in the plane of the ER 
membrane, triggering autocatalytic phosphorylation of the cytoplasmic domain and 
activation of its ribonuclease activity. IRE1 is an endoribonuclease that catalyses 
the unconventional splicing of mRNA coding for x-box binding protein 1 (XBP1). 
Spliced XBP1 upregulates the transcription of several genes involved in the initial 
UPR responses described above, i.e. up regulation of chaperones and proteins 
involved in ERAD (Todd et al., 2008). IRE1 also catalyses cleavage and destruction 
of a subset of mRNA’s linked to the rough ER, reducing the entry of new proteins 
into the ER lumen. The activated, phosphorylated form of IRE1 also interacts with 
tumour necrosis factor receptor associated factor 2 (TRAF2), activating JUN N-
terminal kinase (JNK), which has downstream involvement in apoptosis and 
autophagy (Ogata et al., 2006; Szegezdi et al., 2006; Oh and Lim, 2009).  
GRP94 is the only HSP90-like protein resident in the ER. GRP94 is a 
ubiquitously expressed chaperone protein with increased expression in the 
secretory tissues. The most important role for GRP94 is in directing the folding 
and/or assembly of secreted and membrane proteins. GRP94 is more selective 
than other ER chaperones. Its clients include integrins, immunoglobulins, IGF and 
TLR. The only common feature between them all is the presence of disulphide 
bonds. In vitro As the ER workload increases, the level of GRP94 transcription is 
co-regulated with other chaperones to increase the protein folding efficiency and to 
decrease the chance of misfolded proteins leaving the ER. 
BiP and GRP94 are the most abundant ER proteins, and not just when the ER 
is undergoing stress. GRP94 follows BiP in folding immunoglobulins and 
thyroglobulins. IGF interacts with GRP94 and not BiP. Different proteins may have 
different chaperone requirements. GRP94 cooperation with BiP is not an inherent 
property of GRP94’s mode of action. GRP94 has not been shown to act with lectin 
chaperones. Mammalian cells show a compensatory relationship between 
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chaperones. BiP knockout, BiP cleavage by subtilase, or BiP mutations cause 
expression of GRP94, PDI, calreticulin and Ep57. Silencing of calreticulin increases 
the expression of GRP94 and PDI, and calreticulin null embryonic fibroblast show 
increased levels of GRP94 and other ER proteins. However, GRP94 null cells do 
not demonstrate increased expression of other chaperones. BiP +/- mice show an 
adaptive transcriptional response with induction of chaperones including GRP94. 
GRP94 +/- mice do not show increased levels of BiP, calnexin or calreticulin. 
GRP94 has roles in protein folding, calcium binding and targeting proteins to the 
ERAD. 
The results shown in this thesis (section 3.5.3) show that XBP1 and GRP94 
were indeed upregulated in Y64H mice. Although statistical significance was not 
reached in the data reported here, later analyses using increased numbers of 
animals and carried out by Dr Martin Barron University of Manchester (Brookes et 
al., 2014) showed that the upregulation was significant. Amelogenin transcription 
was found to be statistically down regulated in this thesis (figure 62). The reason for 
the difference between the data reported here and the data obtained in Manchester 
(in terms of reaching mathematical significance) is unclear. However, the work 
presented here was carried out early in the research program and it may be as 
simple as the dissection technique improved with practice and the diluting effect of 
non-ameloblast cells (see section 2.5.2) was less of an issue.   Regardless, these 
data strongly suggest activation of the IRE1 branch of the UPR is present in Y64H 
mice. It would appear that the UPR is attempting to relieve the ER stress caused by 
Y64H amelogenin retention in the ER by reducing the transcription of new 
amelogenin in the ameloblasts.     
 
4.9.1.2 The PERK pathway 
Dissociation of BiP from PERK aims to reduce protein load in the ER by 
switching off protein synthesis through phosphorylation of the  -subunit of 
eukaryotic translation-initiation factor 2 (eIF2) which in turn increases translation 
of activating transcription factor 4 (ATF4) mRNA (Harding et al., 1999).  ATF4 
activates the expression of several UPR target genes involved in antioxidant 
responses, such as the transcription factor Nrf2, apoptosis, and autophagy (Harding 
et al., 2003; Cullinan and Diehl, 2004). 
 PERK is a transmembrane protein with a C-terminal cytoplasmic domain with 
serine/threonine kinase activity, and an ER luminal domain that binds BiP in its 
inactivated state, similar to IRE1. BiP dissociates from PERK as the levels of 
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misfolded protein increases in the lumen of the ER, leading to autophosphorylation, 
oligomerisation and activation of the kinase domain. PERK signals downstream 
effectors such as GADD34 and CHOP.  Activated PERK phosphorylates and 
inactivates eukaryotic translation initiation 2α (eIF2α). This is required for 80S 
ribosome assembly. As a consequence of this, a down regulation of protein 
synthesis occurs, decreasing the flow of newly synthesised unfolded protein into the 
ER.  Interestingly, some mRNAs such as that encoding ATF4, a 39 kDa 
transcription factor, have a more efficient translation when eIF2α is phosphorylated. 
ATF4 mRNA has a series of 5’ open reading frames that result in inefficient 
translation under non-stressed conditions (Lu et al., 2004). Phosphorylated eIF2α 
alters the reading dynamics of these open reading frames, resulting in increased 
ATF4 synthesis. ATF4 is a member of the cAMP-response element binding (CREB) 
family. It activates genes involved in the UPR such as the chaperones BiP and 
GRP94, genes involved in oxidative stress suppression, and genes involved in 
amino acid transport and metabolism. ATF4 also triggers the expression of CHOP 
(CCAAT/enhancer-binding protein homologous protein) which has been associated 
with ER-stress induced apoptosis (Zinszner et al., 1998).  
CHOP is also known as growth arrest and DNA damage-inducible gene 153 
(GADD153) and is a component of the ER stress apoptosis pathway. CHOP is a 29 
kDa protein consisting of 169 amino acids in humans and 168 amino acids in 
rodents.  The GADD genes are induced by genotoxic stress and growth arrest 
signals. C/EBP’s form a family of transcription factors that regulate genes involved 
in physiological processes such as immune functions, cell proliferation and 
differentiation. CHOP protein consists of 2 functional domains – an N terminal 
transcriptional activation domain and a C terminal basic leucine zipper (bzip) 
domain, made up of a basic amino acid rich DNA binding region and a leucine 
zipper dimerization motif. CHOP contains 2 serines at positions 79 and 82 that are 
capable of acting as substrates of the p38 Map kinase family. The bzip domain is 
important for CHOP induced apoptosis. C/EBP members are capable of forming 
homodimers and heterodimers. CHOP is a heterodimer. CHOP is able to inhibit 
C/EBP’s function and act as an activator of other genes. 
CHOP is ubiquitously expressed at very low levels and is present in the 
cytosol. Under stress conditions, CHOP is induced and accumulates in the nucleus. 
CHOP has been identified in stress conditions such as UV radiation, genotoxic 
stress, and nutrient depletion. CHOP expression is mainly regulated at the 
transcriptional level. Transcriptional upregulation occurs in response to ER stress. 
BiP acts as a sensor of unfolded proteins. Under normal ‘non-stressed’ conditions, 
BiP binds to the luminal domains of the stress transducers PERK, IRE1α and 
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IRE1β to prevent homodimerisation transport to Golgi. During stress, BiP binds to 
the unfolded proteins instead thereby releasing the transducers into their active 
state. 
The PERK/eIF2α signalling pathway induces CHOP in ER stress and is 
dominant over ATF6 and IRE1/XBP1 signalling pathways. For maximum CHOP 
induction though, all three pathways are necessary. Activated PERK 
phosphorylates SER51 on Eif2α which causes blocking of the Mer-tRNA binding to 
ribosome by decreasing Eif2β turnover, resulting in a decrease in the general 
translation due to decreased recognition of AUG initiation codon. ATF4 mRNA is 
still translated due to small upstream open reading frames (ORF’s). ATF4 can bind 
to the ATF/CRE consensus sequence 5’-TGACGTCA-3’ and the amino acid 
regulatory element (AARE) core sequence 5’-ATTGCATCA-3’. BiP-free Patf6α (p) 
and pATFβ (p) are transported the Golgi for cleavage by Site-1 and Site-2 
proteases. The cleaved N-terminal domains Patf6α(N) and Patf6β(N) are 
transported to the nucleus, where they bind to the ERSE due to their bZip domains. 
This binding with ERSE activates NF-Y trimer. Activated IRE1α and IRE1β cleave 
XBP-1 mRNA, which removes a 26-nucleotide intron, triggering an ORF switch to 
yield bZip and transactivation domains, binding ERSE and UPRE sequences in 
interaction with NF-Y.  
CHOP expression is also regulated by mRNA stability. CHOP mRNA 5’ UTR 
consists of highly conserved UORF’s which repress CHOP translation. CHOP 
undergoes phosphorylation by Map Kinases during ER stress. CHOP 
overexpression results in cell cycle arrest and/or apoptosis. BiP overexpression 
results in decreased CHOP induction and thus decreased apoptosis. CHOP null 
mice have reduced apoptosis in response to ER stress. All these show that CHOP 
is important in ER stress induced apoptosis. 
The results (section 3.5.3) suggested that Chop is upregulated in Y64H mice 
(with the caveat mentioned in section 3.5.3). However, later work carried by Martin 
Barron as a continuation of the work described here showed that Chop  is 
significantly upregulated in  Y64H mice. This data strongly suggests activation of 
the PERK branch of the UPR in Y64H mice. Since Chop induces apoptosis it 
appears that the UPR acting in Y64H is unable to relieve ER stress via survival 
strategies and instead signals cell death as the final solution to the problem.  
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4.9.1.3 The ATF6 pathway 
 ATF6 is a 90 kDa transmembrane protein with a cytoplasmic domain which 
contains a transcription factor with a bZIP motif, and a luminal domain that binds to 
BiP. When an increase in unfolded protein in the ER lumen is detected, Bip 
dissociates and the Golgi-localisation sequences in the ER luminal domain of ATF6 
are exposed (Shen et al., 2005). ATF6 then translocates to the Golgi where the 
protein is cleaved by site 1 and site 2 proteases (Ye et al., 2000). This releases the 
50 kDa cytosolic domain as an active transcription factor, known as ATF650. ATF650 
moves to the nucleus where it activates genes involved in ER quality control such 
as BiP, XBP1, ERAD components and apoptosis inducing Chop.  
We have already discussed the upregulation of XBP1 and Chop with 
reference to the IRE1 and PERK pathways described above.  That upregulation of 
BiP was also observed (page Figure 63 Section 3.5.3). Although not statistically 
significance in the data reported here, later analyses carried out by Dr Martin 
Barron, University of Manchester, (Brookes et al., 2014) showed that BiP 
upregulation was significant . This data strongly suggests activation of the ATF6 
branch of the UPR in Y64H mice is activated. As described above BiP is bound to 
IRE1, RERK and AFT6 in non-stressed cells but the presence of misfolded proteins 
in the ER causes BiP to dissociate from  IRE1, RERK and AFT6 resulting in their 
activation. Once free, BiP acts a chaperone and binds to hydrophobic regions on 
the misfolded proteins in an attempt to reduce protein aggregation. Upregulation of 
BiP is another classic UPR response designed to relieve ER stress. 
In summary, the UPR in the Y64H ameloblasts attempts to relieve the ER stress as 
evidenced by the upregulation of prosurvival factors (BiP, XBP1 and GRP94). 
However, the clear upregulated expression of Chop suggests that the UPR cannot 
rescue the cells from ER stress and commits the cells to apoptosis. It appears 
therefore that ameloblast ER stress and subsequent apoptosis is the pathological 
driver for this form of amelogenesis imperfecta. The validity of this hypothesis is 
explored in the next section by surveying the literature with regard to other 
connective tissue diseases caused by ER stress arising from protein mutations.  
 
4.9.2 ER stress induced diseases  
Mutations identified in ECM structural proteins and their associated post-
translational processing enzymes show that the resulting pathology depends upon 
the function of the protein, the nature of the actual mutation (premature termination, 
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nonsense) and its distribution in the body’s tissues.  The most commonly explored 
ECM mutations and diseases focus on collagen and its associated proteins and 
enzymes; with emphasis on secretion, proteolytic cleavage of the teleopeptide and 
fibril formation. The effects on the ECM resulting from these mutations are due to 
intracellular degradation of the mutant protein prior to secretion and/or release of 
faulty proteins that disrupt the ECM. 
Liang et al., 2014 investigated Col2a1 mutations in 13 mouse models to study 
the resulting phenotypes and possible mechanisms involved in various 
chondrodysplasias (lethal such as hypochondrodysplasia or deforming such as 
Stickler syndrome) or hip and knee joint diseases. All of the above are triggered by 
mutations in the Col2A1 gene encoding the α1 chain of procollagen type II and 
display the common symptoms of a disordered growth plate and slowed 
endochondral ossification. The researchers showed that the severity of the disease 
depended on the mutation type (large deletion vs. point deletion), mutation position 
(Y chromosome or X chromosome) and heterozygous or homozygous (i.e. whether 
some normal type II collagen remained). The mutations in the α1 chain of 
procollagen type II  gene ultimately lead to apoptosis via a series the UPR in the 
cells. Gaiser et al., 2002, and Arita et al., 2002 reported accumulation of the 
mutated collagen in the endoplasmic reticulum with an associated decrease in the 
amount of collagen type II secreted into the ECM.  Further investigations by  Chung 
et al., 2009 and Esapa et al., 2012 showed that these retained mutant collagen II 
molecules could induce ER stress and activate the unfolded protein response 
(UPR) which works to remove the misfolded collagen and maintain homeostasis. 
This is a direct parallel to what is observed in the Y64H amelogenin  mutation. 
Osteogenesis imperfecta (OI) is a disorder of the connective tissues caused 
by mutation in the genes encoding collagen type 1 (COL1A1 and COL1A2). 
Collagen 1 is the principal structural protein of bone and consists of fibrils of 2 
collagen 1 alpha 1 chains a  and 1 collagen 1 alpha 2 chain. The OI phenotype, like 
AI, depends upon the nature of the mutation and ranges from mild risk of bone 
fractures to perinatal lethality. Lisse et al., (2008) used an ENU-mouse model with a 
dominant mutation in the C-propeptide domain of collagen 1. Heterozygous mice 
displayed a severe to lethal phenotype associated with ER stress, and caspase 3 
and 12 activation within the osteoblasts. Immunofluorescence studies showed 
retention of the pro alpha (1) collagen chains in the ER. QPCR studies using 
primary calvarial osteoblasts showed elevated levels of BiP (1.5 to 2.2 fold 
increase), HSP47 (1.5 to 2.28 fold increase) and CHOP (3.7 fold increase). 
Caspase 12 is a specific mediator of the ER stress induced UPR in skeletal tissues 
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(Nakagawa and Yuan, 2000) and its elevation in these models is an indicator for 
apoptosis. 
There is also a growing body of evidence for the role of ER-stress and the 
UPR in age related disorders. The pathogenesis is the destruction of critical cells 
due to the formation of highly insoluble aggregated of the misfolded proteins and 
evidence has been shown for retinitis pigmentosa (Saliba et al., 2002), Alzheimer’s 
disease (Mann et al., 1985), prion disease (Forloni et al., 1993), Huntingdon’s 
disease (Zuleta et al,. 2012) Parkinson’s disease (Gorbatyuk et al., 2012), cancer 
(Mahadevan and Zanetti., 2011) and glaucoma (Anholt and Carbone, 2013). Some 
of these diseases will be discussed next. 
Retinosis pigmentosa (RP) is a group of inherited diseases that, due to the 
progressive death of rod and cone photoreceptors, causes progressive blindness 
(Dryja et al., 1990). Autosomal dominant RP is caused by mutations in rhodopsin. 
The most common mutation in the US is a P23H mutation resulting in protein 
misfolding and the accumulation of retained protein in the ER (Mendes et al., 2005), 
sometimes causing aggregates to form visible intracellular inclusions (Saliba et al., 
2002). This is comparable to the histidine substitution investigated in this thesis and 
the accumulation of amelogenin aggregates in the ameloblasts. Large amounts of 
rhodopsin is produced by the rod photoreceptors and mutant rhodopsin induces the 
UPR highlighting the use of this cascade in photoreceptors for dealing with 
misfolding stress (Lin et al., 2008; Athanisiou et al., 2013). Interestingly, the P23H 
mutation in rhodopsin activates both the UPR and the heat shock response (HSR); 
both of which activate the proteasome downstream for destruction of misfolded 
proteins (Kosmaoglou et al., 2009). Treatment of P23H mutants in rats with 
Arimaclomol, an inducer of the HSR, has been shown to improve vision and protect 
against photoreceptor destruction (Lewin et al., 1998; Parfit et al., 2014). Ablation of 
CHOP did not protect the photoreceptors against P23H mutant rhodopsin triggered 
cell death (Adekeye et al., 2014). 
Primary open angle glaucoma (POAG) is the most common form of glaucoma 
and is a hereditary, autosomal dominant mutation linked to chromosome 1q23-q25, 
known as MYOC. (Anholt and Carbone, 2013).  MYOC encodes a 55kDa secretory 
glycoprotein, myocilin, Myocilin, like amelogenin, is normally secreted into an ECM 
where it interacts with various ECM proteins such as fibronectin, laminin, collagen 
and fibrillin-1 (Myung et al., 2003). Mutant myocilin has been shown to accumulate 
in the ER and induce the UPR (Sidrauski et al., 1998; Mori et al., 2000). Myocilin 
secretion in adult eyes is normally at a low level but can be activated by stress, 
especially by high levels of circulating cortisol, a well-known risk factor for glaucoma 
and a link to diabetes (Anholt and Carbone, 2013). Excessive production of normal 
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myocilin, production of misfolded myocilin or any protein associated with MYOG, 
has been shown to form aggregates that in susceptible patients (those with a 
genetic predisposition to glaucoma) overwhelm the UPR to eliminate them via the 
proteasome. These causes ER stress and activate apoptosis of the TM cells that 
regulate intraocular pressure. Thus POAG may result in adult onset protein 
aggregation followed by neurodegeneration similar to Parkinson’s, Alzheimer’s and 
AI related to the Y64H amelogenin mutation.  A transgenic mouse containing the 
common Y437H MYOC mutation was created to study POAG (Zode et al., 2014). 
Adult mice with the mutation showed the glaucoma phenotype such as increased 
intraocular pressure, retinal ganglion cell death and axonal degeneration. The 
resulting mutant myocilin was not secreted into the aqueous humor as normal 
myocilin is, but accumulated in the ER of the TM cells. This is comparable to the 
accumulation of the Y64H amelogenin in the ER of ameloblasts. Chronic persistent 
ER stress resulted in TM cell death and increased intraocular pressure. Using the 
chemical chaperone phenylbutyric acid (PBA) prevented the glaucoma phenotype 
in the transgenic Y437H mice. PBA works by promoting secretion of the mutant 
myocilin into the aqueous humor and by reducing accumulation of the protein in the 
ER, hence preventing TM cell death (Zode et al., 2014; Shepard et al., 2007). 
It is clear that in mutations in ECM proteins can result in potentially 
pronounced phenotypes associated with a range of pathologies. Interpreting the 
phenotype in the context of what is now understood of ER stress and its resulting 
consequences prompted an ultrastructural characterisation of the enamel 
phenotype in the mice affected by the Y64H amelogenin mutation to investigate 
whether this might provide further evidence of the etiology of the biomineralisation 
defects associated with the mutation. 
4.10 Scanning Electron Microscopy of wild type and Y64H 
amelogenin mutant mouse incisors 
To confirm whether the hypothesis that the ameloblasts in mice containing the 
Y64H amelogenin mutation do deal with the mutation via the UPR, the resulting 
effect impact upon the enamel phenotype, was investigated. It was hypothesized 
that the enamel in wild type mice incisors would appear completely normal, and that 
male mice homozygous for the Y64 mutation would have very poorly formed 
enamel. Female mice heterozygous for the Y64H mutation were expected to exhibit 
enamel, which at first was correctly formed, but then poorly formed once the switch 
from cell survival to apoptosis occurred in the UPR. 
Imaging of transverse sections through erupted mice incisors corroborates the data 
from the immunohistochemistry staining and q-PCR analysis. The SEM in Figure 78 
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shows that in the wild-type tooth, enamel matured normally (see figures 63 and 64 
in section 3.6). It can therefore be inferred that wild type amelogenin protein was 
secreted normally during the earlier secretory stage of amelogenesis. The enamel 
is secreted in an incremental fashion from the dentinenamel junction. The prisms 
exhibit the characteristic interwoven decussating pattern and the enamel is of 
normal thickness. The schematic shows the life history of the ameloblasts as they 
incrementally secrete enamel during secretion and enter the maturation stage. 
During this the UPR is helping the cell cope with the large secretory load of 
amelogenin by operating in prosurvival mode (as discussed in section 4.9).   
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Figure 78. Scanning electron microscopy image of a transverse section 
through a normal wild type mouse incisor (top panel). A corresponding 
schematic to show the progress of enamel formation is shown below 
(middle panel). Note that even in wild type ameloblasts some 
amelogenin misfolds and the UPR acts to promote cell survival. The 
UPR is active in wild type ameloblasts (Kubota et al., 2005). 
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By contrast, SEM analysis across a Y64H amelogenin female (heterozygous) 
mouse incisor displays the effects of the mutation on the phenotype (figure 79, and 
figures 65 and 66 in section 3.6). In heterozygous females about 50% of the 
ameloblast will be normal and 50% will be affected by the mutation (due to X-
chromosome silencing)  The initially secreted inner enamel closest to the 
dentinoenamel junction displays the characteristic interwoven pattern of prisms and 
looks normal; the affected ameloblasts are coping with the ER stress due to the 
UPR acting in pro-survival mode and are surviving (though their secretory activity is 
impaired as the Y64H amelogenin is accumulating intracellularly). However, their 
mere survival ensures the integrity of the ameloblast enamel layer and the 
unaffected ameloblasts evidently secrete enough amelogenin to produce normal 
looking enamel.  Eventually the apparently normal enamel secretion is disturbed 
and the last enamel to be deposited (the outer enamel) is structurally abnormal and 
hypoplastic. It is hypothesised that the UPR switches from pro-survival to pro-
apoptotic mode and affected ameloblasts die. This effectively destroys 50% of the 
ameloblasts and disrupts the ameloblast layer resulting in abnormal enamel 
secretion.    
 
 
 
 
 
 
 
 
 
 
 
 
- 203 - 
 
 
Direction of growth 
   
 
 
Figure 79. Scanning electron microscopy image of a transverse section 
through a female heterozygous mutant mouse incisor (top panel). A 
corresponding schematic to show the progress of enamel formation is 
shown below (middle panel). Note that in affected ameloblasts misfolded 
amelogenin stimulates the UPR. Initially the UPR promotes cell survival 
and the initial enamel layer appears normal. With time, the continuing 
ER stress switches the UPR to promote apoptosis which leads to 
disruption of the ameloblast layer and malformation of the outer enamel 
layer.  
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In males with the amelogenin mutation, all the ameloblasts are expressing the 
mutant amelogenin which isn't being secreted at all so there is very little enamel laid 
down. Any amelogenin that does get secreted is mutated so may not work properly 
in the matrix anyway (but the main point is that full length amelogenin is not even 
getting out of the cells to have a chance of forming the enamel). At first the 
ameloblasts are enduring the ER stress and the UPR is helping them to do this 
(e.g. by reducing amelogenin transcription). This is supported by figure 72 from Dr. 
Martin Barron where the ameloblasts in the early secretion stage look 
phenotypically normal apart from being engorged with vesicles. Eventually the UPR 
trips into apoptotic mode and all the ameloblasts die hence only a thin layer of 
enamel is produced that is far from normal in structure (because there is no full 
length amelogenin being secreted and the cells die early).  
If these hypotheses are true, there are chemicals available that have been 
shown to have the ability to relieve ER stress by relieving the blockage in secretion 
or by inhibiting UPR induced apoptosis. If the mice were treated with such 
chemicals, it may free up the secretory pathway which would allow the ameloblasts 
to live but then we would see for the first time the effect of the mutation on how 
amelogenin behaves functionally once it is in the matrix. In males this would be a 
big question as all the amelogenin would be mutated. But it would remain to be 
seen if just restoring the secretory route would cure amelogenesis imperfecta. 
Other drugs might inhibit apoptosis and in the heterozygous females especially this 
would help by preventing the breakup of the ameloblast monolayer so leaving the 
50% of the wild type ameloblasts to go on secreting a normal enamel layer 
(Brookes et al., 2014). 
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4.11 Summary 
The work presented in this thesis was mainly concerned with the Y64H mutation in 
amelogenin, and how this impacted upon the normal structure-function status of the 
protein and results in amelogenesis imperfecta. The results presented in this thesis 
allow us to hypothesise that this single amino acid change caused a potential 
conformational change in amelogenin structure. Y64H amelogenin was shown to 
bind more strongly to itself. This in turn could cause the protein to aggregate 
abnormally in the ER, stall the secretory process and lead to ER stress. The normal 
structure of the ameloblast ER and Golgi apparatus is highly disturbed as a result 
with abnormal cytoplasmic vesicles packed with amelogenin. This triggers the 
unfolded protein response, which as indicated by the q-RT-PCR studies, reduced 
amelogenin transcription and elevated transcription of the UPR proapoptotic 
transcription factor Chop. Nucleation studies showed that the mutated amelogenin 
was able to nucleate hydroxyapatite mineral as well as the native protein. No 
significant difference was seen in the phosphate levels obtained for wild type or 
mutant amelogenin, alone or with 5 µg/mL enamelin, implying that the mutation in 
the amelogenin protein does not affect the proteins role in hydroxyapatite 
nucleation.  
In vitro nucleation studies using a steady-state system showed that nucleation 
of hydroxyapatite mineral deposits was achieved with recombinant 32 kDa 
enamelin protein. Comparison to known hydroxyapatite nucleators showed that 
enamelin protein had some features in common, whereas amelogenin did not 
(Table 2). The amount of mineral deposited with wild type or Y64H mutant 
amelogenin under the same experimental conditions was similar, with or without the 
Y64H mutation and with or without the presence of recombinant 32 kDa enamelin. 
Therefore the overall conclusion from these in vitro nucleation experiments was that 
the amelogenin imperfecta phenotype observed in mice carrying the Y64H 
amelogenin mutation is not due to the Y64H amelogenin behaving differently from 
the wild type molecule in terms of its behaviour with respect to mineral nucleation. 
Experiments were performed to investigate the importance of the 32 kDa 
enamelin processing product as a discrete entity during amelogenesis. The 32 kDa 
enamelin entity has been shown to be the predominant enamelin in pig enamel, and 
is the most widely studied enamelin protein due to its abundance and ease of 
collection. SDS-PAGE and western blot analysis of rat secretory enamel showed 
that the 32 kDa fragment was not the dominant enamelin species in the rat. 
Bioinformatics alignment of the amino acid sequences of enamelin from several 
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species showed that the cleavage sites for the 32 kDa enamelin are only present in 
the pig. Therefore, the 32 kDa enamelin fragment should be used with caution 
when investigating amelogenesis in general or in relation to other species. 
Amelogenin has been well documented to assemble and form nanospheres, 
thought to be important for nucleation of hydroxyapatite. The presence of vacuoles 
full of unsecreted amelogenin in the ameloblasts of the Y64H amelogenin mutant 
mouse suggested premature/increased aggregation of the mutant protein (Barron et 
al., 2010). Protein-protein interaction studies in vitro using recombinant wild-type 
protein and Y64H mutant amelogenin showed that the Y64H amelogenin- Y64H 
amelogenin binding was 2 to 3 times greater than wild type amelogenin-wild type 
amelogenin binding.  This led to the conclusion that the Y64H amelogenin 
molecules could aggregate within the ameloblasts and block the secretory pathway 
in mice carrying the mutation. This in turn would activate elevated levels of ER 
stress, triggering the UPR and driving the ameloblasts towards apoptosis. This 
hypothesis was supported by the data from quantitative PCR studies that showed 
that amelogenin was statistically significantly downregulated in the Y64H mutant 
mice, implying that the ER stress response and UPR is active, reducing protein 
synthesis to relieve ER stress and prevent apoptosis. The upregulation of Chop and 
Bip were also noted, although not statistically significant (p<0.05) in this study (later 
shown to be, Brookes et al., 2014) indicating that the IRE1 and PERK pathways of 
the UPR were underway in the Y64H mice. 
SEM analysis of the wild type and Y64H mice incisors showed that it was 
possible to identify where the UPR was unable to cope with the high levels of 
unsecreted, aggregated mutant amelogenin, and drives the ameloblasts towards 
apoptosis. This results in the structurally abnormal, hypoplastic enamel, typical of 
the AI phenotype.  
The work presented in this thesis supports the work of Brookes et al., 2014 
confirming that the Y64H amelogenin mutation is not a loss of function mutation but 
rather one that triggers ER stress, reduction of protein secretion and apoptosis of 
ameloblast cells. In the published study, mice with the Y64H mutation displayed the 
morphological characteristics of malformed tooth enamel displayed in the human 
equivalent amelogenesis imperfecta. The presence of the mutation caused the 
intracellular accumulation of the unsecreted protein, triggering apoptosis of the 
ameloblasts via ER stress and the UPR. They proposed that 4-phenylbutyrate, a 
drug already licensed for treatment of in-born errors of the urea cycle, could be a 
potential treatment for AI. Sodium phenylbutyrate is a histone deacytylase inhibitor 
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(HDACI). It is currently being investigated as a potential treatment for cystic fibrosis, 
cancer, motor neurone disease and haemoglobinopathies Sodium phenylbutyrate is 
a short chain aromatic fatty acid that undergoes β-oxidisation in vivo to form 
phenylacetate (PAA). PAA binds with glutamine to form phenacetylglutamine which 
is excreted via the urea cycle (Iannitti and Palmieri, 2011).  It has also been 
proposed that sodium phenylbutyrate acts as a chemical chaperone. Kubota et al., 
2006 investigating the signalling pathways involved in Parkinson disease, looked at 
the effects of phenylbutyrate on the accumulation of Parkin-associated endothelin 
receptor-like receptor (Pael-R). Several findings allowed the authors to conclude 
that phenylbutyrate was able to suppress ER stress by reducing the amount of 
misfolded protein collecting in the ER. These findings included; restoration of 
normal Pael-R expression and reduction of ER-stress with phenylbutyrate 
treatment, activation of ER-stress pathways and neuronal cell death with 
phenylbutyrate treatment, and the restoration of yeast viability in cells which failed 
to trigger an ER stress response under ER stress conditions following treatment 
with phenylbutyrate. Other studies investigating the effects of phenylbutyrate 
treatment include reversal of memory and learning deficits in Alzheimer disease 
mice models, proposing the use of phenylbutyrate to restore memory function in 
Alzheimer patients (Ricobaraza et al., 2009), the use of phenylbutyrate to prevent 
the accumulation of the toxic branched-chain amino acids and α-keto acids in 
Maple Syrup Urine disease (Brunetti-Pierri et al. 2011), efficacy of phenylbutyrate in 
the prevention of lipid-induced insulin resistance and β-cell dysfunction  in 
overweight or obese men (Xiao et al., 2011). Phenylbutyric acid was also used to 
treat mice models for POAG with a Y437H mutation in MYOC (described in section 
4.10.2). 
A number of hypotheses were explored as part of this thesis. 
Hypothesis 1: Is the 32 kDa enamelin breakdown product is conserved across all 
species? The majority of studies to date have used the porcine 32kDa enamelin 
product due to its ready availability. To investigate this hypothesis, western blot 
analysis of porcine and rat enamelin were used, as was a bioinformatics exploration 
of enamelin sequences across many species. The data presented in this thesis 
showed that the 32 kDa enamelin breakdown product was not the major fragment in  
rat enamel. A bioinformatics search of enamelin sequences also revealed that the 
32 kDa enamelin product was not conserved across all species. This has 
significance for the use of the porcine 32 kDa enamelin breakdown product as a 
model for full length enamelin in in vitro studies. 
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Hypothesis 2: The AI phenotype generated as a result of the Y64H amelogenin 
mutation in mice is a result of the mutated protein behaving differently upon 
secretion. To investigate this hypothesis, in vitro nucleation studies were performed 
to explore the effect of the mutation on the ability of amelogenin, and amelogenin in 
conjunction with enamelin, to nucleate hydroxyapatite mineral. In vitro binding 
studies were also be performed using the wild type and Y64H mutant amelogenin to 
investigate the effect of the mutation on protein-protein interactions. The steady 
state agarose gel nucleation studies showed that the Y64H mutation in amelogenin 
did not affect the way the amelogenin nucleated mineral, either alone or with the 
presence of 32 kDa enamelin. This implies that the mutant amelogenin does not 
behave differently with regards to ability to nucleate mineral in an in vitro system. 
The use of an in vitro microplate binding assay to investigate protein-protein 
interactions showed that the Y64H amelogenin bound with more affinity to itself and 
wild type amelogenin, that wild type amelogenin bound to itself. This may result in 
the Y64H mutant amelogenin forming aggregates that were contained in vesicles in 
the ameloblasts. 
Hypothesis 3: The AI phenotype generated as a result of the Y64H amelogenin 
mutation in mice is a result of the mutated protein being retained in the ameloblast 
and not being secreted correctly. Similar mutations in other proteins have resulted 
in endoplasmic stress in cells, resulting in transcription and translation 
downregulation and ultimately apoptosis of the secretory cells.  Quantitative PCR 
and SEM analysis of wild type and Y64H mutant mice incisors were performed to 
probe whether ER stress and the unfolded protein response could be responsible 
for the AI phenotype in Y64H mutant mice. The q-PCR data presented in this thesis 
showed that ER stress was a possible result of the AI genotype. A down-regulation 
in Amelx was noted, indicative of transcriptional and translational attenuation. 
Upregulation of genes involved in the UPR were also noted. 
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Future perspectives  
 
In the 2014 paper, Brookes et al., performed in vitro transfection studies using 
COS-7 cells and wild-type or Y64H amelogenin. A significant increase in apoptosis 
was noted in the cells transfected with Y64H amelogenin. This was abolished by 
the addition of 0.5mM phenylbutyrate. In vivo studies conducted consisted of 
feeding wild type and Y64H mice a diet containing 7g/kg sodium – 4- 
phenylbutyrate. The appearance of incisor teeth in Y64H female mice improved 
with the poor quality enamel being replaced over the course of the experiment by 
translucent, orange coloured enamel similar to the wild type counterparts. 
Histological examination of the incisors showed that the wild-type mice exhibited tall 
secretory stage ameloblasts associated with an eosinophilic enamel ECM. 
Untreated female Y64H showed a reduced secretory zone and thickness of ECM 
with intracellular eosinophilic staining indicating retained matrix protein.  
Phenylbutyrate treated Y64H female incisors showed a reversal of these 
anomalies, with a return to the phenotype displayed by the wild type incisors. 
Western blot analysis of the phenylbutyrate treated male Y64H secretory stage 
ECM showed that amelogenin secretion was still impaired, indicating that the 
phenylbutyrate is unable to restore normal secretory function in affected 
ameloblasts. To probe whether the phenylbutyrate elicited an effect on the UPR, 
the levels of caspase-3, a marker for apoptosis, were compared in the ameloblasts 
of affected mice with and without treatment. No phenylbutyrate treatment resulted in 
large numbers of ameloblasts testing immunopositive for caspase-3, whereas 
treatment with phenylbutyrate reduced the caspase-3 levels to those observed in 
the wild type. This implies that the phenylbutyrate treatment worked by reducing 
apoptosis in the Y64H affected mice ameloblasts. 
The study of hydroxyapatite nucleation in vitro has shown that amelogenin is 
incapable of nucleating hydroxyapatite, and that enamelin is capable of nucleating 
hydroxyapatite production. The two proteins together are capable of hydroxyapatite 
nucleation. The presence of the Y64H mutation in the recombinant amelogenin was 
shown to not effect hydroxyapatite nucleation. Further studies could use this in vitro 
nucleation system to investigate whether known mutations in the 32 kDa enamelin, 
shown in humans to trigger amelogenesis imperfecta, change the ability of the 
enamelin protein to nucleate hydroxyapatite. This would involve producing 
recombinant enamelin protein containing the mutations and repeating the 
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experimental work shown in this thesis with the mutated protein. It would also be 
interesting to see how other proteins identified in vivo in the ECM behave in the in 
vitro steady-state agarose gel nucleation system with regards to nucleating 
hydroxyapatite production. It would be interesting to include recombinant 
ameloblastin, alone and in conjunction with amelogenin and/or enamelin in the 
steady state agarose gel system. This could help elucidate the essential protein 
combination necessary for optimised hydroxyapatite production. 
The q-RT-PCR experiments performed within this thesis have shown a 
decrease in the production of amelogenin in mouse incisors containing the Y64H 
amelogenin mutation. This could be due to activation of the Unfolded Protein 
Response (UPR) removing the mutated protein via apoptosis, or by the UPR 
switching off or slowing down production of the mutated protein while it deals with 
the mutated protein already produced. The q-RT-PCR experiments also showed an 
increase in the amount of CHOP, a stress protein in the UPR pathway. Further 
studies could be performed to investigate this down production of amelogenin, 
using histology and immunochemistry staining of slices of tooth. Q-RT-PCR 
experiments using other genes involved in the UPR pathways could give a fuller 
picture of what is happening to the mutated amelogenin protein. 
Protein uptake and binding studies seemed to show that the mutated Y64H 
amelogenin protein is ‘stickier’, binding to itself and wild-type amelogenin protein 
more strongly. Expansion of these studies could elucidate what is actually 
happening to the protein once it is secreted. Surface Plasmon Resonance (SPR) 
would be able to identify differences in the binding strengths and affinities of these 
proteins. SEM studies could show any differences in nanosphere formation due to 
the amelogenin mutation. 
Identification of a true molecular chaperone for amelogenin would be 
extremely useful for describing the secretory pathway for amelogenin in the 
ameloblast cells. Due to amelogenin and ameloblastin being co-localised on the 
same gene, and being located together, it is highly probable that ameloblastin is the 
molecular chaperone for amelogenin. Co-localisation studies using ELISA, IHC and 
histological staining would help to show if this is a realistic hypothesis. 
It would be beneficial to repeat the proteolytic degradation studies with 
maturation stage enamel from rat incisors to see if the serine proteases present in 
the maturation stage enamel could lead to proteolytic processing and reveal the 
presence of the 32 kDa enamelin processing product in rat, and not just porcine 
enamel. 
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The work in this thesis helps us to understand better the role of the major ECM 
proteins, amelogenin and enamelin, in the development of tooth enamel. There is 
still a long way to go to fully understand the complex interplay of these proteins with 
each other, either in matrix formation or in a chaperoning role during protein 
secretion, and their interaction with hydroxyapatite mineral crystals to form mature 
enamel. The mature tooth enamel is a unique and amazing biomineralised tissue. 
Understanding as much as we can about its production can only help us in our 
quest to design and produce better products for its care and repair, and this effects 
nearly every one of us. 
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List of Abbreviations 
ADJ                                                                                  Amelodental junction 
Ag                                                                                                            Silver 
AI                                                                       Amelogenesis Imperfecta 
ALB                                                                                                      Albumin 
ALP                                                                              Alkaline phosphatase 
AMBN                                                                                           Ameloblastin 
AMG                                                                                               Amelogenin 
APS                                                                             Ammonium persulphate 
ATMP                                                         Amelogenin trityrosyl motif peptide 
BSA                                                                           Bovine Serum Albumin 
CK                                                                                                   Cytokeratin 
CT            Crossing Threshold 
D                                                                                                           Daltons 
DEJ                                                                         Dentino-enamel junction 
DH20                                                                                          Distilled water 
DMSO                                                                               Dimethyl sulphoxide 
DNA                                                                               Deoxyribonucleic acid 
DPP                                                                             Dentinephosphoprotein 
DTT                                                                                          DL-dithiothreitol 
ECM                                                                                   Extracellular matrix 
EDTA -Na2                            Ethylenediaminetetra-acetic acid (disodium salt) 
EDX                                                                            Energy dispersive X-ray 
ELISA                                                    Enzyme linked immunosorbant assay 
EMD                                                                          Enamel matrix derivative 
EMGs                                                                   Enamel matrix glycoproteins 
ER                                                                               Endoplasmic Reticulum 
ERAD                                   Endoplasmic Reticulum Associated Degradation 
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FITC                                                                 Fluorescein Isothiocyanate 
GAG                                                                                   Glycosaminoglycan                  
GlcNAc                                                                       N-Acetyl-D-glucosamine 
GMp1                                                                      GlcNAc mimicking peptide 
HAP                                                                                          Hydroxyapatite 
HCl                                                                                        Hydrochloric acid 
HDPL                                                  Human Dental Peridontal Ligament 
HEPES                           (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HERS                                                               Hertwig’s epithelial root sheath 
HMW                                                                             High molecular weight 
Hr                                                                                                              Hour 
Hrs                                                                                                        Hours 
IgG                                                                                       Immunoglobulin G 
kDa                                                                                                  Kilodaltons 
KLK-4                                                                                              Kallikrein-4 
LAMP’s                                          Lysosomal associated membrane proteins 
LB                                                                                              Loading buffer 
LRAP                                                            Leucine rich amelogenin peptide 
Mg                                                                                                      Milligram 
mL                                                                                                  Millilitre 
MMP                                                                          Matrix Metalloproteinase 
MMP-20                                          Matrix Metalloproteinase 20 – enamelysin 
MUT                                                                                                     Mutant 
MW                                                                                        Molecular Weight 
NaCl                                                                                        Sodium chloride 
Ng                                                                                               Nanogram         
PAGE                                                        Polyacrylamide gel electrophoresis 
PBS                                                                             Phosphate buffered salt 
PCR                                                                        Polymerase chain reaction 
PDL                                                                                  Periodontal ligament  
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PGA                                                                                  Poly L-glutamic acid 
PTM                                                                  Post-translational modification 
Q-RT-PCR                        Quantitative real time polymerase chain reaction 
RGD                                                                      Arginine-glycine-aspartate 
RNA                                                                                        Ribonucleic acid 
Rpm                                                                           Revolutions per minute 
RT                                                                                  Room temperature 
RT-PCR                              Reverse transcriptase polymerase chain reaction 
SDS                                                                          Sodium dodecyl sulphate 
SEM                                                                Scanning electron microscope 
TBS                                                                                 Tris buffered saline 
TBS-T                                               Tris buffered saline – Tween 20 (0.05%) 
TEM                                                            Transmission electron microscope 
TIMP’s                                                 Tissue inhibitors of metalloproteinases 
TRAP                                                           Tyrosine rich amelogenin peptide 
Tris                                                             Tris-(hydroxymethyl)-methylamine 
µg                                                                                                     Microgram 
µL                                                                                                       Microlitre 
UPR                                                                    Unfolded Protein Response 
UV                                                                                                Ultraviolet 
WT                                                                                                 Wild type 
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Appendix 1 
Comparison of mineral nucleating systems 
Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
BSP 1-10 µg/mL 2 µg/mL 2% agarose, 150 mM 
NaCl, 0.01% NaN3, 10 
mM Tris-HCl pH 7.4. 
Flow = 1 mL/h per gel.  
CaCl2 and 
NaPo4 (5.5 mM 
and 7.5 mM 
each tested) 
Hunter and 
Goldberg, 
PNAS (1994)  
 37°C for 5 days 
Osteopontin 1-10 µg/mL No HAP seen 2% agarose, 150mM 
NaCl, 0.01% NaN3, 10 
mM Tris-HCl pH 7.4. 
Flow = 1 mL/h per gel.  
CaCl2 and 
NaPo4 (5.5mM 
and 7.5mM 
each tested) 
Hunter and 
Goldberg, 
PNAS (1994) 
 37°C for 5 days 
BSP 0.3 ng/mL-
100 µg/mL 
0.3 µg/mL 1% agarose, 150mM 
NaCl, 20 mM Hepes 
pH 7.4, 0.01%NaN3 
CaCl2 and 
NaPo4 (6.5 mM 
and 3.9 mM 
each tested) 
Hunter and 
Goldberg,  J. 
Biochem 
(1996)  
3500 mwco 
dialysis 
membrane 
37°C for 5 days 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
Osteopontin 0.3 ng/mL-
100 µg/ml 
No HAP seen 1% agarose, 150mM 
NaCl, 20 mM Hepes 
pH 7.4, 0.01% NaN3 
CaCl2 and 
NaPo4 (6.5 mM 
and 3.9 mM 
each tested) 
Hunter and 
Goldberg  J. 
Biochem 
(1996)  
3500 mwco 
dialysis 
membrane 
37°C for 5 days 
DPP 0.3 ng/mL-
100 µg/mL 
10 µg/mL 1% agarose, 150 mM 
NaCl, 20 mM Hepes 
pH 7.4, 0.01% NaN3 
CaCl2 and 
NaPo4 (6.5mM 
and 3.9mM 
each tested) 
Hunter and 
Goldberg  J. 
Biochem 
(1996)  
3500mwco 
dialysis 
membrane 
37°C for 5 days 
Osteocalcin 0.3 ng/mL-
100 µg/mL 
No HAP seen 1% agarose, 150 mM 
NaCl, 20mM Hepes 
pH 7.4, 0.01% NaN3 
CaCl2 and 
NaPo4 (6.5mM 
and 3.9mM 
each tested) 
Hunter and 
Goldberg  J. 
Biochem 
(1996)  
3500mwco 
dialysis 
membrane 
37°C for 5 days 
BSP - 
untreated 
5 µg/mL higher calcium-
phosphate levels seen 
1% agarose, 150mM 
NaCl, 10mM Tris-HCl, 
0.01% NaN3 flow= 
1ml/h/gel 
CaCl2 and 
NaPo4 (6.0mM 
each, pH7.4) 
Hunter and 
Goldberg, J. 
Biochem 
(1994)  
AP not needed 
for nucleation 
37°C for 5 days 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
0 5 µg/mL  1% agarose, 150mM 
NaCl, 10mM Tris-HCl, 
0.01% NaN3 flow= 
1ml/h/gel 
CaCl2 and 
NaPo4 (6.0mM 
each, pH7.4) 
Hunter and 
Goldberg, J. 
Biochem 
(1994)  
 37°C for 5 days 
Calreticulin 20 µg/mL No HAP seen 1% agarose, 150mM 
NaCl, 10 mM Tris-HCl, 
0.01% NaN3 flow= 1 
mL/h/gel 
CaCl2 and 
NaPo4 (6.0mM 
each, pH7.4) 
Hunter and 
Goldberg, J. 
Biochem 
(1994)  
No HAP 
nucleation  
37°C for 5 days 
Osteopontin 100 µg/mL No HAP seen 1% agarose, 150mM 
NaCl, 10 mM Tris-HCl, 
0.01% NaN3 flow= 1 
mL/h/gel 
CaCl2 and 
NaPo4 )7.5mM 
each, pH 7.4) 
Hunter GK, 
Kyle CL, 
Goldberg HA, 
J.Biochem 
(1994) 
Osteopontin is 
effective 
inhibitor of HAP 
37°C for 5 days 
BSP - native 0.087 µg/mL HAP seen  1% agarose, 150mM 
NaCl, 20mM Hepes 
pH 7.4, 0.01% NaN3 
CaNO3 (7.1mM) 
and NaPo4 
(4.3mM) 
Tye CE, 
Hunter GK, 
Goldberg HA, 
JBC (2003) 
Glutamic acid 
rich region of 
BSP maybe a 
requisite for 
HAP nucleation 
37°C for 5 days 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
BSP- rat 
recombinant 
1.7-3.4 
µg/mL 
Less HAP than native 1% agarose, 150mM 
NaCl, 20mM Hepes 
pH 7.4, 0.01% NaN3 
CaNO3 (7.1mM) 
and NaPo4 
(4.3mM) 
Tye CE, 
Hunter GK, 
Goldberg HA, 
JBC (2003) 
Glutamic acid 
rich region of 
BSP maybe a 
requisite for 
HAP nucleation 
37°C for 5 days 
BSP-poly E 
to poly A 
3 µg/mL Decreased HAP 1% agarose, 150mM 
NaCl, 20 mM Hepes 
pH 7.4, 0.01% NaN3 
CaNO3 (7.1 mM) 
and NaPo4 (4.3 
mM) 
Tye CE, 
Hunter GK, 
Goldberg HA, 
JBC (2003),  
Glutamic acid 
rich region of 
BSP maybe a 
requisite for 
HAP nucleation 
37°C for 5 days 
BSP - poly E 
to poly D 
3 µg/mL  1% agarose, 150 mM 
NaCl, 20 mM Hepes 
pH 7.4, 0.01% NaN3 
CaNO3 (7.1mM) 
and NaPo4 
(4.3mM) 
Tye CE, 
Hunter GK, 
Goldberg HA, 
JBC (2003) 
Glutamic acid 
rich region of 
BSP maybe a 
requisite for 
HAP nucleation 
37°C for 5 days 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
Osteocalcin 100 µg/mL No HAP seen 1% agarose, 150 mM 
NaCl, 20 mM Hepes 
pH7.4, 0.01% NaN3 
flow= 1 mL/h/gel 
CaCl2 and 
NaPo4 (6.5mM 
and 3.9mM, pH 
7.4) 
Hunter GK, 
Goldberg HA , 
J.Biochem 
(1996) 
3500mwco 
dialysis 
membrane + 10 
µg/mL PGA 
used as positive 
control 
37°C for 5 days 
Osteopontin 100 µg/mL No HAP seen - potent 
inhibitor 
1% agarose, 150 mM 
NaCl, 20mM Hepes 
pH7.4, 0.01% NaN3 
flow= 1 mL/h/gel 
CaCl2 and 
NaPo4 (6.5mM 
and 3.9mM, pH 
7.4) 
Hunter GK, 
Goldberg HA, 
J.Biochem 
(1996) 
3500mwco 
dialysis 
membrane + 10 
µg/mL PGA 
used as positive 
control 
37°C for 5 days 
Osteonectin 100 µg/mL No HAP seen 1% agarose, 150mM 
NaCl, 20mM Hepes 
pH7.4, 0.01% NaN3 
flow= 1 mL/h/gel 
CaCl2 and 
NaPo4 (6.5 mM 
and 3.9 mM, pH 
7.4) 
Hunter GK, 
Goldberg HA, 
J.Biochem 
(1996) 
3500mwco 
dialysis 
membrane + 10 
µg/mL PGA 
used as positive 
control 
37°C for 5 days 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
BSP 0.3 µg/mL  1% agarose, 150mM 
NaCl, 20mM Hepes 
pH7.4, 0.01% NaN3 
flow= 1 mL/h/gel 
CaCl2 and 
NaPo4 (6.5mM 
and 3.9 mM, pH 
7.4) 
Hunter GK, 
Goldberg HA, 
J.Biochem 
(1996) 
3500mwco 
dialysis 
membrane + 10 
µg/mL PGA 
used as positive 
control 
37°C for 5 days 
DPP 10 µg/mL  1% agarose, 150mM 
NaCl, 20mM Hepes 
pH7.4, 0.01% NaN3 
flow= 1 mL/h/gel 
CaCl2 and 
NaPo4 (6.5 mM 
and 3.9 mM, pH 
7.4) 
Hunter GK, 
Goldberg HA, 
J.Biochem 
(1996) 
3500mwco 
dialysis 
membrane + 10 
µg/mL PGA 
used as positive 
control 
37°C for 5 days 
Chondrocalci
n 
100 µg/mL No HAP seen 1% agarose, 150mM 
Nacl, 20mM Hepes 
pH7.4, 0.01%NaN3 
flow= 1 mL/h/gel 
CaCl2 and 
NaPo4 (6.5 mM 
and 3.9 mM, pH 
7.4) 
Hunter GK, 
Goldberg HA, 
J.Biochem 
(1996 
3500mwco 
dialysis 
membrane + 10 
µg/mL PGA 
used as positive 
control 
37°C for 5 days 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
BSA 0-500 µg/mL No HAP 96 well plate – 100 µl  
0.5% agarose, 10mM 
Na2HPo4, 50 mM 
Hepes, 10mM CaCl2, 
pH 7.4 
150 µl of 150 
mM NaCl, 50 
mM Hepes, 
10mM CaCl2 
ph7.4 
Couchoural D 
et al, 
J.Inorganic 
Biochem 
(1999) 
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
37°C for 4 hours 
Type 1 
collagen 
(calf skin) 
0-500 µg/mL No HAP 96 well plate – 100 µL 
0.5% agarose, 10 mM 
Na2HPo4, 50 mM 
Hepes, 10 mM CaCl2, 
pH 7.4 
150 µL of 150 
mM NaCl, 50 
mM Hepes, 10 
mM CaCl2 
pH7.4 
Couchoural D 
et al, 
J.Inorganic 
Biochem 
(1999) 
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
37°C for 4 hours 
Fibronectin 
(human 
plasma) 
0-100 µg/mL No HAP 96 well plate – 100 µL  
0.5% agarose, 10 mM 
Na2HPo4, 50mM 
Hepes, 10mM CaCl2, 
pH 7.4 
150 µL of 150 
mM NaCl, 50 
mM Hepes, 10 
mM CaCl2 
pH7.4 
Couchoural D 
et al, 
J.Inorganic 
Biochem 
(1999) 
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
37°C for 4 hours 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
PGA (Sigma 
P-4886) 
0-30 µg/mL HAP at 5 µg/mL 96 well plate – 100 µL  
0.5% agarose, 10 mM 
Na2HPo4, 50 mM 
Hepes, 10 mM CaCl2, 
pH 7.4 
150 µL of 150 
mM NaCl, 50 
mM Hepes, 10 
mM CaCl2  
pH7.4 
Couchoural D 
et al, 
J.Inorganic 
Biochem 
(1999) 
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
37°C for 4 hours 
Phosphoryn 0-20 µg/mL Increased HAP at 20 
µg/mL 
96 well plate – 50 µL 
0.5% agarose, 150 
mM NaCl, 50 mM 
Hepes, pH7.5, plus 
10mM phosphate 
100 µL of 150 
mM NaCl, 50 
mM Hepes, 10 
mM CaCl2, 
pH7.5 
Fujisawa R et 
al, Biochimica 
et Biophysica 
(1996)  
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
25°C for 24 hours 
Osteonectin 
(synthetic) 
0-20 µg/mL Increased HAP at 20 
µg/mL 
96 well plate – 50 µL 
0.5% agarose, 150 
mM NaCl, 50 mM 
Hepes, pH7.5, plus 10 
mM phosphate 
100 µL of 150 
mM NaCl, 50 
mM Hepes, 10 
mM CaCl2, 
pH7.5 
Fujisawa R et 
al, Biochimica 
et Biophysica 
(1996)  
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
25°C for 24 hours 
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Protein Conc. of 
protein 
Optimal conc. for 
hydroxyapatite 
Conditions Buffers Publication Comments Time/ 
temperature 
BSA 0-20 µg/mL Decreased HAP 96 well plate – 50 µl 
0.5% agarose, 150 
mM NaCl, 50 mM 
Hepes, pH7.5, plus 10 
mM phosphate 
100 µL of 150 
mM NaCl, 50 
mM Hepes, 10 
mM CaCl2, 
pH7.5 
Fujisawa R et 
al, Biochimica 
et Biophysica 
(1996)  
96 well plate 
format with 
phosphate 
buffer in gel, 
overlaid with 
calcium 
25°C for 24 hours 
BSP - 
decarboxylat
ed 
5 µg/mL Abolishes HAP 
formation 
1% agarose, 150 mM 
NaCl, 10 mM Tris-HCl, 
0.01% NaN3 flow= 1 
mL/h/gel 
CaCl2 and 
NaPo4 (6.0 mM 
each, pH7.4) 
Hunter and 
Goldberg,  
Biochem 
(1994)  
Modification of 
carboxylate 
groups 
abolishes HAP 
formation 
37°C for 5 days 
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Appendix 2 
Typical profile for Q-RT-PCR from the LightCycler 
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Appendix 3 
Bioinformatics data for 290 enamelin sequences 
C-terminus and N-terminus highlighted  
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Appendix 4 
Poster presentation at Faculty of Medicine Postgraduate Research day at 
Weetwood Hall  November 4th 2009. Winner of best laboratory poster and peoples 
choice award. 
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Poster presentation at Leeds Dental Institute Research day November 18th 2009. 
Winner of best poster prize. 
 
